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1. SUMMARY 
 
Epstein-Barr virus (EBV) latently infects more than 90% of adults worldwide and is 
associated with epithelial and B cell tumors. Primary EBV infections in toddlers are mostly 
asymptomatic, but may develop into the symptomatic infectious mononucleosis (IM) in 
adolescents and adults. T cell responses are known to be essential for the lifelong immune control 
of this tumor virus, however the role of natural killer (NK) cells in EBV infection has not been 
extensively investigated yet. NK cells are composed of several subsets and specific subsets have 
been shown to preferentially expand during acute viral infections other than EBV in humans. 
Based on reports of age-related changes in NK cell subsets distribution and function, we 
postulated that healthy individuals older than 5 years of age exhibit an impaired NK cell immune 
response against EBV, leading to T cell-mediated immunopathology and IM. 
In the work presented here, we longitudinally assessed NK cell responses in pediatric IM 
patients. Our results indicate that children and teenagers with IM exhibit the classical T cell 
features observed in adults. Acute IM drives the preferential proliferation and accumulation of 
early-differentiated CD56dim NKG2A+ KIR- NK cells. Moreover, only this NK cell subset 
further maturates during the first month of IM and remains at increased frequency for up to 6 
months compared to controls. Additionally, we demonstrate that this NK cell subset specifically 
recognizes and responds to EBV-infected B cells with viral reactivation. We also found that the 
frequencies and absolute numbers of this NK cell subpopulation in peripheral blood decrease 
during the first decade of life. Finally, we did not observe any age-related changes in the NK cell-
mediated response against EBV-transformed B cells in vitro.  
This is the first report of an expanding human NK cell subset that directly recognizes 
virus-infected cells in vitro. Our novel findings support the hypothesis that the early NK cell-
mediated immune control of EBV lytic replication is quantitatively impaired after the first decade 
of life and might therefore predisposes to IM. This work provides insight into a protective NK cell 
response in EBV infection, which might be exploited for the development of novel 
immunotherapies against this tumor virus. 
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2. ZUSAMMENFASSUNG 
 
Das Epstein-Barr Virus (EBV) etabliert eine lebenslang persistierende Infektion in mehr 
als 90% der erwachsenen Bevölkerung weltweit und ist mit bösartigen epithelialen und B-Zell-
Tumoren assoziiert. Erstinfektionen mit EBV verlaufen bei Kleinkindern häufig asymptomatisch, 
können aber in Jugendlichen und Erwachsenen zur Entwicklung der Infektiöse Mononukleose 
(IM) führen. T Zell-Antworten sind wesentlich für die lebenslange Immunkontrolle dieses 
Tumorvirus, jedoch wurde die Rolle von natürlichen Killer (NK) Zellen in der EBV Infektion bis 
heute wenig untersucht. NK Zellen bestehen aus verschiedenen Subpopulationen und es konnte 
gezeigt werden, dass bestimmte Subpopulationen bei verschiedenen akuten viralen Infektionen im 
Menschen präferenziell expandieren. Aufgrund von Berichten über altersabhängige 
Veränderungen der Subpopulationenverteilung und der Funktion der NK Zellen schlagen wir die 
Hypothese vor, dass gesunde Leute, die älter als 5 Jahre sind, zeigen eine durch NK Zellen 
ungenügende Immunkontrolle von EBV, die zur durch T Zellen ausgelösten Immunpathologie 
und IM führt. 
In der hier vorliegenden Arbeit wurde anhand einer longitudinalen Studie das Verhalten 
von NK Zellen und deren Subpopulationen in pädiatrischen Patienten mit IM untersucht. Unsere 
Daten zeigen, dass bei Kindern und Teenagers mit IM die klassischen T Zellen Eigenschaften von 
Erwachsenen beobachtet werden. Die akute IM führt zu einer spezifischen Proliferation und 
Akkumulation von früh differenzierten CD56dim NKG2A+ KIR- NK Zellen. Außerdem wird 
ausschließlich diese NK Zellen Subpopulation über den ersten Monat von IM reifer und ihre 
Häufigkeit bleibt erhöht bis 6 Monate nach IM. Darüber hinaus können wir zeigen, dass diese 
Subpopulation von NK Zellen vor allem EBV infizierte B Zellen mit viraler Reaktivierung 
erkennt. Weiterhin belegen unsere Daten, dass Häufigkeiten und Zellzahlen dieser NK Zell-
Population im peripheren Blut über das erste Lebensjahrzehnt abnehmen. Schließlich haben wir 
keine altersabhängige Unterschiede in NK Zellen Antworten gegen EBV transformierte B Zellen 
in vitro beobachtet. 
In dieser Arbeit beschreiben wir erstmalig eine expandierende humane NK Zell 
Subpopulation, die in vitro direkt Virus infizierte Zellen erkennen kann. Unsere neue 
Erkenntnisse passen zur Hypothese, dass die durch NK Zellen vermittelte frühe Immunkontrolle 
von EBV lytischer Vermehrung nach Ablauf des ersten Lebensjahrzehntes quantitativ weniger 
effizient wird und somit zur Entwicklung der IM prädisponiert. Unsere Einblicke in eine 
schützende NK Zell-Antwort gegen die EBV Infektion könnten zur Entwicklung neuer 
Immuntherapien gegen dieses Tumorvirus führen. 
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3. INTRODUCTION 
 
3.1. Epstein-Barr virus  
 
3.1.1 History of EBV 
The Epstein-Barr virus (EBV) belongs to the family of γ-herpesviruses and was first 
described in 1964 by Anthony Epstein in tissue cultures of Burkitt lymphoma biopsies (1). 
Later, thanks to the development of immunofluorescent tests to detect viral antigens by 
Gertrude and Werner Henle, it became clear that EBV infections are ubiquitous and that the 
virus is found widespread in humans (2). The Henles then identified EBV as the causative 
agent for infectious mononucleosis (IM) in 1968, when one technician from their lab suffered 
from this disease and further develop antibodies to this herpesvirus (3). This observation was 
confirmed in a prospective seroepidemiological study of university students, showing that 
only EBV-seronegative individuals developed IM and exhibited seroconversion (4). EBV was 
later detected in tissues from patients with nasopharyngeal carcinoma in the 1970s (5), non-
Hodgkin lymphoma (NHL) in patients with acquired immunodeficiency syndrome (AIDS) in 
the early 1980s (6), and T cell and classical Hodgkin lymphomas (HL) in the late 1980s (7, 8). 
EBV is currently associated with several cancers both in immunocompetent and 
immunocompromised individuals (Table 1, adapted from (9)). 
 
 
            
 
 
 
 
 
 
 
Table 1: EBV-associated malignancies (adapted from (9)) 
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3.1.2. EBV epidemiology  
Seroepidemiologic surveys suggest that EBV infects more than 95% of the adult population 
worldwide (10). The prevalence of EBV antibodies varies in different regions of the world 
depending on the socioeconomic status and the living condition. In the developing countries, 
EBV is usually acquired in early childhood (11, 12), probably through familial contact (13, 
14). Improvement of economic and sanitary conditions might therefore explain the observed 
decrease in the rates of EBV-seroprevalence among children 5-9 years of age in urban Japan 
from more than 80% in 1990 to 59% between 1995 and 1999.  
Primary EBV infections in young children are primarily manifested as nonspecific 
illness (15), and much less frequently as symptomatic IM (16). On the other hand, EBV 
infection in early childhood has become less common in developed countries, where 30 to 
75% of college freshmen are seronegative for EBV (17). Primary EBV infections during or 
after the second decade of life is symptomatic in more than 70% of cases (17) and present as 
infectious mononucleosis (also known as kissing disease), which overall affects around 10% 
of the population in Europe and the US (10). Notably, the incidence of severe IM in adults 
seems to have increased over the last 20 years (18). 
 
3.1.3. EBV biology and life cycle 
EBV, also known as human herpesvirus 4 (HHV4) is a human DNA virus and a member of 
the family Herpesviridae, belongs to the subfamily Gammaherpesvirinae, genus 
Lymphocryptovirus (LCV; also named gamma-1 herpesviruses). LCV are found only in 
primates and EBV is the only LCV restricted to humans. The EBV genome consists of a 
linear double-stranded DNA molecule of around 184 kb in length. When a virus infects a cell, 
its linearized genome does not integrate into cellular DNA, but circularizes into an episome. 
The episome replicates after infection, leading to accumulation of multiple copies in the 
nucleus, which will be equally partitioned to daughter cells during future cell division 
(reviewed in (9)). 
 EBV is transmitted to new hosts via saliva containing infectious viral particles. EBV 
primarily infects the B cell latently in vivo as wells as in vitro, and to a lesser extent some 
type of epithelial cells. EBV entry in B cells is first mediated by attachment to the surface 
receptors CD21 (19) and CD35 (20), followed by binding to the HLA class II molecule, 
which will initiate the fusion of the enveloped virus with the membrane after endocytosis 
(21). 
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 EBV, like all herpesviruses, displays two infection modes, i.e. latent and lytic 
infection (Fig. 1), which are characterized by different gene expression and are initiated by 
the transcription of specific viral trans-activators (the latent gene EBNA2 vs. the immediate-
early lytic genes BZLF1 and BRLF1). 
 
 
Figure 1: EBV life cycle (adapted from (9)) 
 
Latent EBV infection 
EBV infection of primary B cells in vitro results in the expression of 8 latent viral proteins (6 
nuclear proteins and 2 membranes proteins; table 2), leading to B cell transformation and the 
generation of lymphoblastoid cell lines (LCLs). These LCLs resemble proliferating B cell 
blasts with an activated phenotype. Moreover, latent antigens are detected in EBV-associated 
malignancies and several types of latency gene expression patterns can be found in these 
tumors (table 2). In vivo, EBV establishes a life-long latency exclusively in the memory B cell 
pool and up to 1 in 106 peripheral blood B cells are latently infected with the virus in healthy 
EBV carriers (22). During acute infectious mononucleosis (IM), the primary symptomatic 
EBV infection, up to half of all peripheral memory B cells carry EBV (23); however these 
cells are resting and do not express any viral antigens (24), whereas infected B cells in IM 
tonsils exhibit the complete set of latency gene expression (25). EBV latency genes have been 
	  	   9	  
proposed to drive the differentiation of infected naïve B cells into long-lived memory B cells 
(26) and some of these genes are essential for B cell transformation in vitro (27). 
 
 
Table 2: EBV latent genes (adapted from (28)) 
 
Lytic EBV infection 
Lifelong latency in the host is a characteristic feature of herpesviruses such as EBV, 
cytomegalovirus (CMV) and herpes simplex virus (HSV). However, in order to outlive its 
host, a virus must transmit its genome to new hosts. Therefore, herpesviruses use periodic 
lytic reactivation in a fraction of latently infected cells to allow production of free infectious 
virions. EBV reactivation can be observed in the tonsils from IM patients (29, 30) and leads to 
release of infectious viral particles in the saliva (31). Triggering of the EBV lytic cycle in vivo 
is thought to occur in latently infected memory B cells differentiating into plasma cells (32). 
Lytic EBV replication proceeds through a sequential expression of viral gene categories (Fig. 
2), starting with the expression of the two immediate early (IA) genes, followed by expression 
of the early viral genes, and finally of the late viral genes. The cascade begins when 
expression of the IE genes is triggered by host cell transcription factors, as observed upon 
cross-linking of B cell receptor with anti-IgG in EBV-positive Burkitt lymphoma cells in vitro 
(33). This process ends up with production and release of encapsidated, enveloped virions and 
ultimately with the lysis of the infected B cell. 
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Figure 2. EBV lytic reactivation model upon anti-IgG treatment of EBV-positive Burkitt 
lymphoma cells (adapted from (34)) 
 
3.1.4. Infectious mononucleosis 
Most primary EBV infections occur during early childhood 
and are either asymptomatic or result in non-specific 
symptoms. However, individuals that get infected after the 
age of 5 years bear the risk of developing infectious 
mononucleosis (IM) or kissing disease (10). This self-
limiting disease is characterized by fever, tonsillitis, 
generalized lymphadenopathies, hepatosplenomegaly and 
fatigue (Fig. 3). Exaggerated IM-associated T cell 
responses, but not EBV infected B cells, are thought to 
cause the symptoms (35).  
 
 
Figure 3. Clinical picture of infectious mononucleosis in 
a child, depicting tonsillitis, cervical lymphadenopathies 
and hepatosplenomegaly. (kindly provided by Prof. David 
Nadal, University Children’s Hospital of Zurich) 
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While most patients with IM fully recover in two to four weeks, some patients experience 
persistent malaise and fatigue that can last several months. 
The diagnosis of IM is usually based on the aforementioned characteristic clinical symptoms, 
the marked lymphocytosis, the presence of atypical lymphocytes (representing activated T 
cells) on peripheral-blood smear and a specific serological pattern. Most of patients with 
EBV-associated IM exhibit circulating heterophile IgM antibodies directed against viral 
antigens that cross-react with antigens found on sheep and horse red cells. Young children 
with IM might have a false negative heterophile test and need to be further tested for EBV-
specific IgM and IgG serologies.  
 
 
 
  
 
                                                                  
 
 
 
 
 
 
 
Figure 4: Antibody responses during primary EBV infection (adapted from (10)) 
 
Acute primary EBV infection is confirmed by the presence of IgM to the viral capsid antigen 
(VCA) and the absence of IgG to EBNA (Fig. 4). Heterophile-negative IM might also be 
observed in acute cytomegalovirus (CMV), human immunodeficiency virus (HIV) and 
toxoplasmosis infections. 
 
3.1.5. Innate immune responses to EBV  
Innate immunity to EBV is mainly mediated by pathogen-associated molecular pattern 
receptors such as Toll-like receptors (TLRs), different subsets of dendritic cells (DCs) and 
natural killer (NK) cells and this topic has been extensively reviewed in the attached review 
(manuscript N°2 (36)). 
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3.1.6. T cell responses to EBV  
Acute IM is associated with an expansion of activated cytotoxic CD8+ T cells, but not of 
CD4+ T cells (37), which are oligoclonal (38) in their T cell receptor (TCR) usage (39). 
Moreover, these proliferating CD8+ T cells (Fig. 5) were shown to be EBV-specific using 
HLA class I tetramer (40) and ex vivo cytotoxic assays (41), and to be mostly directed against 
epitopes derived from immediate early and early lytic antigens (42). The dynamics of T cell 
responses parallels the rapid decrease of EBV-positive cells in peripheral blood during acute 
IM (23). On the other hand, IM patients exhibit prolonged oral EBV shedding up to one year 
after IM (31, 43). Persistent EBV infection in healthy EBV carriers is primarily controlled by 
T cells (35). Moreover, clinical evidence from transplant patients strongly suggests that latent 
antigen-specific CD8+ T cells are major mediators of host control in vivo (44). 
Immunosuppressive treatment or co-infection with HIV or Plasmodium falciparum in 
holoendemic malaria regions compromises this EBV specific T cell immunity and leads to 
increased frequencies of EBV-associated malignancies like post-transplant 
lymphoproliferative disease and Burkitt lymphoma (9). Accordingly, some of these EBV-
associated malignancies can be treated by adoptive transfer of EBV antigen-specific, in vitro 
expanded T cells (45).  
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Figure 5: Peripheral blood EBV-specific T cell responses and viral loads in saliva and 
peripheral blood during the course of an infectious mononucleosis (from (35)) 
 
Therefore, the priming and maintenance of this EBV specific T cell immune control is 
essential for asymptomatic carriage of this oncogenic virus, and the conditions under which 
this occurs need to be characterized to identify individuals that are susceptible to EBV-
associated malignancies and to mimic these conditions for successful vaccination. 
 
3.1.7. Hypothesis for infectious mononucleosis 
Along these lines it has become clear that symptomatic primary EBV infection manifested as 
IM does not efficiently establish EBV immune control and therefore bears an increased risk 
for developing EBV-associated diseases like classical Hodgkin lymphoma (46) and multiple 
sclerosis (47). Nearly 45 years after the discovery of the link between EBV and IM (3), the 
mechanisms leading to this frequent disease in only some of EBV infected individuals still 
remain unknown.  
It has been proposed that asymptomatic primary EBV infection is associated with 
early adaptive T cell control of EBV in the tonsils (48), without major changes of the 
peripheral blood T cell compartment (49). It has been further postulated that higher viral 
doses lead to stronger cytotoxic T cell (CTL) responses and therefore to IM symptoms. 
Indeed, the dose of orally acquired EBV might be larger during deep kissing in adolescents 
compared to oral transmission during early childhood (50). Another explanation might be 
found in the heterologous immunity concept (51), in which infection during early childhood 
elicits powerful naive CTL responses that rapidly contain the infection. However, in older 
individuals, the T-cell memory compartment, which contains numerous pathogen-specific 
memory T cells, is more likely to elicit weak cross-reactive heterologous CTL response that 
clears the virus inefficiently. Thus, to eliminate infection, cross-reactive T cells, which have 
been observed in IM (52), must be activated more extensively, resulting in the massive CTL 
expansion in IM. Finally, others have proposed that specific polymorphisms of genes such as 
the anti-inflammatory cytokine IL-10 (53) or MHC class I (54) might influence the immune 
control of EBV and therefore predispose for IM.  
We postulated that IM is linked to inefficient innate NK cell-mediated immunity to the 
virus, allowing EBV to replicate to high titers initially (55). This hypothesis will be elaborated 
in the subject of investigation and the discussion parts of the thesis. 
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3.2. Natural killer cells 
 
3.2.1. NK cell functions and biology 
NK cells were originally described as large granular lymphocytes with natural cytotoxicity 
against tumor cells (56-58). This cytotoxic ability did not require any priming and was not 
restricted by the target cell’s expression of major histocompatibility complex (MHC) 
molecules. Experiments in mouse models of bone marrow graft rejection (59) led to the 
proposal that NK cells would kill any target that lacked self–major histocompatibility 
complex (MHC) class I molecules (the “missing self” hypothesis) (60). NK cells were later 
recognized as a separate lymphocyte lineage, with both cytotoxic and cytokine-producing 
effector functions (Fig. 7), and were defined as CD3- CD56+ lymphocytes (61) in humans. 
Their antiviral role was first confirmed in mice infected with murine cytomegalovirus 
(MCMV) using NK cell depletion and adoptive transfer experiments (62).  
 
 
 
Figure 7: NK cell effector functions (adapted from (63)). NK cells can kill target cells via 
directed degranulation of cytotoxic granules or via engagement of death receptors. NK cells 
also secrete large amounts of proinflammatory cytokines such as IFN-γ, which will act on 
virus infected cells or modulate the functions of other immune cells such as dendritic cells 
(DCs). 
 
Recently, NK cells have also been shown to shape the adaptive immune response (reviewed 
in (64)), either by acting on antigen presenting cells (APCs), or by direct killing of activated T 
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cells (Fig. 8). Finally, NK cells seem to play a role in reproduction (65) and in hematopoietic 
stem cell transplantation (66) and have been recently classified as members of the group 1 
innate lymphoid cells (ILCs) (67) 
NK cells can kill virus-infected cells or transformed cells via secretion of cytotoxic granules 
containing perforin and granzyme B, and can secrete large amount of proinflammatory 
cytokines such as IFN-γ. These immune cells recognize target cells via germline-encoded 
surface receptors, that unlike their counterparts on T or B cells, do not require somatic 
recombination and are therefore present at higher precursor frequencies in the NK cell 
compartment, ready to raise rapid and substantial immune responses after activation (68). 
Despite having been originally described as “natural killer”, NK cells from mouse and human 
require priming by various factors, such as IL-15 presented by DC (69) or macrophages (70), 
IL-12 (71) or IL-18 (72), to achieve their full effector potential, highlighting the regulatory 
interactions between NK cells and other immune cells. 
 
 
 
Figure 8: Regulations of adaptive immune responses by NK cells (adapted from (73)) 
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The activation of NK cell cytotoxicity is mediated by a balance of inhibitory and activating 
NK cell receptors (Fig. 9), as well as various adhesion and co-stimulatory molecules (74, 75).  
 
 
 
Figure 9: Simplified model of target cell recognition by NK cells. Activating ligands (L; 
violet) are upregulated on target cells and trigger activating receptors (A; red), which deliver 
activating signals. Inhibitory ligands such as the MHC class I (blue) on the surface of the 
target cell engage inhibitory NK cell receptors such as the killer immunoglobulin-like 
receptors (KIRs) (green) and provide inhibitory signals. The balance of signals will ultimately 
determine the NK cell response, i.e. tolerance or cytotoxic degranulation. 
 
Inhibitory receptors and NK cell licensing 
Under normal circumstances of immune surveillance of self, inhibitory NK cell receptors 
recognize MHC class I molecules as their cognate ligands present on virtually every cell in 
the body. Notably, virus-infected cells or transformed cells can downregulate the expression 
of MHC class I in order to avoid recognition by cytotoxic T cells. Inhibitory human NK cell 
receptors include the killer immunoglobulin-like receptors (KIRs) that bind to classical MHC 
class Ia ligands HLA-A, -B and-C (76, 77), and the inhibitory CD94-NKG2A heterodimeric 
C-type lectin-like receptors that bind the non-classical MHC class Ib HLA-E (78). These 
inhibitory receptors are expressed in a variegated fashion, so that each NK cell expresses 
multiple receptors in a complex combinatorial pattern of inhibitory receptor repertoire (79, 
80). These inhibitory signals are thought to be essential to avoid NK cell mediated killing of 
healthy self cells, i.e. to prevent autoimmunity. Notably, the interactions between inhibitory 
receptors, including NKG2A (81), and their MHC class I ligands during NK cell maturation 
allow the licensing (or education) of the NK cell, which become fully functional (82). Failure 
to receive the licensing signal keeps NK cells in a hypo-responsive state (83). 
NK#cell#
MHC I 
Target#cell#
L A +
KIR -
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Activating receptors 
For many years, NK cells were thought to be controlled only by inhibitory signals, with 
killing of target cells resulting from the absence of inhibition. However, it is now well 
established that NK cells require specific activating signals – and even a combination thereof 
(84) - leading to cytotoxicity. Upregulation of activating NK cell ligands have been described 
on virus-infected cells, tumor cells and during cellular stress, e.g. during activation of the 
DNA damage response (85). In humans, major triggering NK cell receptors include NKG2D 
(receptor for the stress-associated MICA/B and ULBP molecules), DNAM1 (receptor for 
CD112 and CD155), 2B4 (receptor for CD48), activating KIRs (receptors for HLA class I 
molecules), NKG2C (receptor for HLA-E), the natural cytotoxic receptors (NCRs) NKp46, 
NKp44 and NKp30, and CD16 (or FcγRIIIa; low affinity IgG receptor for antibody-
dependent cellular cytotoxicity). 
 
3.2.2. NK cell subsets and differentiation  
NK cells are, along with T and B cells, members of the lymphocyte lineage, which derive 
from common lymphoid progenitors found in the bone marrow. The first differentiation stage 
– the pro-NK cell - migrates from the bone marrow to secondary lymphoid tissues (SLT) such 
as lymph nodes and tonsils. Freud et al. described five stages of NK cell maturation in SLT 
(86), which can be defined by the expression of surface markers (Fig. 10). 
 
 
Figure 10: Proposed model of NK cell differentiation in SLT (adapted from (87)) 
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The pro-NK cell, pre-NK cell, iNK cell and CD56bright NK cell populations are enriched 
within SLT. In this model, the CD56dim NK cells, which are enriched in the peripheral blood 
(88, 89), constitute the final stage of NK cell differentiation, which is completed outside of 
the SLT. The acquisition of the inhibitory receptor CD94/NKG2A in the CD56bright NK cell 
stage in SLT is important because this developmental stage begins to acquire cytotoxicity, 
including perforin-mediated and Fas ligand-mediated killing, and inflammatory cytokine 
production (90). There is reasonable evidence that CD56bright NK cells further develop into the 
CD56dim subset (91-93), but the factors driving this process remain unknown.  
The blood NK cell compartment is mainly composed of the two well-characterized 
functional CD56bright CD16- and CD56dim CD16+ subsets (94). The former NK cell subset 
produces large amounts of cytokines upon monokine stimulation, acquires cytotoxicity only 
after prolonged activation and is enriched in secondary lymphoid organs (88). The latter NK 
cell subset readily kills susceptible targets and can rapidly secrete IFN-γ upon engagement of 
activating receptors (95). 
 
Figure 11: Phenotype and functions of CD56bright CD16- (a) and CD56dim CD16+ (b) NK 
cells (adapted from (96)) 
 
Moreover, both NK cell subsets significantly differ in expression of inhibitory receptors, 
chemokine receptors and cytokine receptors (Fig. 11). Indeed, CD56bright CD16- NK cells 
express NKG2A, but no KIRs, homing receptors for SLT (CD62L and CCR7) and the high-
affinity IL-2 receptor (IL2Rαβγ). On the other hand, the CD56dim CD16+ NK cells display the 
full set of inhibitory receptors, with variegated expression of NKG2A and one or multiple 
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KIR haplotypes (97). Moreover, Juelke et al. reported the presence in peripheral blood of 
CD56dim CD62L+ NK cells, which exhibited intermediate phenotype and functionality, 
compared to CD56bright and CD56dim CD62L- NK cells (98).  
A growing body of evidence indicates that NK cell differentiation continues within the 
mature CD56dim NK subset, as demonstrated by in vitro experiments and longitudinal studies 
of patients with acute viral infections. Indeed, discrete maturation stages of CD56dim NK cells 
can be assessed by expression of the two types of inhibitory receptors NKG2A and KIRs (Fig. 
12 and 13), spanning from the early-differentiated CD56dim NKG2A+ KIR- to the late 
differentiated CD56dim NKG2A- KIR+ (99, 100). 
 
 
Figure 12: Gating strategy to assess CD56dim differentiation stages in peripheral blood 
by flow cytometry.  
 
Recently, CD57 has been proposed as a marker of terminal differentiation of CD56dim NK 
cells (100, 101) and has been shown to be up-regulated on proliferating CD56dim NKG2C+ NK 
cells after acute infection with CMV (102), hantavirus (103) and chikungunya virus (104). 
Terminally differentiated CD57+ CD56dim NK cells exhibit increased cytotoxicity, but 
decreased proliferative capacity and responsiveness to cytokines in vitro. 
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Figure 13: Proposed model of NK cell differentiation in peripheral blood (adapted from 
(100)). Differentiation of CD56dim NK cells is hallmarked by sequential, but not linear, loss of 
NKG2A and acquisition of single or multiple KIRs, as well as up-regulation of CD57. 
 
3.2.3. Antiviral role of NK cells 
The protective role of NK cells against several types of viruses in mouse models is well 
accepted and has been extensively characterized mainly in mouse cytomegalovirus (MCMV) 
infection (105). From this model, we know that NK cells play a non-redundant role, which is 
exclusively conferred upon a well-defined NK cell subset bearing the Ly49H receptor. This 
activating receptor was shown to directly bind to the viral protein (m157) expressed on the 
surface of virus-infected cells.  
Recently, several groups reported the generation of memory-like NK cell responses during 
allergic reactions (106) and viral infections (107, 108) in experimental mice. In the MCMV 
model, Ly49H+ NK cells exhibit adaptive-like immune responses similar to those described 
during antigen-specific T cell responses. Indeed, this NK cell subset exhibits over the course 
of MCMV infection the five phases observed during memory immune responses, namely 
clonal expansion, contraction, persistence of functional memory cells in tissues and finally 
recall or enhanced secondary responses upon viral re-challenge. NK cells combine, thus, 
functions that are attributes of both innate and adaptive immunity, blurring the borders 
between these two arms of the immune response (109). 
In humans, the role of NK cells in viral infections is less clear because of the extreme rarity of 
patients with isolated NK cell deficiencies. Nevertheless, these patients, which possess normal 
T cell responses, exhibit an increased susceptibility to viral infections, mainly to 
herpesviruses (110). This suggests a potential non-redundant function of NK cells, which 
obviously cannot be confirmed in immunocompetent individuals. However, new models of 
mice with human immune system components have been proven useful to study the early 
innate human NK cell responses during infections with human viruses such as EBV (111, 
112).  
Recent longitudinal studies of patients with acute viral infections have reported the 
preferential expansion of a defined NK cell subset in peripheral blood. Indeed, acute 
cytomegalovirus (CMV) and hantavirus virus infections elicit the persistent accumulation of 
the late-differentiated CD56dim NKG2C+ NK cell subset. Interestingly, CD56dim NKG2C+ NK 
cells are found at increased counts in CMV-positive individuals (113) and preferentially 
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proliferate upon exposure of CMV-infected fibroblasts to PBMCs in vitro (114). 
Nevertheless, none of these studies could show that the expanding NK cell subset can directly 
target CMV- or hantavirus-infected cells. Therefore, it remains unclear if such expansions of 
NK cell subsets might be protective or just a bystander inflammatory response with potential 
detrimental effects (115). 
Several lines of evidence indicate a potential role of NK cells in EBV infection. 
Firstly, overall NK cell numbers expand during IM (17, 116-119); secondly, a subset of NK 
cells, which is enriched in the tonsils, restricts the EBV-driven transformation of B cells 
(120); thirdly, NK cells can kill lytically-replicating B cells in vitro (121); fourthly, a recent 
report on XMEN patients which suffer from chronic EBV infection, Mg2+ deficiency and 
neoplasia, highlighted the non-redundant role of the activating NK cell receptor NKG2D in 
the control of this tumor-associated virus (122); and finally, NK cells exhibit a protective role 
in humanized mice infected with EBV (123). Nevertheless, the contribution of particular NK 
cell subsets to the immune control of EBV, especially during primary infection, remains 
elusive. 
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4. SUBJECT OF INVESTIGATION 
 
We postulated that inefficient innate immune control mediated by NK cells allows EBV to 
initially replicate to higher viral loads leading to stronger stimulation and expansion of the T 
cell compartment as observed in IM (124). Moreover, this NK cell-mediated immune control 
might be optimal during early childhood, but impaired in older individuals. Indeed, NK cells 
from children younger than 5 years might better restrict EBV during the early phase of 
infection and therefore decrease the number of EBV infected B cells compared to teenagers 
and adults. This decreased antigenic load will ultimately elicit less T cell stimulation during 
the adaptive immune response (Fig. 14). 
 
 
 
 
 
 
Figure 14: Hypothesis for IM. Age-dependent NK cell deficiency in EBV immune 
control predispose for infectious mononucleosis. Impaired NK cell-mediated early immune 
control of EBV in individuals older than 5 years leads to increased numbers of EBV-infected 
B cells, which will elicit the extensive T cells responses associated with IM symptoms. 
 
The subject of this thesis was to investigate the NK cell response during acute primary 
symptomatic EBV infection or infectious mononucleosis (IM), the specific NK cell-mediated 
recognition of both EBV life forms (lytic vs. latent) and to assess possible age-related changes 
in the phenotype or function of NK cells that could influence the early immune control of 
EBV and therefore the course of primary infection. We also aimed to better understand the 
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NK cell-mediated immune control of EBV in the tonsils and to assess which factor might 
influence the balance between EBV lytic and latent cycles in this secondary lymphoid organ.  
  
To address this subject, the following topics were investigated: 
 
1) Do possible age-related changes in the phenotype and function of NK cell alter the 
recognition of EBV-infected B cells at different ages of life and therefore influence the 
course of primary EBV infection? 
 
Primary EBV infections before 5 years of age often run an asymptomatic course. Older 
individuals have however an increased risk of developing symptomatic primary infection, i.e. 
infectious mononucleosis, which is associated with an increased risk to develop autoimmune 
diseases and EBV-positive tumors. Age-related differences in immune responses have been 
described, but such differences have not been assessed in the context of NK cell-mediated 
immune control of EBV. Thus, we investigated the age-related changes in the distribution of 
blood NK cell subsets, in the expression of different sets of NK cell receptors and in the in 
vitro responses of NK cells against EBV-infected B cells. 
 
2) Does a particular NK cell subset expand and accumulate in peripheral blood of 
patients with acute IM, and if yes, which EBV infection programs does this NK cell 
subset specifically target? 
 
Several reports of patients with acute viral infections have described the accumulation of a 
specific NK cell subset in peripheral blood, but none of these studies could demonstrate a 
direct recognition of the infected cells by the expanding NK cell subset. The role of NK cells 
in the immune control of EBV during primary infection remains largely unknown. Thus, we 
longitudinally studied the NK cell responses during infectious mononucleosis and 
comprehensively assessed the accumulation, maturation and proliferation of each NK cell 
subset over the course of primary infection. Furthermore, we tested their reactivity against 
infected B cells with latent or lytic EBV infection in vitro and their ability to proliferate in an 
in vitro model of primary EBV infection. 
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5. RESULTS 
 
NK cell cytotoxic degranulation against EBV transformed B cells does not differ with 
age 
 
Primary EBV infection is asymptomatic in children < 5 years of age, but it may manifest as 
infectious mononucleosis in older individuals. The reason for this age-dependent 
predisposition to IM is unknown. We postulated that NK cell-mediated early immune control 
of EBV is impaired in individuals > 5 years of age compared to younger children. A 
decreased NK cell-mediated immune control might be caused firstly by a decreased frequency 
of a functional NK cell subset within the bulk NK cell population, which might be protective 
during EBV infection; secondly, this might be explained by an impaired NK cell-mediated 
recognition of EBV-infected cells with either latent or lytic EBV replication or both; thirdly, 
since some activating receptors have been shown to be involved in the NK cell-mediated 
recognition of EBV-transformed B cells and or EBV-infected B cells with lytic replication, an 
age-dependent decrease in the surface expression of such receptors might lead to decreased 
NK cell responses. 
 
We first compared the frequencies of the two main NK cell subsets found in the peripheral 
blood, CD56bright CD16- and the CD56dim CD16+, in healthy uninfected individuals with 
different ages, from the newborn to the young adult (Fig. 14). The former subset has been 
shown to restrict the EBV-driven transformation of B cells via secretion of IFN-γ (120). On 
the other hand, the latter subset might play a role in the killing of EBV-infected cells with 
lytic reactivation (121). 
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Figure 14: Frequencies of CD56bright CD16- and the CD56dim CD16+ subsets in healthy 
individuals with different ages. PBMCs from newborns (cord blood mononuclear cells or 
CBMCs, n=10), from children aged 1-5 years (n=26), from children and teenagers 5-15 years 
(n=29) and from adults aged 20-30 years (n=19) were stained with monoclonal antibodies 
(mAb) and assessed by flow cytometry (see Fig. 12). 
 
 
We observed a decrease in the frequencies of the cytokine-secreting CD56bright CD16- subset 
with increasing age and the opposite pattern for the CD56dim CD16+ subset. This could 
indicate that younger children might better control the EBV transformation of B cells in 
peripheral blood during acute EBV infection. However, EBV gene expression associated with 
transformation has only been observed in the tonsils (25), and not in the peripheral blood 
during acute IM, and IM elicits the preferential accumulation in peripheral blood of a 
CD56dim NK cell subset (see manuscript 1). Therefore, it might be interesting to assess the 
frequencies of these NK cell subsets in the tonsils from healthy individuals with different ages 
in future studies. 
 We next assessed the surface expression level of activating NK cell receptors involved 
in the recognition of EBV-infected cells in vitro on CD56dim NK cells from individuals with 
different ages. Indeed, the expression level of such triggering receptors was shown to 
positively correlate with the magnitude of NK cell activation and cytotoxicity (125). NK cell 
recognition of lymphoblastoid cell lines (LCLs; latent EBV) is mainly mediated by 2B4 
(receptor for CD48) and by LFA-1 (receptor for ICAM1), and both ligands are known to be 
up-regulated on transformed EBV-infected B cells (126, 127). 
Additionally, NK cell-mediated killing of EBV-positive Burkitt lymphoma cells with lytic 
reactivation is impaired upon blocking of the NKG2D ligand ULBP1 and the DNAM1 ligand 
CD112, suggesting an important role of these triggering receptors in the control of EBV lytic 
replication (121).  
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Figure 15: Surface expression level of activating NK cell receptors involved in 
recognition of latent EBV, i.e. 2B4 and LFA-1, and of lytic EBV, i.e. NKG2D and 
DNAM1 in healthy individuals with different ages. PBMCs from children aged < 5 years, 
children aged 5-15 years and adults aged 20-30 years were stained with mAb and analyzed by 
flow cytometry. The mean fluorescence intensities (MFI) of each receptor were quantified on 
CD56dim NK cells using FlowJo. 
 
We observed no significant age-related changes in the expression of these triggering receptors 
(Fig. 15), suggesting that EBV-infected B cells expressing activating ligands might elicit a 
similar cytotoxicity from NK cells at different ages of life. 
We finally investigated the in vitro responses of NK cell from individuals with 
different ages against LCLs. For this assay, we used the allogeneic MHC class I competent 
LCL 721.45 as target cells, which resembles autologous LCLs in terms of activating ligands, 
but differs in MHC class I haplotype expression (indicating possible mismatch KIRs-HLA 
class I). We included additionally the MHC class I deficient LCL 721.221 and the MHC class 
I deficient erythroleukemia cell line K562 as controls. We assessed the cytotoxic 
degranulation (CD107a mobilization) of CD56dim NK cells from healthy individuals at 
different age of life (Fig. 16). 
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Figure 16: Cytotoxic degranulation of CD56dim NK cells upon co-culture with different 
target cells. Freshly isolated PBMCs were stimulated overnight with 100 U/ml rIL-2 and 
were co-cultured the next day with LCL721.45 (MHC class I positive), LCL721.221 (MHC 
class I negative) or K562 (MHC class I negative) at an effector to target (E:T) ratio of 10:1 for 
6 hours. Frequencies of degranulating CD107a+ cells within the CD56dim NK cells were 
assessed by flow cytometry at the end of the co-culture. 
 
The cytotoxic degranulation of CD56dim NK cells against MHC class I deficient target cells 
(LCL721.221 and K562) increased by more than 2-fold from early childhood to adulthood. 
This pattern fits with the age-related increase in the frequency of CD56dim KIRs+ (see 
manuscript 1), which might better target MHC class I deficient cells. We observed an overall 
low cytotoxic degranulation against the MHC class I competent LCL 721.45 and no 
significant changes with age. This low response is explained by the EBV-driven up-regulation 
of MHC class I (HLA A, B, C) and HLA-E molecules (Fig. 17) on EBV infected B cells 
(128), which deliver strong inhibitory signals to the NK cell. 
 
 
B"cells"
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Figure 17: HLA class I and HLA-E expression levels on EBV-infected B cells (red 
histogram) and autologous uninfected B cells (blue histogram). LCLs from one donor 
were generated by infection with wildtype B95.8 EBV of primary B cells and cultured for one 
month. Autologous PBMCs were thawed and cultured overnight. The next day, LCLs and 
autologous PBMCs were stained with mAb and analyzed by flow cytometry. HLA class I and 
HLA-E expression were assessed on CD19+ B cells using Flow Jo. 
 
 
Altogether, we could not demonstrate any age-related changes in the NK cell reactivity to 
infected B cells with latent EBV (LCLs). It would be important to also test the age-related NK 
cell responses against infected B cells with lytic replication, since the switch from latent to 
lytic EBV replication has been shown to enhance the NK cell responses (121). This effect has 
been shown to be mediated by down-regulation of inhibitory surface ligands (MHC class I 
and HLA-E) and up-regulation of activating ligands (ULBP-1 and CD112) during EBV lytic 
replication (121). However, one would need to test these NK cell responses against target 
cells with EBV lytic replication in an autologous setting in order to avoid possible biases from 
KIR-HLA class I haplotype mismatches. 
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CLINICAL STUDY DESIGN 
 
Recruitment of case patients and control subjects 
Pediatric patients (age 1-16 years) presenting between October 2010 and April 2013 on the 
emergency department of the University Children’s Hospital of Zurich with suspected IM 
were invited to participate in the study. Patients and parents were informed about the clinical 
study protocol orally by the responsible physician and in writing using a patient information 
sheet. Informed consent were obtained either from the patient himself depending on his age 
and from his parents. 
Pediatric patients (age 1-16 years) undergoing elective tonsillectomy for tonsilar 
hypertrophy or recurrent tonsillitis at the University Children’s Hospital of Zurich were 
invited to participate in the study. Patients and parents were informed about the clinical study 
protocol orally by the ORL specialists at the preoperative consultation and in writing using a 
patient information sheet. Informed consent were obtained either from the patient himself 
depending on his age and from his parents. The tonsils and 2-5 ml of peripheral blood were 
obtained from each participant during the tonsillectomy. Blood samples were used as controls 
for flow cytometry analysis. 
Healthy adults aged 20 to 30 years working at the University Children’s Hospital of 
Zurich were invited to participate in the study. They were informed about the clinical study 
protocol orally by the research staff. Co-workers who gave informed consent donated 10-20 
ml of peripheral blood. Blood samples were used as controls for flow cytometry analysis. 
 
Ethics approval 
This study was conducted in accordance with the Declaration of Helsinki and was approved 
on 31th May 2010 by the regional ethics committee in Zurich, Switzerland (Reference 
number EK: StV 40/05). 
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Clinical study protocol 
 
 
 
Footnotes: 1IM symptoms included fever, tonsillitis, generalized lymphadenopathies, 
hepatosplenomegaly and fatigue. 2Blood samples obtained on the emergency department 
included complete blood counts, serum sample for EBV PCR and serologies, as well as 5-15 
ml heparinized peripheral blood for study analysis. 3Mouth wash samples were obtained after 
gargling with 5 ml of phosphate-buffered saline. 4Manual blood counts were used to assess 
lymphocytosis as well as the presence of atypical lymphocytes (representing activated T 
cells). 5Monotest was used to assess the presence of heterophile IgM antibodies. 6EBV 
serology was assessed using IgM anti-VCA, IgG anti-VCA and IgG anti-EBNA1. 
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KEY POINTS  
• Early-differentiated NK cells accumulate and proliferate during infectious mononucleosis 
• These early-differentiated NK cells preferentially target lytic EBV infected B cells in vitro 
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ABSTRACT 
A growing body of evidence suggests that the human natural killer (NK) cell compartment is 
phenotypically and functionally heterogeneous and composed of several differentiation 
stages. Moreover, NK cell subsets have recently been shown to exhibit adaptive immune 
features during herpesvirus infection in experimental mice and to preferentially expand during 
viral infections in humans. However, both phenotype and role of NK cells during acute 
symptomatic Epstein-Barr virus (EBV) infection, termed infectious mononucleosis (IM), 
remain unclear. Here, we longitudinally assessed the kinetics, the differentiation and the 
proliferation of subsets of NK cells in pediatric IM patients. Our results indicate that acute IM 
is characterized by the preferential proliferation of early-differentiated CD56dim NKG2A+ 
KIR- NK cells. Moreover, this NK cell subset exhibits features of terminal differentiation and 
persists at higher frequency over at least the first 6 months after acute IM. Finally, we 
demonstrate that this NK cell subset preferentially degranulates and proliferates upon 
exposure to EBV-infected B cells expressing lytic antigens. Thus, early-differentiated NK 
cells might play a key role in the immune control of primary infection with this persistent 
tumor-associated virus. 
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INTRODUCTION 
Natural killer (NK) cells are a subset of innate lymphocytes that exhibit non-redundant 
antiviral functions in experimental mice (105). In mice infected with the murine 
cytomegalovirus (MCMV), a subset of NK cells bearing the activating receptor Ly49H 
expands and persists at increased frequency for more than 2 months following primary 
infection. Notably, these cells display an enhanced protective response against MCMV in 
adoptive transfer experiments (108). In humans, the peripheral blood compartment of NK 
cells is heterogeneous and accounts for 5 to 15 % of lymphocytes. It is composed of diverse 
differentiation stages, which can be defined by the expression of surface markers, such as the 
two types of inhibitory receptors NKG2A and killer-cell immunoglobulin-like receptors 
(KIRs) (99, 100). Human NK cells seem to play an important antiviral role since patients with 
isolated NK cell deficiencies exhibit an increased susceptibility to herpesviruses (110). 
Furthermore, patients with acute viral infections due to hantavirus, cytomegalovirus, or 
chikungunya virus (102-104) accumulate the late-differentiated CD56dim NKG2C+ KIR+ NK 
cell subset in peripheral blood. However, none of these previous studies demonstrated a 
protective role for specifically accumulated human NK cell subsets against virus-infected 
cells in vitro or in vivo (99, 100). 
A ubiquitous persistent human virus, which has not been investigated in detail in this 
respect, is the primarily B-cell-tropic Epstein-Barr virus (EBV). EBV is a γ-herpesvirus, 
which latently infects the vast majority of the adult human population worldwide, and is 
associated with B cell and epithelial cell malignancies (130). EBV displays two modes of 
infection. One mode expresses latency genes (latent EBV) leading to B cell transformation in 
vitro and subsequent generation of lymphoblastoid cell lines (LCLs). The other mode 
expresses lytic genes (lytic EBV) leading to production of infectious viral particles and lysis 
of the host cell (131). Most primary EBV infections occur before the age of 5 years and are 
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usually asymptomatic. Nevertheless, primary EBV infection occurring beyond this age may 
manifest as infectious mononucleosis (IM) that affects around 10% of the population in 
Europe and the US (17, 132). The usually self-limiting IM is characterized by a vigorous 
CD8+ T cell response that mainly targets EBV lytic epitopes (35) and is associated with an 
increased risk of developing EBV-positive classical Hodgkin lymphoma (46).  
The contribution of particular NK cell subsets to the immune control of EBV, 
especially during primary infection, remains elusive. Here, we examined how blood NK cell 
subsets accumulate and respond during IM, and to which extent they can recognize latently 
and lytically EBV-infected B cells. 
 
MATERIAL AND METHODS 
Study design.  
Twenty-two pediatric patients diagnosed with acute IM at the University Children’s 
Hospital of Zurich were prospectively enrolled between October 2010 and April 2013. The 
date of symptoms onset was used as reference for the longitudinal study. Twelve pediatric 
patients with IM symptoms, but lacking the serological pattern compatible with acute EBV 
infection, were also enrolled (IM-like) and donated peripheral blood at diagnosis. All serum 
samples from IM-like patients were negative for HCMV DNA. Healthy children and healthy 
adults aged 20 to 30 years were used as healthy controls according to their EBV serology. 
Further details are outlined in supplemental data. 
All participants gave informed consent, and the institutional ethics committee 
approved all protocols used.  
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Monoclonal antibodies and flow cytometry.  
Samples were acquired on a FACSCanto II and a LSR Fortessa (BD Biosciences). Details of 
handling of PBMCs, flow cytometry analysis and antibodies used are described in 
supplemental data. 
   
Cell lines.  
Preparation of viral stocks, cell lines used and induction and isolation of lytic AKBM cells as 
well as the degranulation assay are described in supplemental methods.  
 
Viral loads quantification.  
EBV DNA levels were determined by real-time PCR. The details of viral load measurements 
are outlined in the supplemental methods.  
 
Statistical analysis.  
Data were analyzed using Prism software (GraphPad Software, Inc.). P-values of < 0.05 were 
considered significant and calculated with the nonparametric Mann-Whitney test or the 
Wilcoxon matched-pairs signed ranks tests. Spearman’s rank correlation was used to examine 
associations between two quantitative values. 
 
RESULTS 
Pediatric acute IM patients exhibit accumulation of activated CD8+ T cells and CD56dim 
NK cells. 
In young adults, IM is characterized by vigorous T cell responses mediated mainly by EBV-
specific CD8+ T cells (35). Nevertheless, neither T cell nor NK cell responses in pediatric IM 
have been characterized. Since we examined pediatric IM patients only, we first assessed the 
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dynamics of the T cell and NK cell subset responses in pediatric patients over the first 6 
months of IM. Uninfected healthy individuals and pediatric patients with IM-like diseases 
were used as controls. Acute IM patients exhibited a 2-fold increased median frequency of 
CD8+ T cells (Figure 1A), a 15-fold increased median frequency of activated CD8+ T cells 
(Figure 1B) and 60-fold increased median HLA-DR+ CD8+ T cell counts (data not shown) 
compared to controls. The numbers of activated T cells normalized within 6 months. These 
changes paralleled those of the cellular EBV DNA levels over time (Figure 1C). Neither EBV 
DNA levels nor frequency of CD8+ T cells correlated with age (Supplementary Figure 1). 
Therefore, pediatric IM patients as young as 2 years of age seem to exhibit the classical 
immunological features found in young adults with IM.  
Moreover, we observed a 1.7-fold increase in the median numbers of NK cells in acute 
IM compared to controls. These numbers returned to baseline levels after one month (Figure 
1D). The blood NK cell compartment is mainly composed of two well-characterized 
functional subsets, the CD56bright CD16- and the CD56dim CD16+ subsets (94). The former NK 
cell subset produces large amounts of cytokines upon monokine stimulation, acquires 
cytotoxicity only after prolonged activation, and is enriched in secondary lymphoid organs 
(88). The latter NK cell subset readily kills susceptible targets and can rapidly secrete IFN-g 
upon engagement of activating receptors (95). Acute IM patients displayed unchanged counts 
of CD56bright CD16- NK cells (Figure 1F) and a 1.2-fold increase in the median count of 
CD56dim CD16+ NK cells (Figure 1H) compared to controls. Interestingly, the intermediate 
NK cell subset CD56dimCD16- was increased in frequency during acute IM (Figure 1E and 
supplementary Figure 2A) and exhibited a 3.7-fold increase in median cell counts compared 
to controls (Figure 1G). Thus, we found a selective increase of the total CD56dim NK cell 
subset during acute IM.  
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Early-differentiated CD56dim NKG2A+ KIR- NK cells accumulate during IM and 
terminally differentiate as well as persist afterwards.  
To dissect the CD56dim NK cell subset, we analyzed the expression patterns of the inhibitory 
receptors NKG2A and KIRs, which might allow assessment of subtle maturation stages 
spanning from early-differentiated CD56dim NKG2A+ KIR- to late-differentiated CD56dim 
NKG2A- KIR+ NK cells (99, 100). Acute IM patients exhibited a 1.8-fold increased median 
frequency of CD56dim NKG2A+ KIR- NK cells (Figures 2A and 2B), but a 1.5-fold reduced 
median frequency of CD56dim NKG2A- KIR+ NK cells compared to EBV-negative and EBV-
positive control individuals (Figure 2C). Moreover, acute IM patients displayed 4.8-fold and 
3.5-fold increased median absolute numbers of CD56dim NKG2A+ KIR- NK cells compared to 
EBV-negative and EBV-positive control individuals, respectively (Supplementary Figure 2B), 
but unchanged cell counts of the late-differentiated CD56dim NKG2A- KIR+ NK cells. We 
observed no major changes in the frequencies and cell counts of the CD56dim NKG2A- KIR- 
and CD56dim NKG2A+ KIR+ NK cell subsets (Supplementary Figures 2B and 2C). 
Furthermore, IM-like patients, i.e. patients with IM symptoms but no acute EBV infection, 
did not exhibit NK cell subset accumulation similar to that of IM patients. We did not find 
any differences in the frequency of this NK cell subset between EBV-seronegative and EBV-
seropositive control individuals. Surprisingly, the frequency of CD56dim NKG2A+ KIR- NK 
cells remained significantly elevated in longitudinally followed IM patients up to 6 months 
after acute IM, but returned to baseline after 2 years (Figure 2B). 
Recently, CD57 has been proposed as a marker of terminal differentiation of NK cells 
(100, 101) and has been shown to be up-regulated on CD56dim NKG2C+ NK cells during acute 
infection with CMV, hantavirus or chikungunya virus (102-104). Therefore, we hypothesized 
that if the accumulated CD56dim NKG2A+ KIR- subset found in acute IM patients is 
preferentially involved in the immune response against EBV, it should acquire CD57 during 
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the acute phase of IM to complete its terminal differentiation. Indeed, we observed a 2.5-fold 
increase in the median frequency of CD57+ within the CD56dim NKG2A+ KIR- subset from the 
acute IM phase to one month later, but no changes in the CD56dim NKG2A- KIR+ subset 
(Figures 2D and 2E, respectively). Thus, acute symptomatic EBV infection elicits the specific 
accumulation of the CD56dim NKG2A+ KIR- NK cell subset, its terminal differentiation as 
well as its persistence at higher frequency over the first 6 months after acute IM. 
 
IM patients exhibit a stable KIR repertoire and unchanged frequencies of CD56dim 
NKG2C+ NK cells.  
The KIR repertoire is composed of several activating and inhibitory receptors specific for 
distinct groups of HLA class I alleles (76), is highly variable among individuals and is stable 
over time in healthy adults (133). Particular KIR receptors might be involved in the immune 
control of viruses such as the human immunodeficiency virus (HIV) (134-137), the hepatitis 
C virus (HVC) (138, 139) or CMV (133, 140). Therefore, to exclude that IM does not lead to 
an accumulation of NK cells bearing specific KIRs, we performed a comprehensive 
phenotypic KIR analysis (141) in a group of CMV-seronegative healthy controls and IM 
patients. The KIR repertoire of IM patients remained stable over the first month of IM (Figure 
3A) and the frequencies of single KIR+ CD56dim NK cells in IM patients were overall low 
compared to controls (Figure 3B). Thus, IM is associated with the accumulation of a CD56dim 
NKG2A+ NK cell subset, which does not carry any increase in activating, nor inhibitory KIR 
molecule expression. Furthermore, CD56dim NK cells expressing NKG2C, the activating 
counterpart of NKG2A (78), accumulate upon CMV infection (102, 113, 142), as well as 
upon other viral infections in CMV-positive individuals (103, 104, 143-145). Thus, we 
assessed if a similar   accumulation takes place upon EBV infection and therefore investigated 
CMV-seronegative IM patients and controls to avoid bias associated with CMV carriage 
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(146). We observed no changes in the frequency of NKG2C+ NK cells within the CD56dim 
NKG2A- NK cell subset (Figure 3C and 3D) nor within the expanding CD56dim NKG2A+ 
KIR- NK cell subset (data not shown). Thus, CD56dim NKG2A+ KIR- NKG2C- NK cells 
accumulate during IM. 
 
The preferential proliferation of CD56dim NKG2A+ KIR- NK cells positively correlates 
with cellular EBV loads during acute IM.  
We next investigated whether the increase in the absolute numbers of CD56dim NKG2A+ KIR- 
NK cells might be caused by active proliferation of this NK cell subset. We assessed the 
expression of the proliferation marker Ki-67 in the CD56bright, the CD56dim NKG2A+ KIR- and 
the CD56dim NKG2A- KIR+ NK cell subsets in acute IM and one month later. We found a 2-
fold and a 3-fold increase in the median frequency of Ki-67+ cells within the CD56dim 
NKG2A+ KIR- NK cells in acute IM compared to controls and IM 1 month, respectively 
(Figures 4A and 4B). However, we did not observe any increased proliferation in the more 
differentiated NKG2A- KIR+ NK subset and there was no difference when comparing EBV-
negative with EBV-positive controls (Figures 4A and 4B and data not shown). In addition, the 
precursor CD56bright NK cell subset, which exhibits strong proliferation properties and 
responds to minute doses of cytokines in vitro, did not show an increased frequency of Ki-67+ 
cells in acute IM patients (Figure 4B). Notably, the frequencies of proliferating Ki-67+ cells 
within the CD56dim NKG2A+ KIR- positively correlated with EBV DNA levels in PBMCs 
(Figure 4C), but not in serum (data not shown). No such correlation was observed within the 
CD56dim NKG2A- KIR+ NK cell subset. This suggested that the proliferation of early-
differentiated CD56dim NK cells might be directly driven by EBV-infected B cells in IM 
patients. We next asked whether the proliferation of the CD56dim NKG2A+ KIR- NK cell 
subset differs according to CD57 expression. Surprisingly, proliferation was exclusively 
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found within the CD57- fraction (Fig. 4D and 4E). Our finding is in line with previous studies 
showing a decreased proliferative potential of CD57+ NK cells compared to CD57- NK cells 
(100, 101). Thus, CD56dim NKG2A+ KIR- CD57- NK cells seem to preferentially proliferate 
during acute IM but not one month later. Moreover, in the acute phase, proliferation parallels 
the accumulation of this NK cell subset which displays a 7-fold and a 4.8-fold median 
increase compared to EBV-negative and EBV-positive controls, respectively (Figure 4F). In 
addition, CMV status did not seem to influence the NK cell response (Supplementary Figure 
3). We did not observe any correlation between the count of the CD56dim NKG2A+ KIR- 
CD57- NK cells, nor the count of total NK cells, and the EBV DNA levels in PBMCs or in 
serum (data not shown). Thus, early-differentiated NK cells accumulate in IM patients after 
EBV-driven proliferation. 
 
CD56dim NKG2A+ KIR- NK cells preferentially target EBV-infected B cells with lytic 
reactivation.  
CD56dim NKG2A+ KIR- NK cells are functional against HLA-class-I-deficient target cells, 
including the EBV-positive LCL 721.221 cell line (99), but their reactivity towards HLA 
class I competent autologous LCLs has not been assessed yet. We observed a low overall 
frequency of degranulating NK cells upon co-culture with autologous LCLs. Nevertheless, the 
CD56dim NKG2A+ KIR- NK subset, which accumulates during IM, displayed a more than 2-
fold increase in degranulation compared to the CD56bright and CD56dim NKG2A- KIR+ NK cell 
subset (Figure 5A). In contrast, the EBV-negative allogeneic B-cell line L428, which exhibits 
an activated phenotype comparable to LCLs, elicits an increased response in the CD56dim 
NKG2A- KIR+ NK subset only (Figure 5B). This low NK cell response against autologous 
LCLs might be due to their high surface level of HLA class I and HLA-E which might engage 
the NK cell inhibitory receptors KIR and NKG2A, respectively. Indeed, EBV-infected B cells 
up-regulated HLA class I (147) and HLA-E (Figure 5C).  
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On the other hand, induction of the lytic cycle of EBV infection has been shown to 
sensitize EBV-infected B cells to NK cell killing using the EBV-positive Akata Burkitt 
lymphoma (BL) reporter cell line AKBM (121), which allows the purification of BL cells 
with and without EBV lytic reactivation, respectively. Hence, we tested the degranulation of 
the CD56dim NKG2A+ KIR- NK subset against either latent AKBM or lytic AKBM cells from 
convalescent IM patients and healthy EBV-positive controls and compared it to the CD56bright 
and the CD56dim NKG2A- KIR+ subsets. In order to avoid HLA class I/KIR mismatch bias, we 
specifically assessed the degranulation in KIR+ matched (KIR2DL2/DL3/3DL1+) NK cells 
according to the AKBM genotype (Bw4/C1/C1). We could confirm increased responses of 
NK cells against lytic compared to latent AKBM cells (Figure 5D to 5F) previously shown to 
be mediated by a down-regulation of the inhibitory ligands HLA-class I and HLA-E and an 
up-regulation of the activating ligands CD112 and ULBP-1 (121). Similarly, we also found 
increased expression of activating ligands on lytic EBV infected LCLs (Supplementary Figure 
4D to 4G), however the expression of the respective activating receptors in the CD56dim 
NKG2A+ KIR- NK cell subset was unaltered in IM patients (Supplementary Figure 4A to 4C). 
Importantly, the CD56dim NKG2A+ KIR- NK cell subset exhibited a significantly stronger 
degranulation against lytic AKBM cells compared to all other subsets (Figure 5F). We found 
no difference in the degranulation capacity of CD56dim NKG2A+ KIR- NK between 
convalescent IM patients and controls, suggesting that these NK cells are functional and not 
in an exhausted state in the aftermath of acute IM. Thus, CD56dim NKG2A+ KIR- NK cells 
preferentially recognize lytic EBV replicating B cells. 
 
EBV lytic replication triggers in vitro proliferation of NKG2A+ KIR- NK cells.  
Finally, we examined the proliferation of NKG2A+ KIR- NK cells using staining for Ki-67 
(148) in an in vitro model of primary EBV infection of cord blood mononuclear cells 
(CBMC) infected with either wildtype (WT) EBV or lytic replication incompetent BZLF1-
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KO (BZ1KO) EBV. Both viruses elicited similar IFN-type I responses 24 hours post-infection 
(Figure 6A) and exhibited comparable infection capacity, as evaluated by the frequencies of 
GFP+ EBV-infected B cells 3 days post-infection (Figure 6B). Since most NK cells up-
regulated CD56 surface expression during in vitro culture (Figure 6C, first row), we did not 
distinguish between the CD56bright and CD56dim NK cells for further analysis. We observed an 
increased proliferation of NKG2A+ KIR- NK cells 7 days after infection with WT EBV 
compared to mock (Figure 6C and 6D). Infection with BZ1KO EBV, with abolished 
expression of all EBV lytic antigens, elicited a twofold reduced proliferation of NKG2A+ 
KIR- NK cells, in comparison to WT EBV (median ratio 2.9 vs. 6.3, P=0.04). This indicates 
that the proliferation of NKG2A+ KIR- NK cells partially depends on the presence of EBV-
infected cells expressing lytic antigens. Notably, NKG2A- KIR+ NK cells exhibit similar 
proliferation upon infection with WT EBV, but this is not affected by the absence of lytic 
antigens (data not shown). Finally, we assessed a possible age-dependent distribution of this 
early-differentiated NK cell subset in peripheral blood from healthy individuals that might 
correlate with the known age-dependent prevalence of primary symptomatic EBV infection. 
Indeed, CD56dim NKG2A+ KIR- NK cells both decreased in frequency (Figure 6E) and in 
absolute numbers (Figure 6F) over the first decade of life, while the counts of CD56dim 
NKG2A- KIR+ NK cell remained unchanged with age (data not shown). Thus, CD56dim 
NKG2A+ KIR- NK cells, which decrease in frequency in the first decade of life, preferentially 
degranulate and proliferate in response to lytic EBV replicating B cells. 
 
DISCUSSION 
Here we demonstrate in longitudinally followed pediatric IM patients that an early-
differentiated CD56dim NKG2A+ KIR- NK subset selectively accumulates during primary 
symptomatic EBV infection and persists at increased frequencies for months. Moreover, our 
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data indicates that these NK cells specifically recognize B cells undergoing lytic EBV 
replication. Our findings are unprecedented and suggest that responses of NK cell subsets to 
viral infections may not be confined to late-differentiated populations (6-8). Moreover, 
distinct NK cell subsets may be rather pathogen-specific. 
Remarkably, although we found increased counts in the cytotoxic CD56dim NK cell 
subset, but not in the less differentiated CD56bright CD16- NK cell subset, we could not 
confirm the previously reported expansion of CD56bright CD16+ NK cells during acute 
symptomatic EBV infection (119). We rather observed an unusual increase of the 
intermediate CD56dim CD16- NK cell subset, which might be explained by down-regulation of 
CD56 on CD56bright NK cells or by down-regulation of CD16 such as observed in 
degranulating CD56dim NK cells upon co-culture with K562 (unpublished observations). This 
CD56dim NK cell subset is distinctly characterized by NKG2A expression and by the absence 
of KIRs. It strikingly differs from that of other acute viral infections such as CMV, 
hantavirus, or chikungunya virus infection (102-104), in which the CD56dim KIR+ NKG2C+ 
NK cell subset was shown to be expanded. CD56dim NKG2A+ KIR- NK cells are considered 
early-differentiated (99) as suggested by the specific temporal reconstitution of the NK cell 
subsets in hematopoietic stem cell transplanted patients (149-151) and in mice with human 
immune system components (100). Based on our results, ongoing differentiation of these 
early-differentiated NK cells seems to occur during the first weeks of IM; this is further 
supported by studies in EBV-infected mice with human immune system components (62).   
Another striking feature of the IM-associated NK cell response is the persistence of 
elevated frequencies of the CD56dim NKG2A+ KIR- NK cells for up to 6 months long after 
CD8+ T cell numbers have normalized. Nevertheless, we observed no difference in the 
peripheral blood frequencies of these NK cells between EBV-seropositive and EBV-
seronegative control individuals, contrasting the situation after CMV infection where late 
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differentiated NK cells persist at increased levels (113). This might be explained by 
compartmentalized NK cell accumulation during asymptomatic EBV infection, as has been 
proposed for EBV-specific T cell responses in the tonsils (48, 49) and suggests that the acute 
symptomatic EBV infection systemically imprints the NK cell compartment differently. 
Accordingly, CD56bright NKG2A+ and mostly KIR- NK cells were found enriched in tonsils of 
EBV-seropositive compared to EBV-seronegative individuals (16). Indeed, this could result 
from ongoing lytic EBV replication at these sites in asymptomatic EBV carriers (62). 
Additionally, we determined that the increased CD56dim NKG2A+ KIR- NK cell numbers 
during acute IM were caused by the selective proliferation of this subset. Such selectivity has 
not been reported to our knowledge during other acute viral infections. Since the CD56dim 
NKG2A+ KIR- NK subset only actively proliferated during the acute phase of IM and was 
only increased in absolute numbers at this stage, the persistently increased frequency of this 
subset might be caused by either a longer survival of these NK cells in peripheral blood or a 
continuous EBV-driven proliferation in tissues followed by recruitment and accumulation in 
the peripheral blood. Indeed, the numbers of EBV-infected B cells quickly decrease in the 
peripheral blood after acute IM (23) and EBV turns off antigen expression in these cells (24). 
Thus, an EBV-driven proliferation of NK cells during IM convalescence might not be 
expected in peripheral blood. Nevertheless, IM patients exhibit prolonged oral EBV shedding 
up to one year after IM (17, 31), indicating that EBV replication takes place in the 
oropharynx. This, in turn, may result in local EBV-driven proliferation of NK cells after IM 
that are subsequently recruited in peripheral blood. 
Several lines of evidence support the hypothesis that EBV-infected B cells, and not 
proinflammatory cytokines, directly drive the unique proliferation of early-differentiated NK 
cells: firstly, a similar expansion is not observed in patients with IM-like symptoms; secondly, 
the precursor CD56bright NK cell subset, which possesses strong proliferative responses to 
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cytokines, does not display an enhanced proliferation during acute IM; thirdly, the frequency 
of proliferating early-differentiated NK cells positively correlates with EBV loads in blood 
cells. On the other hand, we did not observe any correlation between overall NK cell counts 
and viral load. These findings are in conflict with previous studies reporting a negative 
correlation between NK cell frequencies and counts and cellular EBV DNA levels (119) or a 
positive correlation between NK cell counts and EBV DNA levels in whole blood (17). 
Hence, acute IM elicits the proliferation of CD57- CD56dim NKG2A+ KIR- NK cells, which 
then differentiate to become CD57 positive. A fraction of this subset might represent antigen-
experienced NK cells that specifically responded to EBV-infected cells in a similar fashion as 
during MCMV infection of experimental mice where these NK cells are suggested to 
constitute memory NK cells (108).  
These early-differentiated NK cells exhibit enhanced degranulation against EBV-
infected B cells with lytic reactivation. Reduced HLA-E-mediated inhibitory signals on EBV-
infected cells expressing lytic antigens might lead to preferential recognition by NKG2A+ NK 
cells and could be caused by decreased availability of class I leader signal peptide (121) or via 
direct modulation of HLA-E by EBV-derived peptides (152). In addition to these diminished 
inhibitory signals, we and others have observed an increased expression of activating ligands 
in lytic EBV infection (17) and NKG2D and DNAM1 have been identified as the main 
activating NK cell receptors for the recognition of B cells with lytic EBV infection in vitro 
(17). In good agreement, loss of NKG2D function has been recently found to confer 
susceptibility to uncontrolled EBV infection and neoplasia in XMEN patients in vivo (18). 
How lytic EBV infection leads to the up-regulation of activating ligands, however, remains 
unclear. NKG2D ligands have been reported to get up-regulated upon induction of the DNA 
damage response and cytosolic DNA recognition (63). Although EBV like other 
herpesviruses packages its DNA into the viral capsid in the nucleus during lytic replication, 
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some of it might become accessible during capsid transit through the cytosol and trigger this 
pathway of NKG2D ligand up-regulation. Newly infected B cells transiently express several 
lytic antigens, mostly from the immediate early and early lytic genes (153), and some of these 
antigens might contribute to the proliferation of NKG2A+ KIR- NK cells upon EBV infection 
of CBMCs.  
We suggest that CD56dim NKG2A+ KIR- NK cells preferentially recognize autologous B cells 
with lytic EBV infection, and that recognition of lytic EBV replication drives the 
characteristic NK cell accumulation that we observed in acute IM patients. Since IM only 
manifests in older children, adolescents and young adults with decreased frequencies of this 
herein newly described EBV-reactive NK cell subset, we postulate an age-dependent impaired 
NK cell-mediated immune control of EBV infection as one possible cause of IM. 
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Figure 5. Increased cytotoxic degranulation of the CD56dim NKG2A+ KIR- NK subset against EBV-
infected B cells with lytic replication. (A) PBMCs from 6 healthy EBV-positive donors were 
co-cultured with autologous LCLs and (B) EBV-negative L428 at an effector to target ratio of 10:1 for 6 
hours. Frequencies of degranulating (CD107a+) cells within the CD56bright (Bright), the CD56dim NKG2A+ 
KIR-  (Dim N+/K-) and the CD56dim NKG2A- KIR+ (Dim N-/K+) NK cell subsets were assessed by flow 
cytometry at the end of the co-culture. (C) HLA class I and HLA-E expression on CD19+ B cells from 
PBMCs (light gray histogram) and from autologous LCLs (dark gray histogram). Isotype controls are 
depicted as white histogram. (D) Representative example of frequencies of CD107a+ NK cells within 
the 3 NK cell subsets after co-culture with latent AKBM or lytic AKBM. Frequencies of degranulating 
(CD107a+) NK cells within the CD56bright (Bright), the CD56dim NKG2A+ KIR- (Dim N+/K-) and the CD56dim 
NKG2A- matched KIR+ (Dim N-/K+) NK cell subsets in PBMCs from 3 convalescent IM patients (open 
symbols) and 3 healthy EBV-positive donors (filled symbols) co-cultured with (E) latent AKBM or (F) 
lytic AKBM  (n=6). Horizontal lines indicate median values of a given subset, Wilcoxon matched-pairs 
signed ranks tests.
Bri
gh
t
Dim
 N+
/K-
Dim
 N-
/K+
0
1
2
3
4
5
n.s.
P = 0.03
%
CD
10
7a
+
EBV-negative L428
Bri
gh
t
Dim
 N+
/K-
Dim
 N-
/K+
0
1
2
3
4
5
P = 0.03
n.s.
%
CD
10
7a
+
Autologous LCLs
	  	   59	  
 
A B
C
D
E F
Ne
wb
orn
s
1-5
 ye
ars
5-1
5 y
ear
s
Ad
ults
0
20
40
60
80
P < 0.0001
P = 0.006
n.s.
P = 0.02
%C
D5
6d
im
 NK
G2
A+
 KI
R-
1-5
 ye
ars
5-1
5 y
ear
s
Ad
ults
0
50
100
150
200
250 P = 0.0008
P = 0.0008
n.s.
CD
56
dim
 NK
G2
A+
 KI
R-
 (c
ell
s/µ
l)
WT
 EB
V
BZ
1K
O E
BV
0.0
2.5
5.0
7.5
10.0
P = 0.04
Ki
-67
+ c
ell
s w
ith
in 
NK
G2
A+
 KI
R-
 
(fo
ld 
inc
re
as
e o
ve
r m
oc
k)CD56
3DC
NKG2A
RIK
Ki-67
CSF
0 102 103 104 105
0
102
103
104
105
22
0 102 103 104 105
14.7
0 102 103 104 105
8.2
0 102 103 104 105
24.4
0 102 103 104 105
0
50K
100K
150K
200K
250K
1.5
0 102 103 104 105
9.82
0 102 103 104 105
6.15
0 102 103 104 105
17.5
0 102 103 104 105
0
102
103
104
105 7.94 19.2
45.7
0 102 103 104 105
5.09 16.4
57.9
0 102 103 104 105
7.38 16.2
49.2
0 102 103 104 105
9.55 39.8
40.2
MOCK WT EBV BZ1KO EBV IL-2
MO
CK
WT
 EB
V
BZ
1K
O E
BV
0
25
50
100
200
300 n.s.
IF
N
-α
 (p
g/
m
l)
5
GFP
91DC 0 102 103 104 105
0
102
103
104
105
0 102 103 104 100 102 103 104 105
60100 0 65 35 40
MOCK WT EBV BZ1KO EBV
Figure 6. EBV-driven in vitro proliferation of NKG2A+ KIR- NK cells partially depends on 
expression of lytic antigens. Proliferation of NK cell subsets was assessed 7 days after inocula-
tion of CBMCs with either wildtype (WT) EBV, BZLF1-KO (BZ1KO) EBV or PBS (MOCK). (A) 
Concentrations of IFN-α in supernatant 24 hours post-inoculation upon MOCK, WT EBV and 
BZ1KO EBV infection (pg/ml; n=5). (B) Representative example of CD19 and GFP co-staining 
within live lymphocytes 72 hours post-infection. Numbers indicate frequencies of GFP-negative or 
GFP-positive cells within the CD19+ B cell population. (C) Frequencies of Ki-67+ NKG2A+ KIR- NK 
cells 7 days after inoculation of CBMCs with mock, WT EBV or BZ1KO EBV or after stimulation 
with IL-2. The depicted gates were assessed within live lymphocytes (first row), CD3- CD56+ NK 
cells (second row) and NKG2A+ KIR- NK cells (third row). (D) Ratio of NKG2A+ KIR- Ki-67+ NK cell 
counts from WT EBV- or BZ1KO EBV- over mock-infected CBMCs. (E) Frequencies of CD56dim 
NKG2A+ KIR- NK cells in newborns (n=8), children aged 1-5 years (n=16), children aged 5-15 
years (n=17) and adults aged 20-30 years (n=15). (F) Counts of CD56dim NKG2A+ KIR- NK cells 
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(n=15). Horizontal lines indicate median values of a given age group, Mann-Whitney tests.
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SUPPLEMENTARY DATA 
 
Material and methods 
 
Study design and human samples.  
Twenty-two pediatric patients diagnosed with acute IM at the University Children’s Hospital 
of Zurich were prospectively enrolled between October 2010 and April 2013. The date of 
symptoms onset was used as reference for the longitudinal study. Heparinized peripheral 
blood samples were obtained from IM patients at diagnosis (IM acute), as well as for some 
study patients at one (IM 1 month) six months (IM 6 months) and 2 years (IM 2 years) after 
the first medical assessment. IM patients with duration of symptoms of < 4 weeks were 
included in the IM acute group. Two IM patients with symptoms lasting > 4 weeks were 
included in the IM 1 month group. Diagnosis of acute IM was established on the basis of the 
presence of IM symptoms such as fever, tonsillar enlargement, hepatosplenomegaly and 
generalized lymph node enlargement, plus detectable immunoglobulin M (IgM) to viral 
capsid antigen (VCA) and absent immunoglobulin G (IgG) to EBV nuclear antigen 1 (EBNA 
1) in serum (Immuno-DOT; GenBio). Twelve pediatric patients with IM symptoms, but 
lacking the serological pattern compatible with acute EBV infection, were also enrolled (IM-
like) and donated peripheral blood at diagnosis. All serum samples from IM-like patients were 
negative for HCMV DNA by qPCR analysis as well as negative for IgM to HCMV (Immuno-
DOT; GenBio). 
Heparinized peripheral blood samples from healthy children undergoing elective 
tonsillectomy and healthy adults aged 20 to 30 years were obtained. These individuals were 
used as healthy controls according to their EBV serology. EBV carriers were defined as EBV-
seropositive individuals (presence of IgG to VCA in serum). Acute EBV and CMV infections 
were excluded in healthy controls by the absence of detectable IgM to VCA and IgM to 
HCMV in serum samples (Immuno-DOT; GenBio). 
All participants gave informed consent, and the institutional ethics committee approved all 
protocols used.  
 
Sample collection and handling.  
Peripheral blood samples were centrifuged and serum was collected and frozen at –80°C for 
later use. PBMCs were isolated by density gradient centrifugation (Ficoll-Paque PLUS, GE 
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Healthcare) per the manufacturer’s instructions and frozen at –160°C. Peripheral blood 
volumes and yielded PBMCs counts were recorded and used for calculation of NK cell 
subsets counts. Cell counts of cord blood mononuclear cell (CBMC) samples were not 
available. 
 
Monoclonal antibodies and flow cytometry.  
The following monoclonal antibodies (mAbs) were used (clone names are given within 
parentheses): anti-CD56 (NCAM 16.2) PE-Cy7, anti-CD107a (H4A3) FITC, anti-Ki-67 (B56) 
FITC, anti-CD57 (NK1) FITC, anti-CD4 (RPA-T4) FITC, anti-CD8 (HIT8a) PE (BD 
Pharmingen); anti-CD159a or NKG2A (Z199) PE, anti-CD158a, h or KIR2DL1/2DS1 
(EB6B) APC and PC5.5, anti-CD158b1/b2, j or KIR2DL2/2DL3/2DS2 (GL183) APC 
(Beckman Coulter); anti-KIR3DL1 (DX9) APC (R&D systems); anti-CD3 (UCHT1) pacific 
blue (Invitrogen); anti-CD3 (HIT3a) APC-Cy7, anti-CD57 (HCD57) pacific blue, anti-CD16 
(3G8) APC-Cy7, anti-HLA-DR (L243) APC-Cy7, anti-CD19 (HIB19) pacific blue, anti-
CD107a (H4A3) pacific blue (BioLegend); anti-HLA-ABC (clone W6/32) FITC, anti-HLA-E 
(clone 3D12HLA-E) PE (eBioscience), anti-NKG2D (1D11) APC, anti-DNAM-1 
(clone11A8) and anti-2B4 (C1.7) FITC, anti-EBV ZEBRA (BZ1) unlabeled (Santa Cruz 
Biologicals), anti-CD155/PVR (TX21) PE (Acris Antibodies), anti-PVRL/CD112 (TX31) 
(LifeSpan Biosciences), anti-CD48 (248) PE (SinoBiologicals). Additionally, the following 
polyclonal antibody was used: rabbit anti-human MICA PE (LifeSpan Biosciences). Pan-KIR 
staining was performed with a combination of KIR2DL1/2DS1, KIR2DL2/2DL3/2DS2 and 
KIR3DL1 mAbs  (all in APC). 
 For phenotypic analyses, frozen PBMCs were thawed, washed and stained with mAbs 
at 4°C for 30 minutes. LIVE/DEAD Fixable Aqua (Invitrogen) was used for dead cell 
exclusion in every flow cytometry analysis. Intracellular staining was performed after fixation 
and permeabilization with the BD Cytofix/Cytoperm Kit (BD Biosciences) according to the 
manufacturer’s protocol. Samples were acquired on a FACSCanto II or a LSR Fortessa (both 
BD Biosciences) and all flow cytometry analyses were performed with FlowJo Version 9 
software (Tree star, Inc). 
The comprehensive single KIR analysis was performed using the following mAbs: 
KIR2DL3 (180701) FITC, NKG2A (Z199) APC, KIR3DL1 (DX9) Brilliant violet 421, CD57 
(TB01) functional grade purified, CD14 (clone M5E2) Horizon-V500, CD19 (HIB19) 
Horizon-V500, KIR2DS4 (179315) Qdot.585, KIR3DL2 (DX31) biotin, KIR2DL1 (143211) 
Alexa fluor 700, NKG2C (134522) PE, CD56 (N901) ECD, CD3 (UCHT1) PE-Cy5, 
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KIR2DL2/S2/L3 (GL183) PE-Cy5.5, KIR2DL1/S1 (EB6) PE-Cy7. Biotin-conjugated 
antibodies were visualized using streptavidin-Qdot 605. CD57 was visualized using an anti-
mouse IgM (II/41) eFluor 650. KIR2DS4 was conjugated in house with Qdot 585 and Qdot 
705 conjugation kits (Invitrogen), respectively. Samples were acquired on a LSR Fortessa 
(BD Biosciences). 
 
Preparation of virus stock and generation of autologous lymphoblastoid cell lines 
(LCLs).  
The EBV-infected marmoset B95-8 cells were seeded at a density of 106 cells/ml and were 
stimulated to release virus by being cultured for 4 days in RPMI 1640 medium (Sigma-
Aldrich) with 10% heat-inactivated fetal bovine serum (Life Technologies), 1% L-glutamine 
and 1% penicillin-streptomycin (referred to hereafter as R10) containing 50 ng of 12-O-
tetradecanoylphorbol-13-acetate (TPA; Sigma-Aldrich)/ml. Cell suspensions were centrifuged 
at 1000 x g for 10 min. Supernatant was passed through a 0.45-µm-pore-size cellulose acetate 
filter (Millipore, Zug, Switzerland) and stored at −80°C. The cell-free supernatants contained 
approximately 1 x 108 EBV DNA copies/ml as evaluated by real-time PCR.  
 Freshly isolated PBMCs from EBV-positive healthy adult donors and IM subjects 
were infected with the B95-8 EBV at a MOI of 0.2. Cyclosporin A (400 ng/ml; Sigma-
Aldrich) was immediately added to inhibit the killing of EBV-infected cells by EBV-specific 
T cells. The cells were seeded on a 96-wells plate and kept in culture for at least 6 weeks 
before use as target cells in degranulation assays. 
Recombinant GFP-Epstein-Barr virus (EBV) B95.8 wildtype and BZLF-1 KO were produced 
in 293 cells (kindly provided by Prof. Henri-Jacques Delecluse) as described elsewhere (154). 
Titration of viral concentrates was done on Raji cells in serial dilutions and calculated as Raji 
infecting units (RIU) using flow cytometric analysis of GFP-positive Raji cells 2 days after 
infection of cells. 
   
Cell lines.  
The B95-8 marmoset cell line, the EBV negative L428 B cell line, established LCLs, K562 
and the Raji cell lines were maintained in R10. LCLs for analysis of NK cell activating 
ligands were kept for one week without medium change before being analyzed. AKBM cells 
(genotype HLA A 24/31, B 35/51; C 3/14) were maintained under selection in R10 with 
200µg/ml Hygromycin B (HygroGold, InvivoGen). 293 cells were maintained in D10 with 
100µg/ml Hygromycin B. 
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Isolation of AKBM cells in lytic cycle.  
The induction of the lytic cycle in AKBM cells and their purification were done as described 
before (17). Briefly, AKBM cells were stimulated with 100µg/ml polyclonal rabbit anti-
human F(ab) IgG (DAKO) for 2 hours at 37°C, washed and further cultured at 37°C. After 24 
hours, AKBM cells in lytic cycle expressing the rat CD2 on the surface were purified by 
MACS sorting (Miltenyi Biotec) using the mouse anti-rat CD2 antibody (clone OX34; 
Abcam) and the anti-mouse IgG2a+b Microbeads (Miltenyi Biotec). Both the purified lytic 
and latent AKBM cells were used directly in degranulation assays. 
 
Degranulation assay.  
To evaluate the cytotoxic degranulation of NK cells, frozen PBMCs from IM patients and 
EBV-positive healthy donors were thawed and rested overnight and 106 PBMCs were co-
cultured the next day with target cells at an effector to target ratio of 10:1 for 6 hours in the 
presence of anti-CD107a antibody. To detect spontaneous degranulation, a control without 
target cells was included. After 1 hour, monensin (1µg/ml BD Golgi Stop; BD Pharmingen) 
was added to all samples. At the end of the incubation, cells were stained with mAbs and 
analyzed by flow cytometry. The spontaneous degranulation (background) from NK cell 
subsets was subtracted in each degranulation analysis.   
 
Infection of cord blood mononuclear cells with recombinant EBV and NK cell 
proliferation assay. 
Cord blood mononuclear cells (CBMCs) depleted from CD34+ cells (kindly provided by 
Prof. Roberto Speck) were thawed and rested overnight in R10. The next day, CBMCs were 
counted, resuspended in R10 at a concentration of 2x 106 cells/ml and inoculated for 1 hour at 
37°C with either mock, WT EBV or BZ1KO EBV at an MOI of 0.5 (106 RIU/ml). After 
inoculation, CBMCs were washed, resuspended in R10 at a concentration of 2 x 106 cells/ml 
and 0.5 x 106 cells were plated in duplicate wells of a U-bottom 96-well plate and incubated at 
37°C for 7 days. IL-2-stimulated CBMCs (100U/ml; Peprotech) were used as positive control 
for NK cell proliferation. After 24 hours, 100µl of supernatant were removed for further 
quantification of IFN-α by ELISA (Mabtech) and replaced with R10. After 7 days, CBMCs 
were counted, washed, stained with mAbs and analyzed by flow cytometry to assess 
proliferation of NK cell subsets. 
 
	  	   64	  
Viral loads quantification.  
DNA was extracted from frozen PBMCs, and after addition of herring sperm DNA (Life 
Technologies) from sera, using the QIAamp DNA mini kit (Qiagen) according to the 
manufacturer’s instructions. EBV DNA levels were determined by the TaqMan (Applied 
Biosystems) real-time PCR technique targeting a 101-base pair sequence conserved in the 
EBV BamHI W region (155). PCR primers (Microsynth) were designed with the following 
sequences: 5’-GCCAGACAGCAGCCAA-TTGT-3’ and 5’-GACTCCTGGCGCTCTGATG-
3’. Within this region, the hybridization probe was designed with the sequence 5’-FAM-
ACTGCCCCTGGTATAAAGTGGTCC-TAMRA-3’ (Applied Biosystems). Amplification of 
DNA sequences was performed using TaqMan® Gene Expression Master Mix (Applied 
Biosystems) and was analyzed using an ABI 7900HT Fast Real-Time PCR System (Applied 
Biosystems). Serial dilutions of a pUC18 plasmid containing the targeted sequence were 
included in every PCR run as an internal control and for calibration. To quantify the EBV 
DNA copy numbers in 106 PBMCs, the BamHI Ct values were normalized to the Ct value of 
the single-copy human hydroxymethylbilane synthase (HMBS) gene. Amplification was done 
with the primers: 5’-GCTCGCATACAGACGGACAG-3’ and 5’-
AGGCCAGGGTACGAGGCTT-3’ and the probe 5’FAM-TGGTGGCAACATTG-MGB-3’ 
(Applied Biosystems).  
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SUPPLEMENTARY FIGURES 
 
IM Age Duration of HLA-DR+ NK cells EBV DNA copies EBV DNA copies CMV 
subjects symptoms CD8+ T cells / ml serum / 10*6 PBMCs serology
(years) (weeks) (x10*3 /ml) (x10*3 /ml)
IM01 15 2 1384 341 2178 275 neg
IM02 14 2 270 - < 100 169 pos
IM03 4 < 1 - - 170 367 neg
IM04 6 3 843 245 n.d. 9844 neg
IM05 15 2 1432 188 371 88 neg
IM06 3 2 899 530 118 1632 neg
IM07 5 2 4185 1354 410 2910 neg
IM08 15 > 4 252 118 < 100 131 neg
IM09 10 1 2726 1344 2349 6298 neg
IM10 12 2 1083 316 n.d. 50 neg
IM11 2 2 3276 969 8520 2966 pos
IM12 14 < 1 919 212 < 100 1260 pos
IM13 15 < 1 1228 231 2578 31561 neg
IM14 14 > 4 117 160 148 12 pos
IM15 13 < 1 1665 239 721 3811 neg
IM16 7 1 2154 277 382 3922 pos
IM17 5 1 1113 718 4236 9394 pos
IM18 12 1 1602 230 896 5230 neg
IM19 6 < 1 1522 380 13065 16255 neg
IM20 14 < 1 765 307 18473 32157 neg
IM21 15 1 3630 601 4368 347 neg
IM22 3 < 1 816 365 11741 2960 pos
mean age median age age range median HLA-DR+ median NK cell CMV sero-
(years) (years) (years) CD8+ T cell counts counts postive subjects
(x10*3 /ml) (x10*3 /ml) (%)
IM subjects 9.9 12 2-15 1408 329 31.8
Healthy subjects 11.4 8 2-28 23 185 37.5
IM-like subjects 8.9 9.5 3-15 32 132 58.3
SupplementaO Table 1. Patients’ characteristics. (A) Characteristics of IM patients at acute 
phase, including age, duration of symptoms, HLA-DR+ CD8+ T and NK cell counts, viral load in 
plasma and in PBMCs, as well as CMV serology. (B) Comparisons between IM patients, IM-like 
patients and healthy controls.
B
A
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Supplementary Figure 1. Lack of correlation of age and CD8+ T cells or EBV DNA loads 
(A) Correlation of age (years) and frequencies of CD8+ T cells from acute IM patients. Spear-
man r = 0.41, P (two-tailed) = 0.070, n=20. (B) Correlation of age (years) and EBV DNA loads 
(copies per 106 PBMCs) from acute IM patients. Spearman r = -0.11, P (two-tailed) = 0.647, 
n=20.
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A
B
C
Supplementary Figure 2. Frequencies  and cell counts of NK cell subsets during IM. (A) 
Frequencies of CD56bright CD16-, CD56dim CD16- and CD56dim CD16+ NK cell subsets within the CD3- 
CD56+ NK cell population in healthy controls (n=37), IM-like patients (n=12) and IM acute (n=17), 1 
month (n=11) and 6 months (n=10) patients. (B) Frequencies of CD56dim NKG2A- KIR- and CD56dim 
NKG2A+ KIR+ NK cells in healthy EBV-negative controls (n=17), healthy EBV-positive controls (n=20), 
IM-like patients (n=12) and IM acute (n=17), 1 month (n=11) and 6 months (n=10) patients. Counts of 
(C) CD56dim NKG2A+ KIR- and CD56dim NKG2A- KIR+ NK cells and (D) CD56dim NKG2A- KIR- and 
CD56dim NKG2A+ KIR+ NK cells in healthy EBV-negative controls (n=14), healthy EBV-positive controls 
(n=17), IM-like patients (n=11) and IM acute (n=17), 1 month (n=10) and 6 months (n=8) patients. 
Horizontal lines indicate median values of a given symbol. Mann-Whitney tests.
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C
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Supplementary Figure 3. No significant differences between CMV+ and CMV- IM patients 
or CMV+ and CMV- healthy controls. PBMCs from healthy controls, IM-like patients and IM 
patients at acute phase (IM acute), at 1 (IM 1 month) and 6 months (IM 6 months) were ana-
lyzed by flow cytometry. Counts of (A) NK cells and (B) CD56dim CD16+ NK cells in healthy 
controls (CMV- n=19; CMV+ n=12), IM-like (CMV- n=5; CMV+ n=6) and IM acute (CMV- n=13; 
CMV+ n=5), 1 month (CMV- n=8; CMV+ n=2) and 6 months (CMV- n=7; CMV+ n=1) patients. 
(C) Frequencies of CD56dim NKG2A+ KIR- in healthy EBV-negative controls (CMV- n=14; CMV+ 
n=3), healthy EBV-positive controls (CMV- n=10; CMV+ n=10), IM-like patients (CMV- n=5; 
CMV+ n=7) and IM acute (CMV- n=12; CMV+ n=5), 1 month (CMV- n=9; CMV+ n=2) and 6 
months (CMV- n=8; CMV+ n=2) patients. (D) Frequencies of Ki-67+ cells within the CD56dim 
NKG2A+ KIR- CD57- NK cells in healthy controls (CMV- n=7; CMV+ n=8), IM patients acute 
(CMV- n=5; CMV+ n=4) and 1 month (CMV- n=3; CMV+ n=1) patients. (E) Count of CD56dim 
NKG2A+ KIR- CD57- in healthy EBV-negative controls (CMV- n=11; CMV+ n=3), healthy EBV-
positive controls (CMV- n=8; CMV+ n=9), IM-like (CMV- n=5; CMV+ n=6), IM acute (CMV- n=12; 
CMV+ n=5), 1 month (CMV- n=8; CMV+ n=2) and 6 months (CMV- n=7; CMV+ n=1) patients. 
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Supplementary Figure 4 was provided by Anna Lünemann who performed the according 
experiments, analyzed the data and prepared the figure. 
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COLLABORATIONS 
 
Oropharyngeal Group A Streptococcal Colonization Disrupts Latent 
Epstein-Barr Virus Infection 
 
Seigo Ueda, Satoshi Uchiyama, Tarik Azzi, Claudine Gysin, Christoph Berger, Michele 
Bernasconi, Yasuaki Harabuchi, Annelies S. Zinkernagel, and David Nadal 
 
J Infect Dis. 2014 Jan 15;209(2):255-64.  
 
Abstract 
Epstein-Barr virus (EBV) infects more than 90% of the human population within the first two 
decades of life and establishes reversible latent infection in B cells. Which stimuli leads to 
switching from latent to lytic EBV infection in vivo are still elusive. Group A Streptococci 
(GAS) are a common cause of bacterial pharyngotonsillitis in children and adolescents and 
colonize tonsil and pharynx of up to 20% of healthy children. Thus, concomitant presence of 
EBV and GAS in the same individual is frequent. Here, we show that EBV carriers who are 
colonized with GAS shed EBV particles in higher numbers in their saliva compared to EBV 
carriers not colonized with GAS. mRNA levels of the master lytic regulatory EBV gene 
BZLF1 were more frequently detected in tonsils from EBV-carriers colonized with GAS than 
from not colonized. Heat-killed GAS, potentially mimicking GAS colonization, elicited lytic 
EBV in latently infected lymphoblastoid cell lines (LCLs) partially via TLR2 triggering, as 
did purified GAS peptidoglycan. Thus, EBV may benefit from colonizing GAS that by 
increasing the EBV load in saliva may contribute to enhancing the viral spread to other hosts. 
 
Own contribution: I performed experiments and contributed to vital reagents and human 
primary cells. 
For detailed information, see attached manuscript N°3. 
 
 
 
 
 
	  	   72	  
A distinct subpopulation of human NK cells restrict B cell transformation 
by EBV 
 
Lünemann A, Vanoaica LD, Azzi T, Nadal D and Münz C. 
 
J Immunol. 2013 Nov 15;191(10):4989-95. 
 
Abstract 
NK cells constitute the first line of defense against pathogens and transformed cells. They 
mature in secondary lymphoid organs, including tonsils, where common pathogens, such as 
EBV, enter the host and potentially imprint differentiating cells, which then patrol the body 
via the blood stream. Therefore, we set out to characterize a distinct human NK cell 
population in tonsils that produces high amounts of the immunomodulatory and antiviral 
cytokine IFN-γ. We found that the tonsilar IFN-γhigh NK cell subset is CD56bright NKG2A+ 
CD94+ CD54+ CD62L-, is present in tonsils ex vivo and is more mature than other CD56bright 
NK cells in tonsils and less mature than other NK cells in blood, shows very low plasticity 
even after prolonged cytokine stimulation, accumulates in tonsils of EBV carriers, and is able 
to potently restrict EBV-induced transformation of B cells. Thus, we characterized a distinct 
and stable IFN-γhigh NK cell subpopulation that can specifically restrict malignant 
transformation of EBV-infected B cells. This subset should be exploited for future 
development of cell-based therapeutic approaches in EBV-associated malignancies. 
 
Own contribution: I contributed to vital human primary cells. 
 
 
For detailed information, see attached manuscript N° 4. 
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6. DISCUSSION AND OUTLOOK 
 
NK cells have been originally classified as innate lymphocytes that mediate rapid and 
unspecific immune responses during viral infections (57). From nearly 40 years of intensive 
NK cell research, we learned that human NK cells are composed of several subsets, which can 
preferentially respond to specific viral challenges and exhibit some adaptive immune 
functions similar to those observed in pathogen-specific T cell responses. Indeed, several 
longitudinal studies have reported the preferential accumulation of late-differentiated CD56dim 
NKG2C+ (102, 103) or CD56dim KIR+ (136) NK cell subsets. 
In this thesis, we longitudinally investigated the responses of NK cell subsets in 
peripheral blood from pediatric patients with acute primary symptomatic EBV infection or 
infectious mononucleosis (IM). We reported for the first time that 1) EBV-associated IM 
elicits the expansion and long-lasting accumulation of only one specific NK cell subset as 
observed during other acute viral infections; 2) however, IM drives the unique and specific 
proliferation of an early-differentiated CD56dim NKG2A+ KIR- NK cell subset, which has 
never been described in other infectious or immunological diseases; 3) this particular NK cell 
subset can directly recognize and target EBV-infected cells with lytic replication, but not 
EBV transformed B cells or LCLs. This suggests that a rapid response from CD56dim 
NKG2A+ KIR- NK cells might limit early lytic EBV replication, and therefore consistently 
decrease the numbers of EBV-infected B cells before the development of the adaptive T cell 
responses; 4) the frequencies and absolute numbers of these NK cells consistently decrease 
with increasing age, suggesting that the early innate NK cell-mediated immune control of 
EBV lytic replication might be stronger during early childhood. This hypothesis would fit 
with the age-related predisposition to infectious mononucleosis. 
The preferential proliferation of CD56dim NKG2A+ KIR- NK cells during acute IM, as 
demonstrated with ex vivo staining for the proliferation marker Ki-67, seems to be directly 
triggered by cell-contact with EBV-infected B cells, and is not a consequence of bystander 
activation mediated by proinflammatory cytokines. This is suggested by several observations: 
firstly, other acute viral infections with high levels of cytokines elicit expansion of other NK 
cell subsets; secondly, our control group of age-matched pediatric patients with IM-like 
symptoms does not exhibit such NK cell subset expansions; thirdly, the CD56bright precursor 
subset, with its well established superior proliferative responsiveness upon cytokine 
stimulation, does not display increased proliferation during acute IM. Moreover, our study 
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suggests that the proliferation of this NK subset partially depends on expression of EBV lytic 
antigens, as shown by in vitro infection of cord blood mononuclear cells (CBMCs) with the 
recombinant wildtype EBV compared to the recombinant BZLF1-KO EBV, which does not 
express any lytic antigens. These findings are in good agreement with the recently published 
work by Chijioke and colleagues on EBV infection in mice with human immune system 
(123). In this model CD16+ NKG2A+ KIR- NK cells accumulate upon EBV infection and 
mediates immune protection exclusively against the wildtype EBV strain expressing lytic 
antigens, but not against a BZLF1-knockout virus with defective lytic replication. This further 
support the role of early-differentiated NK cells during EBV infection in humans. 
 Furthermore, we could also demonstrate that the proliferating CD56dim NKG2A+ KIR- 
CD57- NK cells terminally differentiate into the CD57+ subset, and not into the KIR+ subset, 
during the first month of IM. This represents the first in vivo description of NK cell terminal 
differentiation within the NKG2A+ NK cell subset. Interestingly, convalescent IM patients 
still exhibited at the first month visit post-IM increased numbers of CD56dim NKG2A+ KIR- 
CD57+ NK cells compared to EBV-naïve uninfected controls. The maturation marker CD57 
has been postulated to be a marker of human memory NK cells, which might be up-regulated 
on expanding NK cells during viral infections (101). Thus, if the adaptive features of mouse 
NK cells turn to be conserved in humans, a fraction of the CD56dim NKG2A+ KIR- CD57+ NK 
cell subset could actually represent EBV-specific memory NK cells, which have been primed 
during infectious mononucleosis.  
Nevertheless, the exact mechanisms behind the specific recognition of EBV-infected 
B cells by CD56dim NKG2A+ KIR- NK cells remain unclear, but need to be further addressed 
in detail. Future studies should determine which activating NK cell ligands are up-regulated 
on EBV-infected cells, therefore triggering NK cell activation, and how lytic EBV infection 
leads to the up-regulation of these ligands. Stress-associated ligands such as NKG2DL have 
been reported to get up-regulated upon induction of the DNA damage response and cytosolic 
DNA recognition (156). Although EBV packages its DNA into the viral capsid in the nucleus 
during lytic replication, some of it might become accessible during capsid transit through the 
cytosol and trigger this pathway of NKG2D ligand up-regulation. Indeed, the triggering of 
lytic reactivation in B cell lines latently infected by EBV elicits a cellular DNA damage 
response with activation of the ataxia telangiectasia-mutated (ATM) signal transduction 
pathway (157). 
 On the other hand, the presence of the inhibitory receptor NKG2A, and not of the KIR, 
on virtually proliferating NK cells during IM is not clear. This might be explained by the 
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preferential proliferation of NKG2A+ NK cells or the selective up-regulation of this receptor 
on NKG2A- proliferating NK cells. Our degranulation data against AKBM however rather 
support the former hypothesis, since NKG2A+ NK cells preferentially recognize B cells with 
lytic reactivation. The selective proliferation advantage of NKG2A+ NK cells over KIR+ NK 
cells during acute IM might be due to an higher inhibition threshold for the former receptor, 
allowing this NK cell subset to get activated and proliferate faster in the inflammation 
environment in IM individuals. Additionally, the potential role of EBV-specific peptides in 
the modulation of interactions between HLA-E and NKG2A (152, 158, 159), as well as 
between HLA-C and activating KIRs (128), also needs to be clarified.  
Despite efficient innate and adaptive immune responses, this herpesvirus manages to 
establish latency in memory B cells in a very successful way since it persistently infects the 
vast majority of the adult population worldwide. Some of these infected B cells exhibit 
periodic viral reactivation mainly in the tonsils and viral shedding is observed in saliva from 
convalescent IM patients (31, 43)as well as from some EBV-seropositive children with and 
without tonsilar enlargement (160). Such persistent EBV lytic replication in the tonsils might 
indicate an impaired immune control at this site. Indeed, several viral proteins of the lytic 
cycle are known to provide EBV with immune evasion mechanisms (161). However, the 
reason why some EBV-seropositive children exhibit an increased shedding in saliva and 
therefore increased EBV reactivation in tonsils is unclear. Co-infections with other pathogens 
or commensals in the tonsils such as group A streptococci (GAS) might influence the switch 
between latent and lytic EBV infection. Indeed, we could demonstrate in collaboration with 
Annelies Zinkernagel’s lab (Division of Infectious Diseases, University Hospital of Zurich) 
that the amount of viral shedding in saliva as well as the frequency of tonsils positive for 
BZLF1 (master lytic regulatory EBV gene) mRNA expression was significantly higher in 
EBV carriers with concomitant GAS colonization compared to without GAS colonization 
(attached manuscript N°3; (162)). Exposure of EBV latently infected LCL to heat-killed 
GAS, potentially mimicking GAS colonization, could trigger the lytic reactivation of these 
cells as measured by BZLF1 mRNA expression. This effect was shown to be partially TLR2-
dependent, since exposure to purified GAS peptidoglycan (TLR2 ligand) also elicits BZLF1 
up-regulation on LCLs, which was partially inhibited in TLR2 blocking experiments. 
Most of this work focused on the NK cell-mediated cytotoxicity against EBV-infected 
B cells with lytic replication by a newly described functional subset. On the other hand, we 
could show that the early-differentiated NK cell subset, as well as other NK cell subsets from 
peripheral blood, cannot target the EBV-transformed B cell or LCL in vitro. This is probably 
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due to the EBV-mediated up-regulation of the inhibitory ligands HLA class I and HLA-E, 
which protects the LCL from NK cell killing. However, the immune control of transformed B 
cells in vivo is probably mainly mediated by EBV-specific T cells during primary infection of 
immunocompetent individuals. Accordingly, post-transplant lymphoproliferative disease (or 
PTLD) in immunocompromised patients can be cured by infusion of EBV-specific in vitro 
expanded T cell lines (45). NK cells might rather play a role in delaying the viral 
transformation process of the infected B cells in the tonsils, the portal of entry of EBV, until 
the development of EBV-specific T cell responses. Indeed, tonsilar NK cells restrict B cell 
transformation more efficiently than peripheral blood NK cells. This process depends on IFN-
γ production by NK cells after their activation by DCs-secreted IL-12 (120). IFN-γ is able to 
curb the B cell transformation in vitro by delaying the expression of EBV main oncogene 
LMP1. Notably, this restriction is only possible during the first four days of EBV infection 
and treatment with recombinant IFN-γ at latter time points during transformation does not 
influence anymore the outgrowth of LCLs. Recently, Lünemann et al. could show in 
collaboration with our lab that a newly characterized tonsilar NK cell subset mediates this 
restriction via a superior secretion of IFN-γ (attached manuscript N°4; (163)) and that this 
subset accumulates in the tonsils, but not in peripheral blood, of EBV-seropositive children. 
Interestingly, these NK cells are CD56bright NKG2A+ and mainly KIR- and might actually be 
the direct precursors of CD56dim NKG2A+ KIR- NK cells that are preferentially proliferating 
in peripheral blood of acute IM patients. Future studies should analyze the phenotype and 
function of NK cell subsets in acutely infected tonsils from IM patients, although emergency 
tonsillectomies are only performed on IM patients with life-threatening upper airway 
obstruction and are therefore extremely rare (164). 
Age-related manifestations of primary infections have been described with several 
viruses such as EBV, CMV, human immunodeficiency virus (HIV) and varicella zoster virus 
(VZV). Indeed, primary infections with these viruses in early childhood are often 
asymptomatic or less severe compared to primary infections in older individuals such as 
teenagers and adults. In this thesis, we could not observe any differences in age-dependent 
NK cell responses against EBV transformed B cells or any differences in age-dependent 
expression level of NK cell activating receptors known to be involved in recognition of EBV 
infected cells. However, we report major changes in the distribution of blood NK cell subsets 
according to age. Indeed, CD56bright CD16- and CD56dim NKG2A+ KIR- NK cells, which are 
considered immature or early-differentiated, are significantly more prominent in young 
children. This age-dependent maturation of the NK cell compartment is probably driven by 
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environmental stimuli such as pathogen encounters during the lifetime of the individual. A 
picture is now emerging in which late-differentiated NK cell subsets predominate in 
peripheral blood later in life time, as also suggested by the specific temporal reconstitution of 
the NK cell subsets in hematopoietic stem cell (HSC) transplanted patients (149-151)and in 
mice with humanized immune system (100).Our data indicate that decreased numbers of 
CD56dim NKG2A+ KIR- NK cells in peripheral blood of teenagers or adults might lead to an 
impaired early immune control of the EBV lytic replication, leading to increased numbers of 
EBV-infected B cells with lytic antigens, which could trigger the extensive IM-associated 
immune responses with the characteristic expansion of CD8+ T cells specific for EBV lytic 
epitopes. This hypothesis has been supported recently in a study of EBV infection in 
humanized mice (123). In these mice, more than 70% of human NK cells are early-
differentiated and exhibit an NKG2A+ KIR- phenotype such as observed in children younger 
than 5 years. Depletion of human NK cells before EBV infection leads to decreased immune 
control of EBV-infected B cells (increased viral loads and increased tumor formation) and 
enhance IM symptoms (increased CD8+ T cell frequency, increased level of IFN-γ and 
increased spleen size) compared to non-depleted infected animals. Cytokine treatment of 
reconstituted mice leads to NK cell differentiation and increased expression of KIR 
molecules, resembling NK cells in individuals older than 5 years. However these late-
differentiated NK cells control EBV less well in vivo, suggesting that older individuals might 
display a quantitatively impaired NK cell-mediated immune control of EBV compared to 
young children. Such a hypothesis could in the end only be verified prospectively by 
analyzing the NK cell compartment in peripheral blood of EBV-negative individuals before 
and after the development of IM. Such an approach has been proven feasible with EBV-
negative university students (17)and would provide a fantastic tool to better understand and 
study innate immune responses during primary EBV infection.  
EBV infection is associated with several malignancies of the B cell and epithelial cell 
origin (see table 1) both in immunocompetent and immunocompromised individuals, and 
might also be linked to autoimmune diseases (165). The role of NK cell subsets in the 
immune control of EBV-positive tumors is unclear and NK cell responses in patients with 
such pathologies have not been investigated. In this thesis, we could show that CD56dim 
NKG2A+ KIR- NK cells preferentially react to EBV-infected B cells with expression of lytic 
antigens, and not with the transformation-associated latent antigens. This might indicate that 
this NK cell subset can only target EBV-positive tumors expressing lytic antigens. 
Interestingly, patients suffering from EBV-positive tumors such as Burkitt lymphoma (166), 
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Hodgkin lymphoma (167, 168)and nasopharyngeal carcinoma (169)exhibit raised titers of  
antibodies specific for the late lytic viral capsid antigen (VCA). The expansion of these 
antibody responses probably follows the availability of their respective antigens, indicating 
that some of the EBV-positive tumor cells might express lytic antigen and could therefore be 
targeted by NK cell-mediated immunotherapy. 
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ABSTRACT
EBV persists life-long in 95% of the human adult popu-
lation. Whereas it is perfectly immune-controlled in
most infected individuals, a minority develops EBV-as-
sociated diseases, primarily malignancies of B cell and
epithelial cell origin. In recent years, it has become ap-
parent that the course of primary infection determines
part of the risk to develop EBV-associated diseases.
Particularly, the primary symptomatic EBV infection or
IM, which is caused by exaggerated T cell responses,
resulting in EBV-induced lymphocytosis, predisposes
for EBV-associated diseases. The role of innate immu-
nity in the development of IM remains unknown. There-
fore, it is important to understand how the innate im-
mune response to this virus differs between symptom-
atic and asymptomatic primary EBV infection.
Furthermore, the efficiency of innate immune compart-
ments might determine the outcome of primary infec-
tion and could explain why some individuals are sus-
ceptible to IM. We will discuss these aspects in this re-
view with a focus on intrinsic immunity in EBV-infected
B cells, as well as innate immune responses by DCs
and NK cells, which constitute promising immune com-
partments for the understanding of early immune con-
trol against EBV and potential targets for EBV-specific
immunotherapies. J. Leukoc. Biol. 94: 000–000; 2013.
EBV INFECTION AND ASSOCIATED
DISEASES
EBV belongs to the  subfamily of herpesviruses and was first
identified in cultured lymphoma cells derived from an African
BL patient [1]. The global seroprevalence is very high, sug-
gesting that 95% of adults worldwide are infected with EBV
[2]. In contrast to diseases that are associated with persistent
infection [3], primary infection with EBV usually occurs in
childhood and remains asymptomatic during the acute phase,
whereas in adolescents and adults, primary infection is symp-
tomatic in 70% of cases [4] and presents as IM. IM is a self-
limiting disease with characteristic clinical symptoms of phar-
yngitis, fever, fatigue, cervical lymphadenopathy, hepatospleno-
megaly, and T cell lymphocytosis in the peripheral blood.
Although EBV persists in infected individuals, both after
asymptomatic primary infection and IM, it is usually immune-
controlled but without viral clearance for the rest of the host’s
life [5]. However, during the first 5 years after resolving IM,
the risk for EBV-positive Hodgkin lymphoma is increased up
to five times [6, 7], and a history of IM increases the risk to
develop multiple sclerosis by twofold [8, 9]. In rare cases, pri-
mary infection is fatal and is the most common cause of infec-
tion-associated HLH [10]. Therefore, symptomatic primary
EBV infection predisposes for diseases associated with this vi-
rus.
EBV is associated with several malignancies of B cell origin,
the primary target of EBV. Almost 100% of endemic BL is pos-
itive for EBV. Because of the invariant presence of c-myc trans-
locations in BL, however, the exact role of EBV in the trans-
forming process is still not defined clearly [11, 12]. Similarly,
classical Hodgkin lymphoma, most frequently of the mixed
cellularity subtype, is associated with EBV in 40% of cases.
However, as in BL, the culprit for tumorigenesis might not be
EBV alone, as this disease is multifactorial [13]. The impact of
the host immune response on the control of EBV becomes
evident in immunosuppressed patients and patients with pri-
mary immunodeficiencies. PTLDs comprise a variety of lym-
phoid disorders, ranging from polymorphic lymphoid hyper-
plasia to malignant lymphoma, and are associated mostly with
EBV infection [14]. The risk for EBV-associated PTLDs corre-
lates with the degree of immunosuppression, such that the
highest incidence is found in solid organ transplant patients
with the most intense immunosuppressive regimes. Moreover,
virtually all AIDS-related CNS lymphomas and leiomyosarco-
mas are associated with EBV [15, 16]. Patients suffering from
XLP disease are exclusively fragile to primary EBV infection
but not any other pathogens and develop fulminant and some-
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times lethal IM, as well as B cell lymphomas, after severe pri-
mary EBV infection. The disease-causing mutations lead to an
impairment of T and NK cells to target EBV-infected cells [17–
20]. In rare cases, EBV infects T or NK cells, leading to the
development of T cell [21] and NK cell lymphomas [22]. EBV
is also associated with nonlymphoid malignancies, such as na-
sopharyngeal carcinoma [23] and EBV-positive gastric carci-
noma [24]. In both entities, EBV infection seems to occur be-
fore malignant transformation, as EBV is monoclonal in tumor
cells [25, 26]. The exact contribution of EBV in this plethora
of associated malignancies is still ill-defined, but the presence
of EBV gene products capable of inducing cellular transforma-
tion on their own, infection of every tumor cell, and epidemio-
logical evidence supports the notion of a pathogenic role for
EBV.
EBV-ASSOCIATED MOLECULAR
PATTERNS THAT ELICIT IMMUNE
ACTIVATION
The formidable immune control that keeps EBV in check for
50 years in most infected individuals requires priming of
protective T cell responses [5]. For this to occur, EBV-associ-
ated molecular patterns need to be recognized by the immune
system, probably directly by APCs for optimal T cell priming
[27]. APCs carry a number of PRRs, including TLRs, nucle-
otide-binding oligomerization-like receptors, retinoic acid-in-
ducible gene-like receptors, and C-type lectin-like receptors
[28]. Of these, TLR3 and TLR9 have been implicated in sens-
ing of EBV and might complement each other for the recogni-
tion of this virus by cDCs and pDCs, respectively (Fig. 1). In
addition, monocytes, upon detection of EBV via TLR2, secrete
cytokines and chemokines [29–31], whereas TLR7 signaling
has been reported to be modulated by EBV [32, 33]. Notably,
B cells, the primary target of EBV, also express TLR3 and
TLR9 [34]. In contrast to mice, TLR3 and TLR9 are on sepa-
rate DC subsets in humans. TLR3 is expressed primarily by
cDCs, whereas TLR9 is restricted to pDCs [35]. Therefore,
both major human DC subsets could detect different cues dur-
ing EBV infection, whereas the primary target cell of EBV is
furnished with both receptors.
TLR3 recognizes dsRNA in endosomal compartments of hu-
man cDCs. EBERs have been described to form stem-loop
structures, and the resulting RNA was reported to bind to
TLR3 [36]. EBERs were found to be released from EBV-in-
fected cells in complex with the La protein, a frequent autoan-
tigen in systemic lupus erythematosus and Sjögren’s syndrome.
Sera of patients with IM, chronic active EBV infection, and
EBV-associated HLH, diseases whose pathology might be
mainly mediated by the release of large amounts of proinflam-
matory cytokines, were demonstrated to contain high concen-
trations of EBERs. Indeed, these sera elicited TLR3-dependent
cytokine production and DC maturation in vitro. These data
suggest that dsRNA structures of EBERs might stimulate cDCs
via TLR3 to allow them to prime protective EBV-specific T cell
responses.
In contrast, it is much less clear to which extend human
pDCs can initiate T cell responses. However, they seem to be
able to recognize EBV DNA via the endosomal receptor TLR9
[31, 37], which recognizes unmethylated CpG DNA motifs.
Linear dsDNA in EBV particles is unmethylated, but circular-
izes after cellular infection and then gets hypermethylated suc-
cessively [38], suggesting that especially noncell-associated vi-
rus-encapsulated EBV DNA should be immunostimulatory via
TLR9. In addition to pDCs, TLR9 is expressed prominently in
human B cells, and its stimulation seems to facilitate B cell
transformation by EBV [39]. Once infection, however, has oc-
curred, EBV seems to down-regulate TLR9-mediated signaling
[33]. The LMP-1 of EBV down-regulates TLR9 signaling dur-
ing latent infection [40], whereas the lytic EBV antigen BGLF5
down-regulates TLR9 during lytic replication [41] (Fig. 2). In
addition, even UV-inactivated EBV has been reported to down-
regulate TLR9 [32]. In this fashion, EBV possibly protects it-
self from cell death-inducing and lytic reactivation-inhibiting
functions of TLR9 signaling [42, 43]. Thus, EBV, possibly pri-
marily the virus-encapsulated DNA, can be sensed by TLR9 in
pDCs and B cells, but the virus protects itself from innate im-
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Figure 1. Innate immune recognition via identified PRR ligands and
innate restriction of EBV. EBV seems to activate pDCs and cDCs with
its unmethylated viral DNA and EBER, respectively. These pathogen-
associated patterns engage TLR9 on pDCs and TLR3 on cDCs. NK
cells, which can be activated by pDCs and cDCs to produce IFN- in
response mainly to IL-12 and increase cytotoxicity upon encountering
IFN-/, can restrict EBV infection. NK cells prevent B cell transfor-
mation via IFN- and kill lytically EBV-replicating cells.
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mune signaling via this receptor by down-regulating it during
latent and lytic infection.
DCs IN INNATE IMMUNE CONTROL OF
EBV INFECTION
This TLR-mediated recognition seems to alarm the immune
system to EBV infection and matures DCs to form a first bar-
rier against it. Particularly, pDCs have been described as supe-
rior sources of the antiviral type I IFN (IFN-/) cytokines
[44]. In a PBMC transfer model into immunocompromised
SCID mice, this IFN- production by pDCs seemed to be nec-
essary to control EBV infection [37]. PBMCs depleted for
pDCs supported disseminated EBV infection, whereas pDC
supplementation of PBMCs was able to control infection better
after EBV challenge in vivo. The pDC activation by EBV was
TLR9-mediated in this system and led to enhanced NK and T
cell activation (Fig. 1). As the PBMCs in this model were de-
rived from EBV-seropositive individuals, however, pDCs most
likely only supported secondary T cell responses that had been
primed in the PBMC donor. It is likely that these secondary
responses supported the observed, lasting immune control
over EBV infection for 1–2 months, as IFN- has only been
described to block EBV infection of B cells for the first 24 h
after infection [45]. The TLR9-mediated detection of EBV by
pDCs leading to IFN- production has been confirmed in in-
dependent studies [31, 46]. Thus, pDCs produce the antiviral
cytokine IFN- in response to EBV infection, which restricts
the virus initially as well as stimulates other innate immune
cells and promotes the development of adaptive immune re-
sponses.
These adaptive, particularly T cell-mediated immune re-
sponses are, however, most likely not primed by pDCs and also
not by EBV-infected B cells [47, 48]. In contrast, inflammatory
DCs, modeled in humans by differentiation from monocytes,
are able to prime EBV-specific T cell responses, which in turn,
can control B cell transformation by EBV in vitro [47]. To ful-
fill this priming function, monocyte-derived DCs are most
likely activated by EBV via TLR2 or TLR3 [31, 36]. However,
only TLR3-mediated DC maturation has been reported to lead
to the up-regulation of costimulatory molecules and antigen
presentation [36], whereas TLR2-mediated monocyte stimula-
tion was shown to lead to the production of MCP1 and the
immune-suppressive cytokine IL-10 [31]. In addition, the mo-
lecular identity of a TLR2 agonist in EBV is still unknown.
Thus, cDCs or inflammatory DCs are probably involved in the
priming of protective T cell responses against EBV.
The major human DC subsets—cDCs, inflammatory, and
pDCs—are activated, most likely, by EBV after uptake of viral
particles or fragments of EBV-infected B cells. Indeed, human
monocyte-derived DCs can cross-present EBV-infected B cell
fragments to stimulate CD4 and CD8 T cells [49, 50]. More-
over, pDCs get activated by purified viral DNA [31]. However,
the possibility still exists that a small subset of inflammatory
DCs and pDCs is also infected directly by EBV. Along these
lines, entry of the virus and access of the viral DNA to the nu-
cleus have been, at least, demonstrated for monocyte-derived
DCs and pDCs [46, 51]. However, viral antigen expression has,
so far, not been demonstrated convincingly in DCs. Thus, DCs
detect, most likely, virus particles directly or products of EBV-
infected cells to mount innate immune responses and initiate
adaptive immune control of EBV.
NK CELLS IN EBV RESTRICTION
NK cells are known to be important players involved in im-
mune control of cancer and virus-infected cells [52]. In the
case of EBV, observational data in humans support a role for
human NK cells during innate immune responses to this virus.
During symptomatic, primary EBV infection, IM, numbers, and
frequency of NK cells in peripheral blood are increased [4,
53–56]. However, one cohort study reported a direct correla-
tion of NK cell count and blood EBV DNA load [4], whereas
another smaller study showed an inverse correlation of NK cell
frequency and blood EBV DNA load, as well as an inverse cor-
relation of NK cell count and severity of symptoms [55], sug-
gestive of a direct, beneficial contribution by human NK cells
in the latter report. However, during viral infections, distinct,
terminally differentiated NKG2CKIR NK cell subsets have
been found to be expanded. This was observed during acute
and persistent infection with human CMV, hantavirus, or chi-
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Figure 2. Known interactions between EBV and innate immunity ele-
ments in B cells. The published, studied interactions between EBV
and innate immunity elements in B cells are virtually limited to TLR9.
The unmethylated DNA of EBV triggers TLR9, which suppresses lytic
reactivation of EBV by suppressing transcription of the master regula-
tory lytic gene of EBV, BZLF1, and activates NF-B, which also sup-
presses BZLF1 transcription but to a lower extent, whereas triggering
the BCR activates BZLF1 and switches infection to the lytic cycle. Con-
versely, LMP-1 of EBV suppresses transcription of the TLR9 gene via
NF-B activation, and the lytic-phase of EBV protein, BGLF5, contrib-
utes to down-regulating TLR9 levels by degrading RNA.
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kungunya virus [57–59]. Therefore, interrogating the bulk NK
cell response might not necessarily identify the potentially pro-
tective impact of these cells during primary EBV infection.
The antitumoral role of NK cells was highlighted by a recent
report of a patient with selective NK cell deficiency, who devel-
oped a rare EBV-positive smooth muscle tumor [60]. In an-
other case report, EBV-associated lymphoproliferative disease
occurred in a patient with NK cell deficiency [61]. On the mo-
lecular level of pathogenesis, mechanistic insight was gained
from examining defective immune responses in XLP disease,
characterized by extreme susceptibility to EBV [62–64]: block-
ade of the surface molecules 2B4 and NK-T-B antigen (NTB-
A), expressed on normal NK cells and CD8 T cells, was
shown to decrease NK cell cytotoxicity to EBV-positive target
cells [17, 18], and both molecules act as inhibitory receptors
rather than activating in XLP patients, as a result of mutations
in the gene encoding the adaptor protein SLAM-associated
protein [65], such that NK and CD8 T cells are no more
able to lyse EBV-infected B cells or respond specifically by cy-
tokine production [17–20]. Furthermore, natural cytotoxicity
receptors (i.e., NKp30, NKp44, and NKp46) and NKG2D, all
activating NK cell receptors, have been described to be in-
volved in cytotoxic recognition of EBV-positive cell lines [66].
The activating KIR, KIR2DS1, might also play a part in NK cell
recognition of EBV-infected cells, as only EBV, but not other
herpes viruses, up-regulate ligands for KIR2DS1 upon infec-
tion, and the blocking of this receptor diminishes lysis of EBV-
positive target cells to some extent [67]. Interestingly, lytic
EBV infection compared with latent infection renders target
cells more susceptible to NK cell killing (Fig. 1), probably as a
result of down-regulation of MHC-I molecules and increased
expression of UL16-binding protein 1 and CD112, ligands for
the activating receptors NKG2D and DNAX accessory mole-
cule-1 (DNAM-1), respectively [68]. Finally, NK cells might
function tissue-specifically, as it has been shown that tonsillar
NK cells restrict B cell transformation more efficiently than
peripheral blood NK cells. This process depends on IFN- pro-
duction by NK cells after their activation by IL-12, produced
by DCs [69]. In summary, there is growing evidence that hu-
man NK cells are involved in the immune response against
EBV in vivo. However, the receptor-ligand interactions that are
important for NK cell-mediated immune control of EBV and
which infection program is restricted by NK cells in vivo still
need to be better defined.
CONCLUSIONS AND OUTLOOK
EBV is one of the examples of a persistent human pathogen
that can be controlled by the immune system for extended
time periods, suggesting that the respective protective immune
responses have been primed to cope optimally with this life-
long challenge. Thus, this herpesvirus can teach us how pro-
tective immunity has to be shaped and which innate immune
compartments must be engaged to achieve this lasting im-
mune control. This knowledge might lead us to the develop-
ment of novel vaccine adjuvants that stimulate innate immune
responses and therefore, promote long-lasting protection
against other chronic infectious diseases. Along these lines, we
have learned that EBV probably provides different PAMPs that
engage pDCs and cDCs for optimal T cell priming. Further-
more, innate lymphocyte compartments, such as NK cells,
might have been selected during evolution to restrict the early
phases of EBV infection to gain time for the adaptive immune
response to build its comprehensive immune control. Finally,
EBV has hijacked part of the intrinsic immune recognition
mechanisms in B cells to improve infection and regulate reac-
tivation. However, the fact that IM patients already exhibit
strong adaptive immune responses when they seek medical
care complicates the study of early events during acute EBV
infection. Thus, to learn more about EBV-specific innate im-
munity, experimental systems that allow the dissection of hu-
man immune responses in vivo have to be developed further.
With the advent of humanized mouse models that support re-
constitution of human immune system compartments, such
systems become available, which will not only allow dissection
of innate immune responses to EBV in more detail but also
provide a platform to test vaccine candidates, whose protective
efficiency can then be challenged in vivo.
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Key Points
• Early-differentiated NK cells
accumulate and proliferate
during IM.
• These early-differentiated
NK cells preferentially
target lytic EBV-infected
B cells in vitro.
Agrowingbodyof evidencesuggests that thehumannatural killer (NK)-cell compartment
is phenotypically and functionally heterogeneous and is composed of several dif-
ferentiation stages. Moreover, NK-cell subsets have been shown to exhibit adaptive
immune features during herpes virus infection in experimental mice and to expand
preferentially during viral infections in humans. However, both phenotype and role
of NK cells during acute symptomatic Epstein-Barr virus (EBV) infection, termed in-
fectious mononucleosis (IM), remain unclear. Here, we longitudinally assessed the
kinetics, the differentiation, and the proliferation of subsets of NK cells in pediatric
IM patients. Our results indicate that acute IM is characterized by the preferential
proliferation of early-differentiated CD56dim NKG2A1 immunoglobulin-like receptor-
NK cells. Moreover, this NK-cell subset exhibits features of terminal differentiation and persists at higher frequency during at least
the first 6 months after acute IM. Finally, we demonstrate that this NK-cell subset preferentially degranulates and proliferates on
exposure to EBV-infected B cells expressing lytic antigens. Thus, early-differentiated NK cells might play a key role in the immune
control of primary infection with this persistent tumor-associated virus. (Blood. 2014;124(16):2533-2543)
Introduction
Natural killer (NK) cells are a subset of innate lymphocytes that
exhibit nonredundant antiviral functions in experimental mice.1 In
mice infected with the murine cytomegalovirus (MCMV), a subset
of NK cells bearing the activating receptor Ly49H expands and
persists at increased frequency for more than 2 months following
primary infection. Notably, these cells display an enhanced pro-
tective response against MCMV in adoptive transfer experiments.2
In humans, the peripheral blood compartment of NK cells is het-
erogeneous and accounts for 5% to 15% of lymphocytes. It is
composed of diverse differentiation stages, which can be deﬁned by
the expression of surface markers, such as the 2 types of inhibitory
receptors NKG2A and killer-cell immunoglobulin-like receptors
(KIRs).3,4 HumanNK cells seem to play an important antiviral role,
because patients with isolated NK-cell deﬁciencies exhibit an in-
creased susceptibility to herpes viruses.5 Furthermore, patients with
acute viral infections resulting from hantavirus, cytomegalovirus
(CMV), or chikungunya virus6-8 accumulate the late-differentiated
CD56dim NKG2C1 KIR1 NK-cell subset in peripheral blood.
However, none of these previous studies demonstrated a protective
role for speciﬁcally accumulated human NK-cell subsets against
virus-infected cells in vitro or in vivo.9,10
A ubiquitous persistent human virus, which has not been in-
vestigated in detail in this respect, is the primarily B-cell-tropic
Epstein-Barr virus (EBV). EBV is a g-herpes virus, which latently
infects the vast majority of the adult human population worldwide,
and is associatedwith B-cell and epithelial-cell malignancies.11 EBV
displays 2 modes of infection. One mode expresses latency genes
(latent EBV) leading toB-cell transformation in vitro and subsequent
generation of lymphoblastoid cell lines (LCLs). The other mode
expresses lytic genes (lytic EBV) leading to the production of in-
fectious viral particles and lysis of the host cell.12 Most primary
EBV infections occur before the age of 5 years and are usually
asymptomatic. Nevertheless, primary EBV infection occurring be-
yond this age may manifest as infectious mononucleosis (IM) that
affects around 10% of the population in Europe and the United
States.13,14 The usually self-limiting IM is characterized by a vig-
orous CD81 T-cell response that mainly targets EBV lytic epitopes15
and is associated with an increased risk of developing EBV-positive
classic Hodgkin lymphoma.16
The contribution of particular NK-cell subsets to the immune
control of EBV, especially during primary infection, remains elusive.
Here, we examined how blood NK-cell subsets accumulate and
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respond during IM, and to what extent they can recognize latently
and lytically EBV-infected B cells.
Material and methods
Study design
Twenty-two pediatric patients diagnosed with acute IM at the University
Children’s Hospital of Zurich were prospectively enrolled between October
2010 and April 2013. The onset date of symptoms was used as reference for
the longitudinal study. Twelve pediatric patients with IM symptoms, but
lacking the serological pattern compatible with acute EBV infection, were
also enrolled (IM-like) and donated peripheral blood at diagnosis. All serum
samples from IM-like patients were negative for HCMV DNA. Healthy
children and healthy adults aged 20 to 30 years were used as healthy
controls according to their EBV serology. Further details are outlined in the
supplemental Methods available on the BloodWeb site.
All participants provided informed consent in accordance with the
Declaration of Helsinki, and the institutional ethics committee approved all
protocols used.
Monoclonal antibodies and flow cytometry
Samples were acquired on a FACSCanto II and an LSR Fortessa (BD Bio-
sciences). Details about the handling of PBMCs, ﬂow cytometry analysis, and
antibodies used are described in the supplemental Methods.
Cell lines
Preparation of viral stocks, cell lines used, and induction and isolation of
lytic AKBM cells as well as the degranulation assay are described in the
supplemental Methods.
Viral loads quantification
EBV DNA levels were determined by real-time polymerase chain reaction.
The details of viral load measurements are outlined in the supplemental
Methods.
Statistical analysis
Datawere analyzed using Prism software (GraphPadSoftware, Inc.).P values
of ,.05 were considered signiﬁcant and were calculated with the non-
parametricMann-WhitneyU test or theWilcoxonmatched-pairs signed ranks
tests. Spearman’s rank correlation was used to examine associations between
2 quantitative values.
Results
Pediatric acute IM patients exhibit accumulation of activated
CD81 T cells and CD56dim NK cells
In young adults, IM is characterized by vigorous T-cell responses
mediated mainly by EBV-speciﬁc CD81 T cells.15 Nevertheless,
neither T-cell nor NK-cell responses in pediatric IM have been
characterized. Because we examined pediatric IM patients only,
we ﬁrst assessed the dynamics of the T-cell and NK-cell subset
responses in pediatric patients during the ﬁrst 6 months of IM.
Uninfected healthy individuals and pediatric patients with IM-like
diseaseswere used as controls. Acute IMpatients exhibited a twofold
increased median frequency of CD81 T cells (Figure 1A), a 15-fold
increased median frequency of activated CD81 T cells (Figure 1B),
and 60-fold increased median HLA-DR1 CD81 T-cell counts (data
not shown) comparedwith controls. The numbers of activated T cells
normalized within 6 months. These changes paralleled those of the
cellular EBV DNA levels through time (Figure 1C). Neither EBV
DNA levels nor frequency of CD81 T cells correlated with age
(supplemental Figure 1). Therefore, pediatric IMpatients as young as
2 years of age seem to exhibit the classic immunologic features found
in young adults with IM.
Moreover, we observed a 1.7-fold increase in the median
numbers of NK cells in acute IM compared with controls. These
numbers returned to baseline levels after 1 month (Figure 1D).
The blood NK-cell compartment is mainly composed of 2 well-
characterized functional subsets, the CD56bright CD162 and the
CD56dimCD161 subsets.17 The formerNK-cell subset produces large
amounts of cytokines on monokine stimulation, acquires cytotox-
icity only after prolonged activation, and is enriched in secondary
lymphoid organs.18 The latter NK-cell subset readily kills sus-
ceptible targets and can rapidly secrete IFN-g on engagement of
activating receptors.19 Acute IM patients displayed unchanged counts
of CD56bright CD162 NK cells (Figure 1F) and a 1.2-fold increase
in the median count of CD56dim CD161 NK cells (Figure 1H)
compared with controls. Interestingly, the intermediate NK-cell
subset CD56dimCD162 was increased in frequency during acute IM
(Figure 1E and supplemental Figure 2A) and exhibited a 3.7-fold
increase in median cell counts compared with controls (Figure 1G).
Thus we found a selective increase of the total CD56dim NK-cell
subset during acute IM.
Early-differentiated CD56dim NKG2A1 KIR2 NK cells accumulate
during IM and terminally differentiate as well as persist
afterward
To dissect the CD56dim NK-cell subset, we analyzed the expression
patterns of the inhibitory receptors NKG2A and KIRs, which might
allow assessment of subtle maturation stages spanning from early-
differentiated CD56dim NKG2A1 KIR2 to late-differentiated
CD56dim NKG2A2 KIR1 NK cells.3,4 Acute IM patients exhibited
a 1.8-fold increased median frequency of CD56dim NKG2A1 KIR2
NK cells (Figure 2A-B), but a 1.5-fold reduced median frequency of
CD56dim NKG2A2 KIR1 NK cells compared with EBV-negative
and EBV-positive control individuals (Figure 2C). Moreover,
acute IM patients displayed 4.8-fold and 3.5-fold increased median
absolute numbers of CD56dim NKG2A1 KIR2 NK cells compared
with EBV-negative and EBV-positive control individuals, respec-
tively (supplemental Figure 2B), but unchanged cell counts of the
late-differentiated CD56dim NKG2A2 KIR1 NK cells. We observed
no major changes in the frequencies and cell counts of the
CD56dim NKG2A2KIR2 and CD56dim NKG2A1KIR1NK-cell subsets
(supplemental Figure 2B-C). Furthermore, IM-like patients, that is,
patients with IM symptoms but no acute EBV infection, did not
exhibit NK-cell subset accumulation similar to that of IM patients.
We did not ﬁnd any differences in the frequency of this NK-cell
subset between EBV-seronegative and EBV-seropositive control
individuals. Surprisingly, the frequency of CD56dim NKG2A1KIR2
NK cells remained signiﬁcantly elevated in longitudinally followed
IM patients up to 6 months after acute IM, but returned to baseline
after 2 years (Figure 2B).
CD57 has been proposed as a marker of terminal differentiation
of NK cells3,20 and has been shown to be upregulated on CD56dim
NKG2C1 NK cells during acute infection with CMV, hantavirus,
or chikungunya virus.6-8 Therefore, we hypothesized that if the
accumulated CD56dim NKG2A1 KIR2 subset found in acute IM
patients is preferentially involved in the immune response against
EBV, it should acquire CD57 during the acute phase of IM to
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complete its terminal differentiation. Indeed, we observed a
2.5-fold increase in the median frequency of CD571 within the
CD56dim NKG2A1 KIR- subset from the acute IM phase to
1month later, but no changes in the CD56dimNKG2A2KIR1 subset
(Figure 2D-E, respectively). Thus, acute symptomatic EBV in-
fection elicits the speciﬁc accumulation of the CD56dim NKG2A1
KIR- NK-cell subset, its terminal differentiation, as well as its
persistence at higher frequency during the ﬁrst 6 months after
acute IM.
IM patients exhibit a stable KIR repertoire and unchanged
frequencies of CD56dim NKG2C1 NK cells
The KIR repertoire is composed of several activating and inhibitory
receptors speciﬁc for distinct groups of HLA class I alleles,21 is
Figure 1. Accumulation of activated HLA-DR1 CD81 T cells and
CD56dim NK cells during acute IM. PBMCs from healthy controls,
IM-like patients, and IM patients at acute phase (IM acute), at 1 (IM
1 month), and 6 months (IM 6 months) were analyzed by flow
cytometry. Frequencies of (A) CD81 T cells within the CD31 T-cell
population and (B) HLA-DR1 CD81 T cells within the CD81 T-cell
population in healthy controls (n 5 19), IM-like (n 5 11), and IM
acute (n 5 20), 1-month (n 5 10) and 6-month (n 5 7) patients. (C)
EBV DNA load in copies per 106 PBMCs in IM-acute (n 5 19),
1-month (n 5 14), and 6-month (n 5 9) patients. Counts (cells/mL
blood) of total NK cells (D) and frequencies of CD56bright CD162,
CD56dim CD162, and CD56dim CD161 NK-cell subsets within the
CD32 CD561 NK-cell population from representative healthy control,
IM-acute and 1-month patient (E). Counts (cells/mL blood) of (F)
CD56bright CD162, (G) CD56dim CD162, and (H) CD56dim CD161 NK
cells in healthy controls (n 5 31), IM-like patients (n 5 11), and
IM-acute (n 5 18), 1-month (n 5 10), and 6-month (n 5 8) patients.
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highly variable among individuals, and is stable throughout time
in healthy adults.22 Particular KIR receptors might be involved
in the immune control of viruses such as HIV,23-26 the hepatitis
C virus,27,28 or CMV.22,29 Therefore, to ensure that IM does
not lead to an accumulation of NK cells bearing speciﬁc KIRs,
we performed a comprehensive phenotypic KIR analysis30 in
a group of CMV-seronegative healthy controls and IM patients.
The KIR repertoire of IM patients remained stable throughout
the ﬁrst month of IM (Figure 3A), and the frequencies of single
KIR1CD56dim NK cells in IM patients were overall low compared
with controls (Figure 3B). Thus, IM is associated with the ac-
cumulation of a CD56dim NKG2A1 NK-cell subset, which does
not carry any increase in activating, nor inhibitory, KIR molecule
expression. Furthermore, CD56dim NK cells expressing NKG2C,
the activating counterpart of NKG2A,31 accumulate on CMV
infection,7,32,33 as well as on other viral infections in CMV-
positive individuals.6,8,34-36 Thus, we assessed whether a similar
accumulation occurs on EBV infection and therefore investigated
CMV-seronegative IM patients and controls to avoid bias as-
sociated with CMV carriage.37 We observed no changes in the fre-
quency ofNKG2C1NKcells within theCD56dimNKG2A2NK-cell
subset (Figure 3C-D) nor within the expanding CD56dim NKG2A1
KIR2 NK-cell subset (data not shown). Thus, CD56dim NKG2A1
KIR2 NKG2C2 NK cells accumulate during IM.
The preferential proliferation of CD56dim NKG2A1 KIR- NK cells
positively correlates with cellular EBV loads during acute IM
We next investigated whether the increase in the absolute numbers
of CD56dim NKG2A1 KIR- NK cells might be caused by active pro-
liferation of this NK-cell subset. We assessed the expression of the
proliferation marker Ki-67 in the CD56bright, the CD56dim NKG2A1
KIR2, and the CD56dim NKG2A2 KIR1 NK-cell subsets in acute IM
1month later.We found a twofold and a threefold increase in themedian
frequencyofKi-671 cellswithin theCD56dimNKG2A1KIR2NKcells
in acute IM compared with controls and IM at 1 month, respectively
(Figure 4A-B). However, we did not observe any increased proliferation
in the more differentiated NKG2A2KIR1NK subset, and there was no
difference when comparing EBV-negative with EBV-positive controls
(Figure 4A-B and data not shown). In addition, the precursor CD56bright
NK-cell subset, which exhibits strong proliferation properties and
responds tominute doses of cytokines in vitro, did not showan increased
frequency of Ki-671 cells in acute IM patients (Figure 4B). Notably, the
frequencies of proliferating Ki-671 cells within the CD56dim NKG2A1
KIR-positively correlatedwithEBVDNAlevels inPBMCs(Figure4C),
but not in serum (data not shown). No such correlation was observed
within the CD56dim NKG2A2KIR1NK-cell subset. This suggested
that EBV-infected B cells in IM patients might directly drive the pro-
liferation of early-differentiated CD56dim NK cells. We next asked
Figure 2. Accumulation and terminal differentiation
of the CD56dim NKG2A1 KIR2 NK-cell subset during
acute IM. PBMCs from controls and IM patients were
analyzed by flow cytometry. (A) Frequencies of CD56dim
NKG2A1 KIR2 NK cells within the CD56dim population
from representative healthy control, IM-acute, 1-month,
and 6-month patients. Frequencies of (B) CD56dim
NKG2A1 KIR2 and (C) CD56dim NKG2A2 KIR1 NK cells
in healthy EBV-negative controls (n 5 17), healthy EBV-
positive controls (n 5 20), IM-like patients (n 5 12), and
IM-acute (n 5 17), 1-month (n 5 11), 6-month (n 5 10),
and 2-year (n 5 4) patients. Frequencies of CD571 cells
within (D) the CD56dim NKG2A1 KIR2 and (E) the
CD56dim NKG2A2 KIR1 NK-cell subsets in healthy
EBV-negative controls (n 5 17), healthy EBV-positive
controls (n 5 20), and IM-acute (n 5 17), 1-month
(n 5 11), 6-month (n 5 10), and 2-year (n 5 4)
patients. Horizontal lines or single symbols indicate
median values. Error bars indicate interquartile ranges.
Mann-Whitney U tests.
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whether theproliferationof theCD56dimNKG2A1KIR2NK-cell subset
differs according to CD57 expression. Surprisingly, proliferation was
exclusively found within the CD57- fraction (Figure 4D-E). Our
ﬁnding aligns with previous studies showing a decreased proliferative
potential of CD571 NK cells compared with CD572 NK cells.3,20
Thus, CD56dim NKG2A1KIR2 CD572NK cells seem to proliferate
preferentially during acute IM but not 1 month later. Moreover, in the
acute phase, proliferation parallels the accumulation of this NK-cell
subset, which displays a sevenfold and a 4.8-fold median increase
compared with EBV-negative and EBV-positive controls, respec-
tively (Figure 4F). In addition, CMV status did not seem to inﬂuence
the NK-cell response (supplemental Figure 3).We did not observe any
correlation between the count of the CD56dimNKG2A1KIR2CD572
NK cells, nor the count of total NK cells, and the EBV DNA levels in
PBMCs or in serum (data not shown). Thus, early-differentiated NK
cells accumulate in IM patients after EBV-driven proliferation.
CD56dim NKG2A1 KIR2 NK cells preferentially target
EBV-infected B cells with lytic reactivation
CD56dimNKG2A1KIR2NKcells are functional againstHLA-class-
I-deﬁcient target cells, including the EBV-positive LCL 721.221 cell
line,4 but their reactivity toward HLA class I competent autologous
LCLs has not yet been assessed.Weobserved a lowoverall frequency
of degranulating NK cells on coculture with autologous LCLs.
Nevertheless, the CD56dim NKG2A1 KIR2 NK subset, which ac-
cumulates during IM, displayed a more than twofold increase in
degranulation compared with the CD56bright and CD56dim NKG2A2
KIR1 NK-cell subset (Figure 5A). In contrast, the EBV-negative
allogeneic B-cell line L428, which exhibits an activated phenotype
comparable to LCLs, elicits an increased response in the CD56dim
NKG2A2 KIR1 NK subset only (Figure 5B). This low NK-cell re-
sponse against autologous LCLsmight be a result of their high surface
level of HLA class I and HLA-E which might engage the NK-cell
inhibitory receptors KIR and NKG2A, respectively. Indeed, EBV-
infected B cells upregulated HLA class I38 and HLA-E (Figure 5C).
On the other hand, induction of the lytic cycle of EBV infection
has been shown to sensitize EBV-infected B cells to NK-cell killing
using the EBV-positive Akata Burkitt lymphoma reporter cell line
AKBM,39 which allows the puriﬁcation of Akata Burkitt lymphoma
cells with and without EBV lytic reactivation, respectively. Hence, we
tested the degranulation of the CD56dim NKG2A1 KIR2 NK subset
against either latent AKBM or lytic AKBM cells from convalescent
Figure 3. Frequencies of single KIR-positive and
NKG2C1 CD56dim NK cells are not altered during
acute IM. (A) Frequencies of CD56dim NKG2A2 NK
cells expressing the 7 analyzed KIRs from 1 repre-
sentative CMV-seronegative IM patient at acute phase
and at 1 month. The presence of 1 KIR in a combination
is represented by a color code below the graph.
(B) Frequencies of single KIR-positive CD56dim NK cells
in healthy controls (Ctl, n 5 11) and IM patients
(n 5 10) at acute phase (A) and at 1 month (M1). (C)
Frequencies of NKG2C1 CD571 NK cells within the
CD56dim NKG2A2 population from 1 CMV-seronegative
and 1 CMV-seropositive IM patient at acute phase
and at 1 month. (D) Frequencies of NKG2C1 NK cells
within the CD56dim NKG2A2 NK cell population
in CMV-seronegative healthy controls (n 5 13),
CMV-seronegative (n 5 10), and CMV-seropositive
(n 5 5, red) IM patients at acute phase and at
1 month (n 5 2 for CMV-seropositive, red lines).
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IM patients and healthy EBV-positive controls and compared it to the
CD56bright and the CD56dim NKG2A2 KIR1 subsets. To avoid HLA
class I/KIR mismatch bias, we speciﬁcally assessed the degranulation
in KIR1 matched (KIR2DL2/DL3/3DL11) NK cells according to
the AKBM genotype (Bw4/C1/C1). We could conﬁrm increased
responses of NK cells against lytic compared with latent AKBM
cells (Figure 5D-F) previously shown to be mediated by a down-
regulation of the inhibitory ligands HLA-class I and HLA-E and
an upregulation of the activating ligands CD112 and ULBP-1.39
Similarly, we also found increased expression of activating ligands
Figure 4. Increased count of CD56dim NKG2A1
KIR2 CD572 NK cells during acute IM is caused
by preferential proliferation. (A) Representative exam-
ples of costaining for NKG2A and Ki-67 and costaining
for KIR and Ki-67 on CD56dim NK cells in healthy control
and IM-acute and 1-month patients. (B) Frequencies of
Ki-671 cells within the CD56bright, CD56dim NKG2A1
KIR2, and CD56dim NKG2A2 KIR1 NK-cell subsets in
healthy controls (n 5 21), in IM-acute (n 5 15), and in
1-month patients (n 5 7). (C) Correlation of EBV DNA
loads (copies per 106 PBMCs) and frequencies of
Ki-671 cells within the CD56dim NKG2A1 KIR2 NK-cell
subset from acute IM patients. Spearman r 5 0.53,
P (2-tailed) 5 .042. (D) Representative example of
costaining for CD57 and Ki-67 on CD56dim NKG2A1
KIR2 NK cells in an IM-acute and 1-month patient.
(E) Frequencies of Ki-671 cells within the CD56dim
NKG2A1 KIR2 NK cells according to CD57 expression
in healthy controls (n 5 15), IM-acute (n 5 9), and
1-month (n 5 4) patients. (F) Count of CD56dim
NKG2A1 KIR2 CD572 in healthy EBV-negative controls
(n 5 14), healthy EBV-positive controls (n 5 17), IM-like
(n 5 11), IM-acute (n 5 17), 1-month (n 5 10), and
6-month (n 5 8) patients. Horizontal lines indicate
median values of a given symbol. Mann-Whitney
U tests.
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on lytic EBV infected LCLs (supplemental Figure 4D-G), however
the expression of the respective activating receptors in the CD56dim
NKG2A1 KIR2 NK-cell subset was unaltered in IM patients
(supplemental Figure 4A-C). Importantly, the CD56dim NKG2A1
KIR2 NK-cell subset exhibited a signiﬁcantly stronger degranulation
against lytic AKBM cells compared with all other subsets
(Figure 5F). We found no difference in the degranulation capacity
of CD56dim NKG2A1 KIR2 NK between convalescent IM patients
and controls, suggesting that these NK cells are functional and
are not in an exhausted state in the aftermath of acute IM. Thus,
Figure 5. Increased cytotoxic degranulation of the
CD56dim NKG2A1 KIR2 NK subset against EBV-
infected B cells with lytic replication. (A) PBMCs
from 6 healthy EBV-positive donors were cocultured
with autologous LCLs and (B) EBV-negative L428 at an
effector to target ratio of 10:1 for 6 hours. Frequencies
of degranulating (CD107a1) cells within the CD56bright
(Bright), the CD56dim NKG2A1 KIR2 (Dim N1/K2),
and the CD56dim NKG2A2 KIR1 (Dim N2/K1) NK-cell
subsets were assessed by flow cytometry at the end of
the coculture. (C) HLA class I and HLA-E expression on
CD191 B cells from PBMCs (light gray histogram) and
from autologous LCLs (dark gray histogram). Isotype
controls are depicted as a white histogram. (D)
Representative example of frequencies of CD107a1
NK cells within the 3 NK-cell subsets after coculture
with latent AKBM or lytic AKBM. Frequencies of
degranulating (CD107a1) NK cells within the CD56bright
(Bright), the CD56dim NKG2A1 KIR2 (Dim N1/K2) and
the CD56dim NKG2A2 matched KIR1 (Dim N2/K1) NK-
cell subsets in PBMCs from 3 convalescent IM patients
(open symbols) and 3 healthy EBV-positive donors
(filled symbols) cocultured with (E) latent AKBM or (F)
lytic AKBM (n 5 6). Horizontal lines indicate median
values of a given subset, Wilcoxon matched-pairs signed
ranks tests.
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CD56dim NKG2A1 KIR2 NK cells preferentially recognize lytic
EBV-replicating B cells.
EBV lytic replication triggers in vitro proliferation of
NKG2A1 KIR- NK cells
Finally, we examined the proliferation of NKG2A1 KIR2 NK cells
using staining for Ki-6740 in an in vitro model of primary EBV
infectionof cord bloodmononuclear cells (CBMC) infectedwith either
wild-type (WT) EBV or lytic replication incompetent BZLF1-KO
(BZ1KO) EBV. Both viruses elicited similar IFN-type I responses
24 hours postinfection (Figure 6A) and exhibited comparable infec-
tion capacity, as evaluated by the frequencies ofGFP1EBV-infected
B cells 3 days postinfection (Figure 6B). Because most NK cells
upregulated CD56 surface expression during in vitro culture
(Figure 6C, ﬁrst row), we did not distinguish between the CD56bright
Figure 6. EBV-driven in vitro proliferation of NKG2A1 KIR- NK cells
partially depends on expression of lytic antigens. Proliferation of
NK-cell subsets was assessed 7 days after inoculation of CBMCs
with either WT EBV, BZLF1-KO (BZ1KO) EBV or PBS (MOCK). (A)
Concentrations of IFN-a in supernatant 24-hour postinoculation on
MOCK, WT EBV, and BZ1KO EBV infection (pg/mL; n 5 5). (B)
Representative example of CD19 and GFP costaining within live
lymphocytes 72 hours postinfection. Numbers indicate frequencies of
GFP-negative or GFP-positive cells within the CD191 B-cell popula-
tion. (C) Frequencies of Ki-671 NKG2A1 KIR2 NK cells 7 days after
inoculation of CBMCs with mock, WT EBV, or BZ1KO EBV, or after
stimulation with IL-2. The depicted gates were assessed within live
lymphocytes (first row), CD32 CD561 NK cells (second row), and
NKG2A1 KIR2 NK cells (third row). (D) Ratio of NKG2A1 KIR2 Ki-671
NK-cell counts from WT EBV- or BZ1KO EBV- over mock-infected
CBMCs. (E) Frequencies of CD56dim NKG2A1 KIR2 NK cells in
newborns (n 5 8), children aged 1 to 5 years (n 5 16), children aged
5 to 15 years (n 5 17), and adults aged 20 to 30 years (n 5 15). (F)
Counts of CD56dim NKG2A1 KIR- NK cells in children aged 1 to 5 years
(n 5 14), children aged 5 to 15 years (n 5 15), and adults aged 20 to
30 years (n 5 15). Horizontal lines indicate median values of a given
age group, Mann-Whitney U tests.
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andCD56dimNKcells for further analysis.We observed an increased
proliferation of NKG2A1KIR2NK cells 7 days after infection with
WT EBV compared with mock (Figure 6C-D). Infection with
BZ1KO EBV, with abolished expression of all EBV lytic antigens,
elicited a twofold-reduced proliferation ofNKG2A1KIR2NKcells,
in comparison withWTEBV (median ratio 2.9 vs 6.3,P5 .04). This
indicates that the proliferation of NKG2A1KIR2NK cells partially
depends on the presence of EBV-infected cells expressing lytic
antigens. Notably, NKG2A2 KIR1 NK cells exhibit similar
proliferation on infection with WT EBV, but this is not affected by
the absence of lytic antigens (data not shown). Finally, we assessed
a possible age-dependent distribution of this early-differentiated
NK-cell subset in peripheral blood from healthy individuals that
might correlate with the known age-dependent prevalence of prima-
ry symptomatic EBV infection. Indeed, CD56dim NKG2A1 KIR2
NK cells both decreased in frequency (Figure 6E) and in absolute num-
bers (Figure 6F) during the ﬁrst decade of life, whereas the counts of
CD56dimNKG2A2KIR1NKcells remained unchangedwith age (data
not shown).Thus,CD56dimNKG2A1KIR2NKcells,which decrease
in frequency in the ﬁrst decade of life, preferentially degranulate and
proliferate in response to lytic EBV-replicating B cells.
Discussion
Here we demonstrate in longitudinally followed pediatric IM
patients that an early-differentiated CD56dim NKG2A1 KIR2 NK
subset selectively accumulates during primary symptomatic EBV
infection and persists at increased frequencies formonths.Moreover,
our data indicate that these NK cells speciﬁcally recognize B cells
undergoing lytic EBV replication. Our ﬁndings are unprecedented
and suggest that responses of NK-cell subsets to viral infections may
not be conﬁned to late-differentiated populations.6-8 Moreover,
distinct NK-cell subsets may be rather pathogen-speciﬁc.
Remarkably, althoughwe found increased counts in the cytotoxic
CD56dim NK-cell subset, but not in the less-differentiated CD56bright
CD16- NK-cell subset, we could not conﬁrm the previously reported
expansion of CD56bright CD161NK cells during acute symptomatic
EBV infection.41 We rather observed an unusual increase of the
intermediate CD56dim CD162 NK-cell subset, which might be
explained by downregulation of CD56 on CD56bright NK cells or by
downregulation ofCD16 such as observed in degranulatingCD56dim
NK cells on coculture with K562 cells (unpublished observations).
This CD56dim NK-cell subset is distinctly characterized by NKG2A
expression and by the absence of KIRs. It strikingly differs from
that of other acute viral infections such as CMV, hantavirus, or
chikungunya virus infection,6-8 inwhich theCD56dimKIR1NKG2C1
NK-cell subset was shown to be expanded. CD56dim NKG2A1 KIR-
NK cells are considered early-differentiated4 as suggested by the
speciﬁc temporal reconstitution of the NK-cell subsets in hemato-
poietic stem-cell transplanted patients42-44 and in mice with human
immune-system components.3 Based on our results, ongoing dif-
ferentiation of these early-differentiated NK cells seems to occur
during the ﬁrst weeks of IM; this is further supported by studies in
EBV-infected mice with human immune-system components.45
Another striking feature of the IM-associated NK-cell response is
the persistence of elevated frequencies of the CD56dim NKG2A1
KIR- NK cells for up to 6 months after CD81 T-cell numbers
have normalized. Nevertheless, we observed no difference in the
peripheral blood frequencies of these NK cells between EBV-
seropositive and EBV-seronegative control individuals, contrasting
the situation after CMV infection where late differentiated NK cells
persist at increased levels.32 This might be explained by compart-
mentalized NK-cell accumulation during asymptomatic EBV in-
fection, as has been proposed for EBV-speciﬁc T-cell responses
in the tonsils,47,48 and suggests that the acute symptomatic EBV
infection systemically imprints theNK-cell compartment differently.
Accordingly, CD56bright NKG2A1 and mostly KIR- NK cells were
found enriched in tonsils of EBV-seropositive compared with EBV-
seronegative individuals.49 Indeed, this could result from ongoing
lytic EBV replication at these sites in asymptomatic EBV carriers.46
Additionally, we determined that the increased CD56dim NKG2A1
KIR- NK-cell numbers during acute IMwere caused by the selective
proliferation of this subset. Such selectivity has not been reported
to our knowledge during other acute viral infections. Because
the CD56dim NKG2A1 KIR2 NK subset only actively proliferated
during the acute phase of IM and was only increased in absolute
numbers at this stage, the persistently increased frequency of this
subsetmight be caused by either a longer survival of theseNKcells in
peripheral blood or a continuous EBV-driven proliferation in tissues
followed by recruitment and accumulation in the peripheral blood.
Indeed, the numbers of EBV-infected B cells quickly decrease in
the peripheral blood after acute IM,50 and EBV turns off antigen
expression in these cells.51 Thus, an EBV-driven proliferation of NK
cells during IM convalescence might not be expected in peripheral
blood. Nevertheless, IM patients exhibit prolonged oral EBV
shedding up to 1 year after IM,14,52 indicating that EBV replication
occurs in the oropharynx. This, in turn, may result in local EBV-
driven proliferation of NK cells after IM that are subsequently
recruited in peripheral blood.
Several lines of evidence support the hypothesis that EBV-
infected B cells, and not proinﬂammatory cytokines, directly
drive the unique proliferation of early-differentiated NK cells:
ﬁrst, a similar expansion is not observed in patients with IM-like
symptoms; second, the precursor CD56bright NK-cell subset, which
possesses strong proliferative responses to cytokines, does not
display an enhanced proliferation during acute IM; third, the
frequency of proliferating early-differentiated NK cells positively
correlates with EBV loads in blood cells. On the other hand, we did
not observe any correlation between overall NK-cell counts and viral
load. These ﬁndings are in conﬂict with previous studies reporting
a negative correlation between NK-cell frequencies and counts and
cellular EBVDNA levels41 or a positive correlation betweenNK-cell
counts and EBV DNA levels in whole blood.14 Hence, acute IM
elicits the proliferation ofCD57-CD56dimNKG2A1KIR2NKcells,
which then differentiate to become CD57 positive. A fraction of
this subset might represent antigen-experienced NK cells that
speciﬁcally responded to EBV-infected cells in a similar fashion
as during MCMV infection of experimental mice in which these
NK cells are suggested to constitute memory NK cells.2,53
These early-differentiated NK cells exhibit enhanced degranula-
tion against EBV-infected B cells with lytic reactivation. Reduced
HLA-E-mediated inhibitory signals on EBV-infected cells express-
ing lytic antigensmight lead to preferential recognition byNKG2A1
NK cells and could be caused by decreased availability of class I
leader signal peptide39 or via direct modulation of HLA-E by EBV-
derived peptides.54 In addition to these diminished inhibitory signals,
we and others have observed an increased expression of activating
ligands in lytic EBV infection,39 and NKG2D and DNAM1 have
been identiﬁed as the main activating NK-cell receptors for the
recognition of B cells with lytic EBV infection in vitro.39 In good
agreement, loss of NKG2D function has been found to confer sus-
ceptibility to uncontrolled EBV infection and neoplasia in XMEN
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patients in vivo.55 How lytic EBV infection leads to the upregulation
of activating ligands, however, remains unclear. NKG2D ligands have
been reported to be upregulated on induction of the DNA damage
response and cytosolic DNA recognition.56 Although EBV, like other
herpes viruses, packages its DNA into the viral capsid in the nucleus
during lytic replication, some of it might become accessible during
capsid transit through the cytosol and trigger this pathway of NKG2D
ligand upregulation. Newly infected B cells transiently express sever-
al lytic antigens, mostly from the immediate early and early lytic
genes,57 and some of these antigens might contribute to the prolifera-
tion of NKG2A1 KIR2 NK cells on EBV infection of CBMCs.
We suggest that CD56dim NKG2A1 KIR- NK cells preferentially
recognize autologous B cells with lytic EBV infection, and that rec-
ognition of lytic EBV replication drives the characteristic NK-cell
accumulation that we observed in acute IM patients. Because IM only
manifests in older children, adolescents, and young adults with
decreased frequencies of this herein newly described EBV-reactive
NK-cell subset, we postulate an age-dependent impaired NK-cell-
mediated immune control of EBV infection as one possible cause
of IM.
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Oropharyngeal Group A Streptococcal
Colonization Disrupts Latent Epstein-Barr
Virus Infection
Seigo Ueda,1,2,5 Satoshi Uchiyama,4 Tarik Azzi,1,2 Claudine Gysin,2,3 Christoph Berger,1,2 Michele Bernasconi,1,2
Yasuaki Harabuchi,5 Annelies S. Zinkernagel,4 and David Nadal1,2
1Experimental Infectious Diseases and Cancer Research, Division of Infectious Diseases and Hospital Epidemiology, 2Children’s Research Center, and
3Division of Otolaryngology, University Children’s Hospital of Zurich, and 4Division of Infectious Diseases and Hospital Epidemiology, University Hospital
Zurich, University of Zurich, Switzerland; and 5Department of Otolaryngology/Head and Neck Surgery, Asahikawa Medical University, Japan
Epstein-Barr virus (EBV) infects >90% of the human population within the ﬁrst 2 decades of life and establish-
es reversible latent infection in B cells. The stimuli that lead to switching from latent to lytic EBV infection in
vivo are still elusive. Group A streptococci (GAS) are a common cause of bacterial pharyngotonsillitis in chil-
dren and adolescents and colonize the tonsils and pharynx of up to 20% of healthy children. Thus, concomitant
presence of EBV and GAS in the same individual is frequent. Here, we show that EBV carriers who are colo-
nized with GAS shed EBV particles in higher numbers in their saliva, compared with EBV carriers not colo-
nized with GAS. Messenger RNA levels of the master lytic regulatory EBV gene BZLF1 were more frequently
detected in tonsils from EBV carriers colonized with GAS than from EBV carriers not colonized. Heat-killed
GAS, potentially mimicking GAS colonization, elicited lytic EBV in latently infected lymphoblastoid cell lines
(LCLs) partially via Toll-like receptor 2 triggering, as did puriﬁed GAS peptidoglycan. Thus, colonization by
GAS might beneﬁt EBV by increasing the EBV load in saliva and thereby enhancing the likelihood of EBV
spread to other hosts.
Keywords. Epstein-Barr virus (EBV); group A Streptococci (GAS); tonsil; oropharynx; lytic; latent; TLR2;
salivary shedding.
More than 90% of the adult population is persistently
and asymptomatically infected with Epstein-Barr virus
(EBV), a human B-lymphotropic γ-herpesvirus [1].
Primary infection with EBV is acquired mainly in
childhood via saliva [1]. The oropharynx is the portal
of entry and exit, where the palatine tonsils act as reser-
voir for EBV [2–4]. In its latent form in B cells, EBV ex-
presses a limited number of genes, does not replicate,
and its DNA is propagated to daughter cells during cell
division. By contrast, in its lytic form, EBV expresses
genes required for replication and generation of infec-
tious virus particles resulting in host cell lysis and virus
release [5]. The default state of EBV infection is the
latent form, which is reversible, permitting the creation
of new viral particles and transmission to other hosts
[6]. The mechanisms responsible for switching to the
lytic form in vivo are not completely understood.
EBV is associated with Burkitt lymphoma (BL),
Hodgkin disease (HD), and posttransplantation lym-
phoproliferative disease [7]. These B-cell tumors display
distinct patterns of EBV latency gene expression [8].
The oncologic potential of latent EBV is indicated by
its unique capacity to growth transform B cells in vitro
to lymphoblastoid cell lines (LCLs) [1]. Thus, disruption
of latency is not only essential to enable transmission of
EBV to other hosts but might be an important factor to
limit EBV-induced B-cell lymphoproliferation.
Being immunocompromised increases the risk of
EBV-associated B-cell tumors [9]. But nonimmunocom-
promised individuals may also develop EBV-associated
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BL or HD. EBV-associated HD is more likely to develop when
primary EBV infection occurs in adolescence and manifests as
infectious mononucleosis with an exuberant immune activation
[10]. In endemic BL, >95% of the tumors are EBV positive, and
they are epidemiologically linked to Plasmodium falciparum
malaria, resulting in chronic immune activation [11]. The
pattern-recognition receptor Toll-like receptor 9 (TLR9) is abun-
dantly expressed in B cells, and it senses DNA and the malaria
parasite’s pigment hemozoin [12–14].We recently demonstrated
that TLR9 activation of B cells inhibits lytic EBV during primary
infection and inhibits the switching of latent to lytic EBV in
chronic infection in vitro [15, 16].
Group A streptococci (GAS) colonize tonsils and the
pharynx of up to 20% of healthy children [17]. Considering the
high prevalence of EBV and GAS, concomitant presence of
both microorganisms in the same individual is frequent. TLR9
senses bacterial DNA and is crucial for controlling GAS infec-
tions [18]. One may thus reason that the presence of GAS in
tonsils may direct the EBV life cycle toward latency, thereby
impairing EBV transmission to other hosts via saliva.
Here, we investigated the inﬂuence of GAS on EBV’s life
cycle and salivary shedding and the mechanisms involved.
METHODS
Ethics Statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. The Ethics Commission of the
Canton of Zurich approved the study (StV 40/05). All subjects
or their caregivers provided written informed consent.
Cell Culture
The EBV-producer cell line B95.8, Akata BL cells, tonsillar
mononuclear cells (TMCs), and LCLs were maintained in
Roswell Park Memorial Institute 1640 medium (Sigma-Aldrich,
Buchs, Switzerland) with 10% heat-inactivated fetal bovine
serum (Life Technologies, Zug, Switzerland), 1% L-glutamine,
and 1% penicillin-streptomycin, referred to hereafter as R10.
Enzyme-Linked Immunosorbent Assay (ELISA)
Interleukin 6 (IL-6) or interleukin 10 (IL-10) levels were mea-
sured using human IL-6 or IL-10 ELISA kits (R&D Systems,
Abingdon, United Kingdom) following the manufacturer’s
instructions.
DNA Extraction and EBV DNA Detection
Saliva samples were obtained and DNAwas extracted as reported
elsewhere [19]. EBV DNA levels were determined by quantitative
real-time PCR (qPCR) targeting the conserved EBV BamHI W
region, as reported elsewhere [20].
RNA Extraction and qPCR
Total RNA was extracted using the RNeasy Mini Kit (Qiagen)
following the manufacturer’s instructions. After DNase I
treatment, 1 µg of total RNA was used as template for reverse
transcription by use of a High-Capacity cDNA Reverse Tran-
scription Kit (Life Technologies). qPCR for human and EBV
gene messenger RNA (mRNA) was performed using speciﬁc
primers and probes for IL-6, IL-10, or BZLF1, as reported else-
where [15], and for TLR1–10 (Life Technologies). All reactions
were performed on a real-time PCR machine (7900HT;
Life Technologies) with TaqMan Gene Expression Master Mix
(Life Technologies). The relative gene expression was calculated
for each gene of interest by using a ΔΔCT method, where CT
values were normalized to the value for the housekeeping gene
hydroxymethylbilane synthase (HMBS) [15].
Isolation of TMCs and EBV Serology
TMCs were isolated from palatine tonsils obtained from pa-
tients who underwent routine tonsillectomy, as reported else-
where [21]. The EBV serologic characteristics of the TMC
donors were determined using the Immunodot-Mono G and
Mono M kit according to the manufacturer’s instructions
(Ruwag Diagnostics, Bettlach, Switzerland).
Preparation of Stock EBV
Supernatant of B95.8 cells was obtained as reported elsewhere
[21] and stored at −80°C. The cell-free supernatants con-
tained approximately 1 × 108/mL EBV DNA as evaluated by
qPCR [20].
GAS Strains
The well-characterized clinical isolate M1T1 GAS strain 5448
[22] was grown to logarithmic phase in Todd-Hewitt broth
(Becton Dickinson, Allschwil, Switzerland) containing 2% yeast
extract (THY; Oxoid, Pratteln, Switzerland) and was resuspend-
ed in Roswell Park Memorial Institute 1640 medium at a ﬁnal
concentration of 2 × 109 colony-forming units/mL. Bacteria
were killed by heating (at 85°C for 60 minutes) or by sonication
(Sonoplus HD2070; Bandelin Electronic, Berlin, Germany) with
20 kHz at 70 W (amplitude, 100%) for 15 minutes on ice.
Detection of GAS Colonization
Explanted tonsils were rolled over 5% sheep blood agar that
was incubated for 48 hours. GAS was identiﬁed by latex aggluti-
nation for Lanceﬁeld group A (Bio-Rad, Cressier, Switzerland)
and detection of pyrrolidonyl peptidase production, using L-
pyrrolidonyl-beta-naphthylamid (0.7%) disks (Oxoid, Pratteln,
Switzerland).
Stimulation of EBV-Infected Cells With GAS
To model acute infection, TMCs plus B95.8 culture superna-
tants were used, and to model persistent infection, LCLs and
Akata cells [23] were used. LCLs were established from TMCs
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by infection with B95.8 EBV. Heat-killed or sonicated GAS at a
multiplicity of infection (MOI) of 100 or 20 µg/mL of GAS
peptidoglycan (Toxin Technology, Sarasota, FL) was added
for 24 hours. Apoptosis was assessed using a PE Annexin V
Apoptosis Detection Kit I according to the manufacturer’s in-
structions (Becton Dickinson). To neutralize TLR2, LCLs were
preincubated with anti-TLR2 polyclonal antibodies (LabForce
AG-InvivoGen, Nunningen, Switzerland).
Flow Cytometry
For TLR2 detection, ﬂuorescein isothiocyanate (FITC)–labeled
anti-TLR2 monoclonal antibodies (TL2.1; LabForce AG-Inviv-
oGen) were used, and FITC-labeled mouse immunoglobulin
G2a (Becton Dickinson) was used as isotype control. For TLR2
and BZLF1 detection, following TLR2 staining, cells were ﬁxed
with 2% paraformaldehyde (Sigma-Aldrich) and permeabilized
using 0.4% Triton X-100 before adding anti-BZLF1 antibodies
(BZ1; Santa Cruz Biotechnology, Heidelberg, Germany)
followed by PE-labeled rabbit anti-mouse immunoglobulin G1
(Santa Cruz Biotechnology). Data on apoptosis or TLR2 and/or
BZLF1 detection were collected using a FACSCanto II (Becton
Dickinson) and were analyzed using FlowJo software.
Statistical Analyses
Analyses of statistical signiﬁcance were based on a 2-tailed
paired or unpaired Student t test, Wilcoxon signed rank test,
Mann–Whitney U test, or χ2 test. Differences with a P value of
<.05 were regarded as statistically signiﬁcant.
RESULTS
Saliva From EBV-Infected GAS-Colonized Individuals
Contained More EBV Than Saliva From EBV-Infected
Individuals Not Colonized With GAS
We asked whether salivary EBV shedding is inﬂuenced by colo-
nization with GAS. Thus, we assayed saliva from EBV-infected
individuals who were or were not colonized with GAS by using
qPCR targeting EBV DNA to detect viral DNA contained in
intact EBV particles. We detected EBV in 7 of 12 GAS-colo-
nized individuals (58%; median age, 6.0 years [range, 2.2–15.0
years]; mean age, 6.2 years) and 9 of 15 GAS-negative individu-
als (60%; median age, 5.3 years [range, 3.1–13.8 years]; mean
age, 6.0 years). The number of EBV DNA copies in saliva from
GAS-colonized EBV-infected individuals was higher than that
in saliva from noncolonized individuals (P = .03; Figure 1).
More-Frequent BZLF1 mRNA Expression in Tonsils From GAS-
Colonized Than From Noncolonized EBV-Infected Individuals
The EBV load in saliva may reﬂect distinct EBV replication in
oropharyngeal epithelial cells, mucosa-associated B cells, or
both. Since determination of EBV replication in primary epi-
thelial cells is not feasible, we measured BZLF1 mRNA expres-
sion in tonsils. BZLF1 is an immediate-early lytic EBV gene,
the expression of which is sufﬁcient to initiate EBV replication.
Tonsil tissues from 5 of 8 GAS-colonized individuals expressed
BZLF1 mRNA (62.5%; median age, 5.3 years [range, 2.8–6.8
years]; mean age, 4.9 years), in contrast to 1 of 8 GAS-negative
individuals (12.5%; median age, 4.8 years [range, 3.1–6.0
years]; mean age, 4.8 years; P = .04; Figure 2A). IL-6 and IL-10
mRNA expression levels determined by human speciﬁc qPCRs
showed no signiﬁcant differences between GAS-positive and
GAS-negative tonsils (Figure 2B and 2C), suggesting a similar
inﬂammation status.
Heat-Killed but Not Sonicated GAS Induced Lytic EBV In Vitro
After EBV Exposure
Heat-killed GAS are intact bacteria that mimic colonizing GAS.
In contrast, sonication disrupts GAS, resulting in fragmentation
and release of bacterial cell wall components and DNA, mim-
icking an acute GAS infection during which GAS are lysed by
both the immune system and antibiotics. We inoculated TMCs
with EBV B95.8 and concomitantly stimulated them with heat-
killed or sonicated GAS at a MOI of 100. We then measured
EBV and HMBS mRNA expression levels by qPCR 24 hours
after inoculation with EBV. Levels of BZLF1 mRNA in TMCs
24 hours after stimulation with heat-killed GAS were higher
than in nonstimulated TMCs or in TMCs stimulated with soni-
cated GAS (P = .03; Figure 3A). Furthermore, heat-killed GAS
did not affect latent EBV (LMP1 and EBNA3C; data not
Figure 1. Saliva from Epstein-Barr virus (EBV)–infected group A strepto-
coccus (GAS)–colonized individuals contained more EBV particles than
saliva from EBV-infected noncolonized individuals. The number of EBV
DNA copies per milliliter in saliva samples from EBV carriers who under-
went routine tonsillectomy was determined by quantitative real-time poly-
merase chain reaction after DNase I treatment. Results for GAS-positive
(n = 12) and GAS-negative (n = 15) individuals were compared. P values
were calculated using the Mann–Whitney U test. *P = .03.
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shown), IL-6, and IL-10 mRNA expression in TMCs, compared
with no stimulus (Figure 3B and 3C). In contrast, sonicated
GAS increased IL-6 and IL-10 mRNA expressions in TMCs,
compared with no stimulus or heat-killed GAS (P = .03;
Figure 3B and 3C). Thus, neither heat-killed nor sonicated GAS
inﬂuenced latent EBV gene expression. In contrast, heat-killed
GAS strongly induced lytic EBV infection in TMCs exposed de
novo to EBV, whereas sonicated GAS did not. The latter
induced strong cytokine gene expression in TMCs, whereas
heat-killed GAS did not.
Heat-Killed GAS Induced Lytic EBV and Caused Cell Death
in Latently EBV-Infected B Cells
Next, we asked whether GAS modulates EBV persistent B-cellular
infection. We used LCLs as a model for persistent (latent) EBV
infection and stimulated them with heat-killed or sonicated GAS
at a MOI of 100. EBV and mRNA expression levels of human
genes were measured by qPCR 24 hours later. BZLF1 mRNA
levels in LCLs exposed to heat-killed GAS were higher (P = .02)
than in LCLs with or without exposure to sonicated GAS
(Figure 4A).
Figure 2. BZLF1 messenger RNA (mRNA) in tonsils from Epstein-Barr virus (EBV)–infected group A streptococcus (GAS)–colonized individuals was more
frequently detectable than in noncolonized individuals. Levels of BZLF1 (A ), IL-6 (B ), and IL-10 (C ) mRNA expression in tonsil tissues from EBV-seropositive
patients who underwent routine tonsillectomy were analyzed by quantitative real-time polymerase chain reaction. Results for GAS-positive (n = 8)
and GAS-negative (n = 8) individuals were compared. BZLF1 expression values above the lower detection limit were considered positive, and those below
the lower detection limit were considered negative. P values were calculated using the χ2 test. *P = .04.
Figure 3. Heat-killed but not sonicated group A streptococcus (GAS) induced lytic Epstein-Barr virus (EBV) after de novo in vitro EBV exposure. Tonsillar
mononuclear cells (TMCs) were inoculated with supernatants from B95.8 cells (EBV-producer cells). Concomitantly, heat-killed or sonicated GAS were
added, and then cell pellets were harvested and subjected to quantitative real-time polymerase chain reaction to determine expression of BZLF1 (A), IL-6
(B ), and IL-10 (C ) messenger RNA (mRNA) expression. Results shown were pooled from TMCs from 6 donors and are expressed as mean values ± standard
error of the mean. P values were calculated using a Wilcoxon signed rank test. *P = .03.
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We asked whether the increased BZLF1 mRNA levels after
exposure to heat-killed GAS were associated with B-cell death.
We assessed late apoptosis by determining the percentage of
7-aminoactinomycin D (7-AAD)–stained cells by ﬂow cytome-
try in LCLs following stimulation or no stimulation. Exposure
to heat-killed GAS for 24 hours resulted in higher percentages
of 7-AAD–stained cells as compared to exposure to sonicated
GAS or controls (P = .008; Figure 4B). There were no differenc-
es in percentages of early apoptotic cells as assessed by ﬂow
cytometry after staining with Annexin V and 7-AAD. This was
conﬁrmed by assessing cell viability, using the Trypan blue
exclusion method (not shown). The number of EBV DNA
copies after DNase I treatment in the supernatants of LCLs
exposed to heat-killed GAS were higher than in controls
(P = .02; Figure 4C), corroborating our above-described in vivo
observations of higher EBV copies in tonsils of GAS-colonized
individuals. Exposure to sonicated GAS resulted in lower EBV
DNA copies, compared with no exposure (P = .02; Figure 4C).
This is in line with our previous study showing that TLR9
triggering results in suppression of switching from latent to
lytic EBV. Sonicated GAS contain increased levels of GAS
DNA, which has been recently demonstrated to trigger TLR9
and subsequently induce proinﬂammatory cytokine expression
[18, 24].
Heat-killed GAS did not affect the levels of EBNA3C latent
EBV (not shown) or IL-6 (Figure 4D), although it slightly upre-
gulated IL-10 mRNA expression (Figure 4E). Similarly, after de
novo EBV exposure, sonicated GAS increased IL-6 (P = .02;
Figure 4D) and IL-10 mRNA expression in LCLs, compared
with no stimulus (P = .03; Figure 4E), as well as IL-6 and IL-10
protein levels (Figure 4F and 4G).
We wondered whether heat-killed or sonicated GAS exhibit-
ed similar effects on EBV-carrying BL cells as on LCLs. We
chose Akata cells because they represent a well-established
model for studying the switching from latent to lytic EBV in
vitro. We analyzed BZLF1 mRNA expression 24 hours after
treatment with heat-killed or sonicated GAS by qPCR. In con-
trast to LCLs, levels of BZLF1 mRNA in Akata cells exposed to
heat-killed GAS were not altered, whereas exposure to sonicat-
ed GAS signiﬁcantly decreased endogenous levels of BZLF1
mRNA expression (Figure 4H). These results suggested that
sonicated GAS might trigger TLR9. Sonicated GAS samples
contain genomic DNA with unmethylated CpG motifs known
to trigger TLR9 [18, 24], and triggering of TLR9 results in sup-
pression of lytic induction in Akata cells [15, 16]. No difference
in the percentage of 7-AAD stained cells was observed in the
cells exposed to heat-killed or sonicated GAS (Figure 4I).
Primary B Cells and LCLs Expressed TLR2, in Contrast to
Akata Cells
Gram-positive bacteria, such as GAS, are recognized by TLR2
on the cell surface and by TLR9 in endosomes [18, 24]. TLRs
are key players in innate immunity and are involved in the rec-
ognition of pathogens and microbial products leading to activa-
tion of antimicrobial effector pathways [25]. TLR2 generally
forms heterodimers with TLR1 or TLR6, which recognize pep-
tidoglycan and lipoteichoic acids from gram-positive bacteria
[26]. We asked whether the differences in lytic EBV gene ex-
pression were due to distinct expression proﬁles of TLRs. Thus,
we analyzed TLR expression in primary B cells, LCLs, and
Akata cells (Figure 5A). Primary B cells, LCLs, and Akata cells
expressed TLR1, TLR6, TLR7, TLR9, and TLR10 mRNA,
whereas TLR5 mRNA expression was detected at extremely low
levels in primary B cells and was not detected in LCLs and
Akata cells. TLR2, TLR3, and TLR4 mRNA was detected at ex-
tremely low levels in Akata cells, in contrast to primary B cells
and LCLs. Similar to TLR2mRNA, TLR2 protein was expressed
in LCLs but not in Akata cells (Figure 5B), and the mean ﬂuo-
rescence intensity on LCLs was higher than on Akata cells
(Figure 5C), as determined by ﬂow cytometry. Since heat-killed
Gram-positive bacteria are known TLR2 ligands [27] above
results suggested that heat-killed GAS might induce lytic EBV
infection in LCLs via TLR2 activation.
Heat-Killed GAS and GAS Peptidoglycan Induce Lytic
EBV via TLR2
Exposure of LCLs to either heat-killed GAS, puriﬁed GAS pep-
tidoglycan used as control for the GAS cell wall component
peptidoglycan, or sonicated GAS did not change the percentag-
es of TLR2-positive cells as determined by ﬂow cytometry
(Figure 6A and 6B upper panel left). Percentages of BZLF1-pos-
itive cells in LCLs exposed to heat-killed GAS were higher than
in nonexposed LCLs or in LCLs exposed to sonicated GAS
(Figure 6A and 6B), corroborating mRNA expression ﬁndings
(Figure 4A), and exposure to GAS peptidoglycan showed
results similar to those for the heat-killed GAS. The propor-
tions of BZLF1-positive cells showed around a 4-fold higher
increase among TLR2-positive cells, compared with TLR2-neg-
ative cells, after exposure to heat-killed GAS or GAS peptido-
glycan (Figure 6B). We conﬁrmed that exposure of LCLs to
GAS peptidoglycan resulted in similar upregulation of BZLF1
and IL-10 mRNA as heat-killed GAS, compared with no expo-
sure (Figure 6C). Similar results were obtained using 2 other
TLR2 ligands, staphylococcal lipoteichoic acid and staphylo-
coccal peptidoglycan (Supplementary Figure 1) [28, 29].
Finally, anti-TLR2 polyclonal neutralizing antibodies inhibited
upregulation of BZLF1 and IL-10mRNA expression (Figure 6C)
in LCLs exposed to heat-killed GAS or GAS peptidoglycan.
DISCUSSION
We examined the inﬂuence of GAS oropharyngeal colonization
on EBV’s life cycle. We found that (1) EBV carriers shed more
EBV particles in their saliva when colonized with GAS, (2)
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Figure 4. Heat-killed group A streptococcus (GAS) induced lytic Epstein-Barr virus (EBV) and caused increased cell death of latently EBV-infected B
cells. Levels of BZLF1 (A), IL-6 (D), and IL-10 (E) messenger RNA (mRNA) expression in lymphoblastoid cell lines (LCLs) were analyzed by quantitative real-
time polymerase chain reaction (qPCR) 24 hours after exposure. B, 7-aminoactinomycin D (7-AAD)–stained LCLs were analyzed by ﬂow cytometry 24 hours
after exposure. The numbers of EBV DNA copies in culture supernatants from LCLs were analyzed by qPCR 24 hours after exposure (C ). Interleukin 6 (IL-6;
F ) and interleukin 10 (IL-10; G ) concentrations in supernatants from LCLs were measured by enzyme-linked immunosorbent assay (ELISA). The results
shown were pooled from LCLs from 7 donors, from 4 donors (done in duplicate), and from 6 donors for qPCR, ﬂow cytometry, and ELISA, respectively, and
are expressed as mean values ± standard error of the mean (SEM). P values were calculated by the Wilcoxon signed rank test. *P < .05, **P < .01. H,
Levels of BZLF1 mRNA expression in Akata Burkitt lymphoma (BL) cells were analyzed by qPCR 24 hours after exposure to heat-killed or sonicated GAS. I,
7-AAD–stained Akata BL cells were analyzed by ﬂow cytometry 24 hours after exposure. Results shown were from Akata BL cells pooled from 3 experi-
ments and are expressed as mean values ± SEM. The P value was calculated using a paired Student t test. *P < .05.
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EBV’s immediate-early lytic gene BZLF1 mRNA expression
was more frequent in tonsils from GAS-positive EBV carriers
than from GAS-negative EBV carriers, (3) heat-killed GAS
induced lytic EBV in tonsils during primary infection with
EBV in vitro and in persistently EBV-infected LCLs resulting
in cell death, and (4) heat-killed GAS and puriﬁed GAS pepti-
doglycan induced lytic EBV in LCLs via TLR2 activation. Thus,
GAS colonization of the oropharynx might beneﬁt EBV by in-
creasing the salivary EBV load and thereby enhancing the like-
lihood of EBV spread to other hosts.
Our observation that concomitant GAS colonization resulted
in higher salivary EBV shedding is unprecedented. Salivary
EBV shedding lasts at least 6 months after primary EBV infec-
tion manifesting as infectious mononucleosis [10, 30, 31].
Frequent and abundant salivary EBV shedding is observed in
EBV-infected children with tonsillar hypertrophy [19], a
condition that is associated with more-frequent GAS coloniza-
tion [32]. Lytic EBV replication in the oropharynx may occur
in epithelial cells, which act as ampliﬁers [33] after acquiring
EBV from tonsillar or other local mucosa-associated B cells
[34]. Investigation of lytic EBV replication in oropharyngeal ep-
ithelial cells has not been successful. Thus, we assessed the
effect of GAS carriage in tonsils from EBV carriers. We found
that GAS carriage was associated with signiﬁcantly higher im-
mediate-early lytic gene BZLF1 mRNA expression, which
induces switching from latent to lytic EBV [1, 6, 35]. In vitro,
upregulation of BZLF1 is induced by sodium butyrate [36], 12-
O-tetradecanoylphorbol-13-acetate [37], cross-linking of B-cell
receptor [38, 39], or the antiinﬂammatory cytokine transform-
ing growth factor β [40]. Based on IL-6 and IL-10 expression,
the inﬂammation status of tonsils from GAS-colonized individ-
uals did not differ from that of tonsils from noncolonized
Figure 5. Primary B cells and lymphoblastoid cell lines (LCLs) expressed Toll-like receptor 2 (TLR2), in contrast to Akata BL cells. A, Messenger RNA
(mRNA) expression levels of TLR1–TLR10 in peripheral blood and tonsillar primary B cells, LCLs (n = 4), or Akata BL cells were analyzed by quantitative
real-time polymerase chain reaction. Representative data of ﬂow cytometry for TLR2 on LCLs and Akata BL cells (B) and the mean ﬂuorescence intensity
(MFI) from Akata BL cells pooled from 3 experiments and LCLs from 3 donors (C) are shown. The closed histogram, dotted line, and solid line represent un-
stained cells, isotype control, and anti-TLR2 antibody, respectively. The P value was calculated using an unpaired Student t test. *P < .05.
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individuals in this study. Thus, enhanced EBV lytic replication
was not due to a lower proinﬂammatory or higher antiinﬂam-
matory state of the tonsils.
Intriguingly, we found that heat-killed GAS and sonicated
GAS exhibited contrasting effects on both EBV and immune
activation. Whereas heat-inactivated GAS induced lytic EBV,
Figure 6. Heat-killed group A streptococcus (GAS) and GAS peptidoglycan induced lytic Epstein-Barr virus via Toll-like receptor 2 (TLR2). A, Representa-
tive ﬂow cytometry ﬁndings for TLR2 and BZLF1 in lymphoblastoid cell lines (LCLs) unstimulated or simulated with heat-killed GAS, GAS peptidoglycan, or
sonicated GAS. B, Percentages of TLR2-positive cells, BZLF1-positive cells, and BZLF1-positive cells among TLR2-positive cells and TLR2-negative cells fol-
lowing no treatment or treatment with heat-killed GAS or GAS peptidoglycan. C, Levels of BZLF1 and IL-10 RNA expression in LCLs following no exposure
or exposure to heat-killed GAS, GAS peptidoglycan, or sonicated GAS without or with antecedent anti-TLR2 polyclonal neutralizing antibodies (anti-TLR2
pAb) treatment were analyzed by quantitative real-time polymerase chain reaction. Results shown are from LCLs from 6 donors and are expressed as mean
values ± standard error of the mean. P values were calculated using a Wilcoxon signed rank test. *P < .05.
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sonicated GAS did not. Sonicated GAS, by contrast, increased
the expression of IL-6 in TMCs, whereas heat-inactivated GAS
did not. Thus, heat-inactivated GAS—intact GAS bacterial cells
that may therefore mimic GAS colonization—seem to activate
the innate immunity differently from sonicated GAS and have
an opposite inﬂuence on EBV. GAS DNA found in sonicated
GAS suspensions triggers TLR9 and subsequently induces
proinﬂammatory cytokine expression [18, 24]. Activation of
Akata cells was diminished when a TLR9 antagonist was added
(Supplementary Figure 2). This is compatible with our observa-
tion of increased IL-6 expression in TMCs exposed to sonicated
GAS but not in TMCs exposed to heat-killed GAS. Important-
ly, we recently demonstrated that TLR9 triggering suppresses
switching from latent to lytic EBV [15, 16].
The upregulation of BZLF1 following exposure to heat-killed
GAS was only approximately 1.5-fold but was highly reproduc-
ible, implying that only a small fraction of B cells was provoked
to switch to lytic EBV infection. Indeed, we found that around
1% of LCL cells upregulated BZLF1 expression after exposure
to heat-killed GAS. An alternative reason for the increase in the
level of EBV shedding in GAS-colonized children might be that
they have an immunological difference that allows coincident
GAS persistence and higher EBV secretion. Nevertheless, no
such difference was observed for IL-6, IL-10 (Figure 2B and
2C), and TNF-α mRNA expression levels (Supplementary
Figure 3A). Surprisingly, heat-killed GAS did not induce
switching to lytic EBV in Akata cells, which are commonly
used as a model to study the switching from latent to lytic EBV.
Thus, we hypothesized that Akata cells may differ from
primary B cells and LCLs in their expression of TLRs. Indeed,
we found that Akata cells expressed TLR2 at remarkably lower
levels, if at all, than primary B cells and LCLs. Exposure of
LCLs to GAS peptidoglycan, a known ligand for TLR2, pro-
voked similar expression of BZLF1 as heat-killed GAS. Upregu-
lation of BZLF1 was around 4-fold higher in TLR2-positive B
cells, compared with TLR2-negative B cells. Importantly, anti-
TLR2 neutralizing antibodies completely abrogated upregula-
tion of BZLF1 following exposure to heat-killed GAS or GAS
peptidoglycan. This strongly suggested that heat-killed GAS
and GAS peptidoglycan upregulated BZLF1 expression in LCLs
via TLR2 triggering. Finally, we showed that other known
TLR2 ligands, namely staphylococcal lipoteichoic acid and pep-
tidoglycan [28, 29], also induced BZLF1 mRNA expression in
LCLs, suggesting the engagement of TLR2 results in lytic reacti-
vation of EBV.
Our novel ﬁndings imply that TLR2 triggering may disrupt
EBV’s default state of latency. This seems to be beneﬁcial for
EBV since it allows EBV to spread to other hosts. However, it
may put EBV latency and the survival of the host cell at stake.
In view that TLR2-expressing EBV-infected cells are likely to
undergo switching to lytic EBV, selection of EBV-infected B-
cells subsets with lower or no expression of TLR2 may take
place over time. Notably, we found that TLR2 mRNA levels in
EBV-negative BL cells were at least 5-fold higher than in EBV-
positive BL cells (Supplementary Figure 3B), suggesting that cells
expressing low TLR2 levels may have been more likely to survive
than cells expressing higher levels of TLR2. Alternatively, EBV
may induce downregulation of TLR2 expression, thereby
preventing switching to lytic infection and securing its latent
state. Indeed, the expression of TLR2 in tonsillar B cells de-
creased in a time-dependent fashion after inoculation with EBV
(Supplementary Figure 3C). Thus, TLR2 signal transduction
may contribute to balancing latent and lytic EBV infection.
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A Distinct Subpopulation of Human NK Cells Restricts B Cell
Transformation by EBV
Anna Lu¨nemann,*,† Liliana D. Vanoaica,* Tarik Azzi,† David Nadal,† and
Christian Mu¨nz*
NK cells constitute the first line of defense against pathogens and transformed cells. They mature in secondary lymphoid organs,
including tonsils, where common pathogens, such as EBV, enter the host and potentially imprint differentiating cells, which then
patrol the body via the blood stream. Therefore, we set out to characterize a distinct human NK cell population in tonsils that
produces high amounts of the immunomodulatory and antiviral cytokine IFN-g. We found that the tonsilar IFN-ghigh NK cell
subset is CD56brightNKG2A+CD94+CD54+CD62L2, is present in tonsils ex vivo and is more mature than other CD56bright NK cells
in tonsils and less mature than other NK cells in blood, shows very low plasticity even after prolonged cytokine stimulation,
accumulates in tonsils of EBV carriers, and is able to potently restrict EBV-induced transformation of B cells. Thus, we char-
acterized a distinct and stable IFN-ghigh NK cell subpopulation that can specifically restrict malignant transformation of EBV-
infected B cells. This subset should be exploited for future development of cell-based therapeutic approaches in EBV-associated
malignancies. The Journal of Immunology, 2013, 191: 4989–4995.
N
atural killer cells are innate lymphocytes that were orig-
inally described for their ability to target virus-infected
and transformed cells without preactivation (1, 2). Al-
though they originally were thought to leave the bone marrow as
fully developed effector cells and to reside primarily in the blood
stream, reservoirs of NK cells were discovered more recently in
other tissues, including secondary lymphoid organs (SLOs) (3, 4).
These NK cells in lymph nodes and tonsils (SLOs) require activation
by primarily dendritic cells to achieve full functional competence
and mediate protection against pathogens (4–6). In tonsils, in con-
trast to peripheral blood, the most mature NK cells are CD56bright,
whereas earlier differentiation stages are CD56dim (7). CD56+ cells
in human tonsils also contain RORgt+ ILC3 cells (8, 9); for a more
detailed characterization of CD56dim tonsilar cells, these cells
would need to be taken into account. In humans, the NK cell
reservoir in SLOs consists mainly of CD56brightCD162 NK cells.
In peripheral blood, NK cells of this subset carry homing markers
to SLOs and constitute only about one tenth of the circulating NK
cells (4, 10). These blood CD56bright NK cells have longer telo-
meres and can develop into functional CD56dimCD16+ NK cells
(4, 11, 12). Subsequently, they seem to acquire more and more
inhibitory receptors, including killer Ig–like receptors (KIRs),
during further differentiation (13). However, in contrast to mouse
NK cells, which excel in their main effector functions (i.e., cy-
tokine production and cytotoxicity) only after terminal differen-
tiation (14), human NK cells acquire already potent cytokine
production at the CD56brightCD162 differentiation stage (10).
Intriguingly, NK cells in SLOs produce much more IFN-g in
response to IL-12 than do peripheral blood NK cells, and this
reactivity resides nearly exclusively in the CD56brightCD162
NK cells of these organs (15). This effector function of NK cells
can be especially useful in secondary lymphoid tissues at mu-
cosal surfaces (e.g., tonsils) for restricting infections, because
these are the sites where pathogens are first encountered as a nat-
ural entrance point.
One such pathogen, which could be targeted by NK cell responses
in tonsils, is EBV. EBV is a common g-herpesvirus that infects
.90% of the human adult population and enters the human body
via tonsils after transmission in saliva (16). In the vast majority of
infected individuals, EBV persists without symptoms under tight
immune control by primarily T cells (17). However, in a subset of
EBV carriers, the B and epithelial cell–transforming capacity of the
virus causes detrimental EBV-associated malignancies (18). In this
respect, the initial immune response to infection seems to be quite
decisive, because symptomatic primary EBV infection (infectious
mononucleosis) can predispose for EBV-associated malignancies
(19, 20) and even autoimmune diseases (21). NK cells are part
of this innate immune response to EBV and have been reported,
somewhat controversially, to correlate either inversely or directly
with viral titers during primary infection (22, 23). A protective
function of these NK cell responses during primary infection is
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indicated by primary immunodeficiencies that affect NK cells and
were suggested to predispose for EBV-associated malignancies (24,
25). Furthermore, X-linked lymphoproliferative disease–associated
mutations, which predispose affected males to fatal lymphoproli-
ferative disease upon primary EBV infection, compromise NK cell
recognition of EBV-transformed cell lines (26). These mutations
also affect other components of cell-mediated immunity, such as
T cells. Nevertheless, NK cells clearly contribute to early restriction
of EBV infection and lower the risk for EBV-associated diseases.
Palatine tonsilar NK cells, which are located at the site of EBV
entry, are ideally suited to mediate this early restriction, and we
demonstrated previously that NK cells of these SLOs can limit
B cell transformation by EBV with their superior ability to produce
IFN-g (15). In the same study, we also noted that only a subset of
tonsilar NK cells produced these high levels of IFN-g. Therefore, in
this study we set out to characterize this IFN-ghigh NK cell subset.
In this article, we report that cells from this IFN-ghigh NK cell
subset are CD56brightNKG2A+CD94+CD54+CD62L2, are enriched
in tonsils of EBV carriers, and specifically restrict EBV transforma-
tion of B cells. Moreover, this subpopulation lacks homing markers to
SLOs and seems to be primed to transition into the periphery to carry
out innate immune control of EBV infection.
Materials and Methods
Ethical approval for human samples
Studies on human samples for the immune control of human g-herpesvirus
infections were reviewed and approved by the cantonal ethical committee
of Zu¨rich, Switzerland (KEK-StV-Nr. 19/08). Tonsils and blood samples
of children were collected after informed consent of the legal guardians.
Lymphocyte concentrates from adult donors were obtained from the Swiss
Red Cross Blutspendedienst Zu¨rich (Zu¨rich, Switzerland) after informed
consent of the donors.
Reagents
The following anti-human mAbs were used in this study: CD3 Pacific Blue
(Invitrogen); CD3 allophycocyanin Cy7, CD56 PE Cy7, IFN-g allophy-
cocyanin, CD19 PE, CD19 allophycocyanin Cy7, CD94 PE, CD62L
allophycocyanin, CD62L PE, CD21 allophycocyanin, CD23 FITC, CD336
PE, CD103 FITC, and isotypes (BD Biosciences); CD117 PE (Miltenyi
Biotec); NKG2C allophycocyanin (R&D Systems); CD45RA FITC and
CCR7 PE, CD57 FITC, CXCR3 allophycocyanin, perforin FITC, CD54
Pacific Blue, and CD16 allophycocyanin Cy7 (BioLegend); NKG2A PE,
NKG2A allophycocyanin, and KIRs—CD158a,h PE, CD158b1,b2,j PE,
CD158a,h allophycocyanin, and CD158b1,b2,j allophycocyanin—(Beckman
Coulter). Live cells were routinely distinguished using the LIVE/DEAD
Fixable Aqua Dead Cell Stain Kit (Invitrogen). The following endotoxin-
free recombinant human (rh) cytokines were used: rhIL-12 (R&D Systems),
rhIL-2 (PeproTech), and rhIL-15 (Sigma).
NK and B cell purification and cell culture
Tonsilar cell single-cell suspensions were obtained by mechanical disso-
ciation of the tissue and mechanical filtration through a 75-mm nylon cell
strainer. After Ficoll-Paque Premium gradient centrifugation (GE Health-
care) to remove dead cells and debris, cells were washed extensively and
partly cryopreserved or used directly. Leukocytes of blood samples and
leukocyte concentrates were purified by Ficoll Paque Premium gradient
centrifugation and washed several times. B cells were isolated through
magnetic bead cell separation (MACS; Miltenyi Biotec) by CD19+ se-
lection. NK cells were isolated through negative MACS selection using the
NK cell isolation kit (Miltenyi Biotec), or CD192 cells were flow sorted
on an Aria III cell sorter (BD Biosciences) through an 85-mm nozzle for
purity. Purity was consistently .95%.
For intracellular IFN-g detection, NK cells were incubated for 18 h with
10 ng/ml rhIL-12, and a final concentration of 2 mM monensin was added
(10003 solution; eBioscience) for the last 6 h. Cells were then harvested,
washed with PBS and, after staining with the surface-binding Abs, fixed
with 2% paraformaldehyde, and intracellular staining was performed in
PBS plus 1% Saponin (Fluka) and BSA 1% (Sigma) using anti–IFN-g Abs
(clone 4S.B3; BD Biosciences).
Preparation of EBV
Wild-type EBV was produced through standard 4-h METAFECTENE PRO
(Lucerna) transfection of the B95-8 bacmid carrying 293HEK cells in 10-
cm dishes, according to the manufacturer’s protocol. In brief, plasmids
(BZLF-1, Amp resistance; and BALF-4, gp110, Amp resistance) were
preincubated with METAFECTENE at room temperature for 20 min and
then added to the cell dishes for 4 h in antibiotic-free medium. Then, RPMI
1640 + 10% FCS medium was replaced with gentamicin-containing RPMI
1640 + 10% FCS medium medium. Supernatant was harvested after
3 d and filtered through 0.45-mm filters, and EBV was further purified and
concentrated by ultracentrifugation at 30,000 3 g for 2 h at 4˚C, resus-
pended in RPMI 1640, and titered on Raji cells. GFP+ cells were counted
2 d later, and titers were calculated in Raji infectious units.
B cell–transformation assay
This assay was adapted from the previously described protocol (15). Briefly,
MACS-isolated B cells (as described above) were plated at 1 3 105 cells
and cultured in RPMI 1640 + 5% human serum (Invitrogen) with 2 mg/ml
gentamicin and infected with wild-type EBV; sorted NK cells were added
at the indicated numbers. IL-12 was added at 10 ng/ml. Cells were har-
vested after 12 d, and the numbers of transformed B cells were quantified
by determining the ratio of live CD19+CD21+CD23+ transformed B cells/
total live cells by flow cytometry. Percentage of restriction of B cell trans-
formation = (1 2 total transformed B cell number of sample with NK cells/
total transformed B cell number of sample without NK cells) 3 100.
Flow cytometry and data analysis
Flow cytometric data were acquired on an LSR II Fortessa cell analyzer
(equipped with four lasers; Figs. 1, 2, 4) or an Aria III cell sorter (five laser
lines; Fig. 3) (both using Diva software; all from BD Biosciences). General
gating strategy for NK cells: lymphocyte population in forward/sideward
scatter (FSC/SSC), live (Aqua2) cells, CD32, CD56+. Data were analyzed
using FlowJo 9.3.1.3. and GraphPad Prism for Mac version 5.0a.
Statistical analysis
Data were compared using the two-tailed Wilcoxon signed-rank test, unless
noted otherwise, or the two-tailed Mann–Whitney U test, if specified in the
figure legends. A p value # 0.05 was considered statistically significant.
Error bars represent the SEM in all figures.
Results
The tonsilar immunoresponsive NK cell subset with high IFN-g
production consists of CD56brightNKG2A+CD94+CD54+
CD62L2 cells
Tonsils harbor a distinct subset of very high IFN-g–producing
CD56bright NK cells, which secrete this cytokine especially after
IL-12 stimulation (4). This subset is not seen in peripheral blood,
might play important bridging functions with the adaptive immune
system, and could be an adaptation to target pathogens in SLOs at
mucosal entry sites. To characterize this subset in more detail, we
first determined its surface marker phenotype. To accomplish this,
we purified NK cells by negative magnetic cell separation (MACS;
Miltenyi Biotec) and stimulated them with 10 ng/ml IL-12 for 18 h.
IFN-ghigh NK cells differ from the total CD56bright NK cells by their
expression of NKG2A/CD94 and CD54, as well as the lack of
L-selectin (CD62L) (Fig. 1A–C, Supplemental Fig. 1 [representa-
tive flow cytometry dot blots of subpopulations]). IL-12 was chosen
for the stimulation of tonsilar NK cells, because it was previously
identified as the primary monokine involved in NK cell activation
by dendritic cells (15). To exclude the possibility that CD62L un-
dergoes shedding and is lost from the surface of the NK cells due
to sample preparation we determined its expression on naive T cells
versus T EMRA cells (effector memory RA+) and found normal
levels of L-selectin expression (Supplemental Fig. 3B). Tonsilar IR
cells expressed slightly less NKG2C than did other CD56bright NK
cells, but the overall expression was very low (data not shown). We
confirmed the phenotype of tonsilar NK cells with high IFN-g
production by gating on CD56brightNKG2A+CD94+CD54+CD62L2
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cells after 18 h of IL-12 stimulation (10 ng/ml, as above) and found
that this population consisted of nearly all IFN-g–producing cells
(Fig. 1D). To exclude overlap with the recently described tonsilar
subset of CD336+CD103+ cells (27), we analyzed coexpression
with these markers, as well as IFN-g production, and found that
both subsets were distinct (Supplemental Fig. 2). Taken together,
these data show that IFN-ghigh NK cells in tonsils can be defined
as CD56brightNKG2A+CD94+CD54+CD62L2.
IL-12 induces accumulation of high IFN-g–producing NK cells
in tonsils, which are more mature than the other tonsilar NK
cells but less mature than peripheral blood NK cells
Next, we addressed whether this distinct NK cell subset (CD56bright
NKG2A+CD94+CD54+CD62L2) is already present in tonsils with-
out stimulation. To determine this, we analyzed tonsilar cells
from children ex vivo and found a significant population of this
subset (Fig. 2A). This subpopulation accumulated after stimula-
tion of purified NK cells with IL-12 for 18 h (Fig. 2A). Expression
of c-kit (CD117) is lost throughout the maturation process of NK
cells (7); hence, its expression characterizes less mature cells. We
found that fewer immunoresponsive (IR) NK cells express c-kit in
tonsils compared with the other CD56bright NK cells in this organ.
Conversely, more NK cells with this phenotype displayed this
marker of immaturity in the peripheral blood compared with the
remaining blood CD56bright NK cells (Fig. 2B, Supplemental Fig.
3A [gating strategy]). As a second parameter of maturation for NK
cells, we determined the expression of KIRs, which are acquired
throughout the maturation process (7). We found that IR NK cells
express significantly more KIRs than do tonsilar CD56bright NK
cells in general (Fig. 2C). In addition, we found that maturation-
associated CD16 expression was significantly higher on tonsilar
IR cells than on the rest of CD56bright cells in tonsils, whereas this
expression pattern is reversed in blood (i.e., blood IR cells carry
less CD16 than do the other peripheral CD56bright cells [Fig. 2G,
2H]). Overall, CD57 and perforin expression was very low, and
there was no significant difference between the analyzed subsets
(Supplemental Fig. 3C, 3D). As shown in Fig. 2E and 2F, we did
not detect any difference in CXCR3 expression between IR and
the rest of the CD56bright subset, nor in NKG2A median fluores-
cence intensity (MFI) on cells pregated on NKG2A+ cells, which
might have further supported the advanced maturation status of
these cells. In conclusion, we demonstrated that the distinct IR
NK cell subset is already present in tonsils and blood ex vivo,
accumulates upon IL-12 stimulation, and is more mature than
the total tonsilar CD56bright NK cells but less mature than blood
NK cells.
The IR NK cell subset shows very low plasticity even after
prolonged cytokine stimulation
Plasticity of immunological receptors determines whether mole-
cules are reliable and characteristic marker molecules, defining the
same cell subset under different activation conditions. High plas-
ticity will hinder traceability of subsets through different conditions.
Therefore, we assessed whether expression of the defined potential
marker molecules was stable, even during prolonged cytokine
stimulation, to determine whether this subset is stable throughout
immunological processes and activation. The subset was sorted into
the IR subset, the rest of CD56bright and the CD56dim NK cells
(subset gating strategy in Fig. 3A) and stimulated for 7 d with IL-12
(10 ng/ml), IL-2 (100 U/ml), or IL-15 (100 pg/ml). Cells were
collected, and expressions of marker molecules were analyzed.
CD56 expression was highly variable after cytokine stimulation
with IL-12 in our experimental setting (Supplemental Fig. 4A) and
with IL-2 and IL-15 (Supplemental Fig. 4B, 4C). The IR subset
became largely CD56dim after prolonged cytokine stimulation,
which suggested a maturation status similar to blood CD56bright NK
cells that were reported to turn into CD56dim upon stimulation (11).
The other CD56bright cells conserved their high CD56 expression.
CD56dim NK cells, which are the less mature NK cell population in
tonsils, turned into CD56bright cells upon prolonged IL-2 stimula-
tion. Thus, CD56 expression was disregarded for reanalysis of the
potential marker molecules NKG2A and absence of CD62L. Ex-
pression of NKG2A was highly stable (Fig. 3B), and L-selectin
negativity was preserved (Fig. 3C), even after prolonged cytokine
FIGURE 1. The human tonsilar IFN-ghigh
NK cell IR subset is characterized as CD56bright
NKG2A+CD94+CD54+CD62L2. Purified NK
cells were stimulated with 10 ng/ml IL-12;
monensin was added after 12 h, and cells were
analyzed after 18 h by flow cytometry. (A)
Gating strategy for analysis of distinct IFN-
ghigh NK cell subset after IL-12 stimulation.
The IFN-ghigh subset in tonsils is CD56bright
NKG2A+CD94+ (B) and CD54+CD62L2 (C).
(D) Gated on this subset, these NK cells are
almost exclusively IFN-g+ after IL-12 stimula-
tion (10 ng/ml, as above). Gating strategy:
lymphocyte population in FSC/SSC, Live cells
(Live/Dead cell stain Aqua2), NK cells (CD32
CD56+), subset gating as in (A). At least three
independent experiments were performed, and
data were summarized from .10 healthy donors.
All error bars represent SEM. *p # 0.05, **p #
0.005, ***p # 0.0005 two-tailed nonparametric
Mann–Whitney U test.
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stimulation with different cytokines in the IR subset. To identify the
origin of the IR cells that accumulated after cytokine stimulation,
expression of NKG2A (Supplemental Fig. 4C) and the absence of
L-selectin (Supplemental Fig. 4D) and of the combined phenotype
(Supplemental Fig. 4E) were analyzed on the rest of the initially
CD56bright and CD56dim subset after prolonged cytokine stimula-
tion. There was significant acquisition of NKG2A, loss of CD62L,
and acquisition of the combined phenotype in CD56dim and the
other CD56bright NK cells as the result of IL-2 and IL-12 stimula-
tion. After prolonged cytokine stimulation of purified tonsilar NK
cells, the IR subset retained the ability for elevated IFN-g pro-
duction (Fig. 3D). In conclusion, the defined potential marker
molecules could be confirmed for the IR subset because they are
preserved and stable throughout immunological activation mod-
eled by prolonged cytokine stimulation; therefore, they define the
subset reliably and characteristically under different activation
conditions and can be acquired by non-IR tonsilar NK cells.
IR NK cells accumulate in tonsils of EBV carriers and are able
to restrict EBV-induced transformation of B cells
To investigate whether the defined IR NK cell subsets could provide
a barrier function against pathogens that infect via the tonsils, we
investigated their enrichment in EBV-seropositive individuals.
Tonsils of children carrying EBV harbored significantly more of the
IR subset of NK cells than did those of age-matched children not
infected with EBV (Fig. 4A). The IR subset exists in peripheral
blood ex vivo, even though this subset is markedly enriched in
tonsils, and there are significantly fewer cells of this subset in the
peripheral blood of EBV-infected children than in age-matched
noninfected children. Adults have even fewer of the IR subset
than do children (Fig. 4B). The IR cells in the peripheral blood
have a higher capacity for IFN-g production after IL-12 stimula-
tion than do the other CD56bright NK cells (Supplemental Fig. 4G).
The elevated frequency of IFN-g–producing IR NK cells, as gated
in Fig. 1A, in EBV+ tonsils was increased further after IL-12
FIGURE 2. The NK cell IR subset is present in tonsils ex vivo and accumulates upon stimulation with IL-12. (A) Percentages of total NK cells in the
tonsil and CD56bright cells. Subset accumulates after 18-h stimulation with IL-12 (10 ng/ml). Significantly fewer tonsilar IR cells express c-kit (CD117) (B),
whereas significantly more blood IR cells express this molecule (C), which is expressed by more immature NK cells. (D) More of the tonsilar IR subset
expresses KIR molecules compared with total or CD56bright NK cells. IR cells express similar levels of CXCR3 (E) and the NKG2A MFI (subset versus
CD56bright total) was not different between IR cells and the other CD56bright cells (F), pregated on NKG2A+ cells. (G) Greater frequency of CD16+ IR cells
than CD16 expression in other CD56bright cells in tonsilar mononuclear cells (TMCs) and a higher level of expression (as measured by MFI ratio [subset/
NK]). (H) In contrast, in PBMCs, a higher frequency of the other CD56bright cells expressed CD16 than did IR cells and to a greater extent, as measured by
MFI ratio (subset/NK). Gating strategy: lymphocyte population in FSC/SSC, Live cells (Live/Dead Cell Stain Aqua2), NK cells (CD32CD56+), subset
gating: CD56brightNKG2A+CD94+CD54+CD62L2, as depicted in Supplemental Fig. 3A. Data represent at least three independent experiments and at least
three donors. All error bars represent SEM. *p # 0.05.
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stimulation (i.e., 1.6-fold in EBV2 donors and 1.25-fold in EBV+
donors) (Fig. 4C). To characterize whether this accumulation of IR
NK cells could provide protection in tonsils of EBV-seropositive
individuals, we tested this NK cell subset’s ability to restrict EBV
infection. EBV restriction by NK cells was measured by the
B cell–regression assay, as described previously (15). Briefly,
100,000 MACS-sorted EBV-exposed autologous B cells were
cocultured with different numbers of flow-sorted NK cell sub-
populations and IL-12 (10 ng/ml) for 10 d. EBV-transformed
B cells were identified by the gating strategy shown in Fig. 5A. IR
NK cells were 4.5-fold more efficient in preventing the out-
growth of EBV-infected B cells in vitro than were other tonsilar
CD56bright NK cells (Fig. 5B). These data provide direct evidence
that the distinct IR NK cell subset has the ability to markedly re-
strict EBV-induced B cell transformation and is the optimum NK
cell population in tonsils to perform this function.
Discussion
NK cells provide the first line of defense and play a crucial role
against invading pathogens and emerging cancer cells (28–32). Our
data demonstrate that these functions are mediated in part by these
innate lymphocytes in SLOs and that the respective tonsilar IFN-
ghigh NK cell subset is CD56brightNKG2A+CD94+CD54+CD62L2,
is present in tonsils ex vivo and is more mature than other CD56bright
NK cells in tonsils and less mature than other NK cells in peripheral
blood, shows very low plasticity even after prolonged cytokine
stimulation, accumulates in tonsils of EBV carriers, and is able to
potently restrict EBV-induced transformation of B cells. Our find-
ings suggest that a distinct NK cell subset is particularly operative
against EBV at its portal of entry and could be exploited for the
treatment of certain EBV-associated malignancies.
Our study indicates that EBV induces the accumulation of
CD56brightNKG2A+CD94+CD54+CD62L2 NK cells with the ca-
pacity to produce high amounts of IFN-g in human tonsils. These
NK cells limit primary EBV infection of B cells more efficiently
than do other tonsilar NK cell subsets and, therefore, could pro-
vide a crucial first innate barrier to infection in this portal organ of
EBV entry. The reduced levels of IR cells in the blood of EBV+
FIGURE 3. The NK cell IR subset shows low
plasticity, even after prolonged cytokine stimulation.
NK cells were sorted into IR cells, other CD56bright
NK cells, and CD56dim NK cells and stimulated with
IL-15 (100 pg/ml), IL-12 (10 ng/ml), or IL-2 (100 U/
ml) for 6 d, and NKG2A positivity and CD62L neg-
ativity were analyzed. CD56 expression changed after
prolonged stimulation, as shown in Supplemental Fig.
4. (A) Sorting strategy; circled subsets are compared.
Regardless of CD56 expression, IR subset shows very
low plasticity in expression of NKG2A positivity (B)
and CD62L negativity (C), even after prolonged
stimulation with cytokines. (D) IR cells retain their
superior ability to produce IFN-g compared with the
other CD56bright cells, as shown by the MFI ratio
(subset/NK) after prolonged stimulation with IL-12 or
IL-2. General gating strategy: lymphocyte population
in FSC/SSC, live cells (Live/Dead Cell Stain Aqua2),
NK cells (CD32CD56+), IR: CD56brightNKG2A+
CD94+CD54+CD62L2, as depicted in Supplemental
Fig. 3A. Furthermore, subset gating for sorting was
performed as in Fig. 1A, and for the analysis after
cytokine stimulation, both NKG2A and CD62L were
assessed. Data represent at least three independent
experiments, with a total of three to six donors. All
error bars represent SEM. *p # 0.05.
FIGURE 4. IR NK cells accumulate in EBV-infected tonsils. (A) Tonsils
of children carrying EBV, a chronic and cancerogenic virus infection en-
tering the human body via the tonsils, harbor significantly more of this
subset of NK cells than do noninfected children. (B) IR subset exists in
peripheral blood ex vivo, even though this subset is enriched in tonsils and
there is significantly less of this subset in the blood of EBV-carrying
children than in noninfected children. Adults have even less of the IR
subset than do children. (C) Increased numbers of IR cells in EBV+ tonsils
after IL-12 stimulation (i.e., mean frequency 1.6-fold in EBV2 donors and
1.25-fold in EBV+ donors). Gating strategy: lymphocyte population in
FSC/SSC, Live cells (Live/Dead Cell Stain Aqua2), NK cells (CD32
CD56+), subset gating CD56brightNKG2A+CD94+CD54+CD62L2, as depic-
ted in Supplemental Fig. 3A. Data represent at least three independent
experiments, with a total of 4–12 donors. All error bars represent SEM.
*p # 0.05, **p # 0.005, ***p # 0.0005 two-tailed nonparametric
Mann–Whitney U test.
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donors might be the result of recruiting or retaining this subset in
tonsils, a further differentiation of this subset in the blood, or
a combination of these factors. Enrichments of distinct NK cell
populations were described for other viral infections in humans,
but superior restriction of the respective pathogens by these sub-
sets is rare. Moreover, a tissue-specific accumulation, as we de-
scribe for human tonsils, has not been reported previously.
Several studies showed persistent alterations in the NK cell
repertoire after viral infections (13, 33, 34) and even protective
effects of murine NK cell subsets (35, 36). Accumulation of ter-
minally differentiated NK cell subpopulations were reported in
hantavirus, chikungunya virus, human CMV, and HIV infections
(13, 33, 37–39). These studies suggested that the respective
viruses drive the accumulation of CD56dimCD16+KIR+CD57+ and
often NKG2C+ NK cells, which could mediate recognition of
infected target cells or, alternatively, just differentiate in response
to the inflammatory cytokines that are secreted during viral
infections. Respectively, these expansions were proposed to reflect
NK cells with memory-like features that prepare the NK cell
compartment for more rapid secondary responses to recurrent or
persistent viral infections (35, 39, 40) or accumulating effector
cells that are activated by memory CD4+ T cells via IL-2 secretion
(41, 42). Very recently, cytokine-induced human memory-like NK
cells were described (43). Both explanations for NK cell subset
accumulation suggest that these innate lymphocyte populations
should be explored for immunotherapy against the respective viral
infections (e.g., by choosing adjuvants that would elicit cytokine
production to promote in vivo differentiation of these NK cell
populations or by adoptively transferring the respective NK cell
subsets during symptomatic infection with the respective viruses
and during dysregulation of persistent infections resulting in det-
rimental malignancies).
Such NK cell–based therapies have been explored successfully
in transplantation settings against hematological malignancies.
Several clinical centers have observed beneficial effects of hap-
loidentical bone marrow transplantation for residual leukemia
clearance after chemotherapy, harnessing NK cell–mediated graft-
versus-leukemia effects (44–47). This therapy seems to be most
effective when bone marrow donor and recipient are mismatched
in HLA class I molecules, and the donor carries significant NK
cell populations that can detect this mismatch via their KIR rep-
ertoire (46, 48) and then target leukemic cells by missing-self
recognition (49). In these instances, transient reconstitution of
NK cells with a donor phenotype before NK cell tolerance against
the recipient is implemented mediates the graft-versus-leukemia
effect. Alternatively, alloreactive NK cell populations that are
expanded in vitro can also be infused (50–52). Thus, these studies
provide good evidence that NK cell therapies that transiently
generate an alloreactive compartment of these innate lymphocytes
are well tolerated and could be readily expanded to harness spe-
cialized antiviral NK cell populations. The recent description of
cytokine-induced human memory-like NK cells suggests that cy-
tokine stimulation for expansion of NK cells before transfusion
could be beneficial in these therapies (43). For the subset of potent
IFN-g–producing NK cells that can restrict EBV-induced B cell
transformation, described in this article, we demonstrated an ac-
cumulation after IL-12 stimulation. Non-IR NK cells can change
their phenotype accordingly after prolonged cytokine stimulation.
This could be readily harnessed to enhance future NK cell–based
therapeutic options by cytokine prestimulation.
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FIGURE 5. IR tonsilar NK cells potently restrict EBV-induced B cell transformation. Gating strategy for B cell analysis is shown in (A). (B) A total of
100,000 autologous B cells was infected with EBVand cocultured with the indicated numbers of sorted NK cells and IL-12 (10 ng/ml) for 10 d. The distinct
IR subset has the ability to significantly restrict EBV-induced B cell transformation in physiological numbers (500 NK versus 100,000 B cells [i.e., 0.5% or
a 5-fold increase]; 2,500 NK versus 100,000 B cells [i.e., 2.5%]). Gating strategy for sorted IR subset: lymphocyte population in FSC/SSC, live cells (Live/
Dead cell stain Aqua2), NK cells (CD32CD56+); subset gating: CD56brightNKG2A+CD94+CD54+CD62L2, as depicted in Supplemental Fig. 3A. Data
from three independent experiments, with a total of four or five donors, are summarized. All error bars represent SEM. *p # 0.05 two-tailed nonparametric
Mann–Whitney U test.
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